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Abstract 
Background 
Streptococcus pneumoniae is a leading cause of childhood mortality and morbidity. 
Nasopharyngeal colonisation precedes infection but the dynamics, modifiers, and 
immunological outcomes of colonisation in infancy are incompletely understood. 
Methods 
We conducted a longitudinal pneumococcal colonisation study of mothers and 
infants in Maela refugee camp in NW Thailand. 965 infants were followed from birth until 
24 months. 
Results 
Pneumococcal colonisation occurred early in infancy (median 46d). Vaccine 
serotypes (PCV13) accounted for 55.8% of isolates from infants and 27.5% from mothers. 
Non-typeable pneumococcal colonisation was common. Previous colonisation did not 
result in protection against subsequent pneumococcal acquisitions in infancy, although 
serotype reacquisitions tended to be delayed and of shorter duration. 
Positive associations were found between colonisation by pneumococci and 
Haemophilus injluenzae (OR 2.9, P<.OOI) or Moraxella catarrhalis (OR 2.1, P<.OOI), 
whereas Staphylococcus aureus colonisation was negatively associated (OR 0.3, P<.OOI). 
During first pneumonia episodes, detection of respiratory syncytial virus was negatively 
associated with pneumococcal colonisation (OR 0.5, P=.02). 
Serum IgG anti-capsular antibody responses to colonisation varied by capsule and 
increased with age: these antibodies were not protective against colonisation in infancy. 
Although cord bloods had high titres of IgG to pneumococcal surface and virulence 
proteins, none were associated with delayed infant colonisation. These proteins were 
immunogenic in infants but antibodies did not protect against colonisation. 
2 
Latex sweep serotyping was 3.9 times, and microarray 4.4 times, more likely to 
detect multiple pneumococcal serotype co-colonisations than standard WHO protocol 
culture (P<.OO 1). 
Conclusions 
Pneumococcal colonisation is influenced by previous exposure to homologous and 
heterologous serotypes. Neither previous exposure nor serum antibodies to capsule or 
surface proteins protect against colonisation in the first 24 months of life. WHO 
methodology significantly underestimates mUltiple serotype colonisations. These 
colonisation data will be a valuable baseline to compare with future studies following 
regional introduction of pneumococcal conjugate vaccines. 
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1 Background and Introduction 
1.1. Streptococcus pneumon;ae 
Streptococcus pneumoniae (the pneumococcus) is a leading infectious cause of 
morbidity and mortality. First identified independently by Pasteur and Sternberg in 1881, 
the organism rapidly became acknowledged as an important cause oflobar pneumonia (1). 
Pneumococcal disease ranges from mild mucosal infection, such as conjunctivitis and 
acute otitis media (AOM), to severe systemic infection, such as bacteraemic pneumonia 
and meningitis. The organism has been estimated to cause around 10% of all deaths in 
HIV -negative under five year olds: a total of 826,000 deaths in the year 2000 (2). The 
majority of these deaths occur in Africa and Asia. In recent years, the introduction of 
pneumococcal conjugate vaccines (peV) has resulted in great reductions in invasive 
pneumococcal disease due to the 7 - 13 serotypes covered by the vaccines (3-6). 
Streptococcus pneumoniae is a catalase-negative, alpha-haemolytic Gram positive 
diplococcus (Figure 1). S. pneumoniae is closely related to the upper respiratory tract 
commensals Streptococcus in/antis, Streptococcus mitis, Streptococcus oralis, and 
Streptococcus pseudopneumoniae (collectively known as the Mitis group streptococci). 
Recent genetic analyses by Kilian and colleagues demonstrated that these species arose 
from a common pathogenic ancestor and that S. pneumoniae represents one lineage in the 
overall pneumoniae-pseudopneumoniae-mitis cluster. This cluster evolved into distinct 
lineages of commensal species as a result of habitat adaptation by virulence gene loss (7). 
Exchange of genetic material within S. pneumoniae, and between species of the larger 
pneumoniae-pseudopneumoniae-mitis cluster, is the principal pneumococcal evolutionary 
mechanism (8). S. pneumoniae can be phenotypically differentiated from the other 
members of the Mitis group of streptococci by its susceptibility to optochin (ethyl 
hydrocuprein hydrochloride) and bile solubility (sodium deoxycholate), although atypical 
pneumococci may be optochin resistant or bile insoluble (9). The species may be 
20 
distinguished from its closest relatives by comparison of sequences seven housekeeping 
genes using multi locus sequence analysis (eMLSA; http://www.eMLSA.net) (10). 
Figure 1. Pneumococcal culture plate and colony morphology 
1.2. Typing of Streptococcus pneumoniae 
1.2.1. Serotyping 
The polysaccharide capsule forms the basis of the major typing system for 
pneumococci. In all but two serotypes, the capsule is synthesised by a WzxlWzy-
dependent pathway encoded by the genes of the capsular polysaccharide synthesis (cps) 
locus (11, 12). A serotype-specific series of genes are responsible for the synthesis of the 
capsule polysaccharide subunit, polyrnerisation of this subunit, and subsequent 
translocation to the cell surface. The capsules of serotypes 3 and 37 are synthesised by an 
alternative synthase pathway. Isolates may be serotyped on the basis of reactions to 
specific anti-capsule antisera. The antisera are raised in rabbits (Statens Serum Institut, 
Hillerod, Denmark) and are divided into pool , group, type, and factor antisera allowing 
serotyping to be carried out in a checkerboard scheme (Table 1 & Table 2). Using the 
Danish numbering system, serotypes are organised into 46 serogroups based on anti-sera 
21 
cross-reactivity, and then separated into serotypes by unique antisera reactions. Individual 
serotypes within a larger serogroup are denoted by a letter suffix (e.g. 19F, denoting the 
first serotype identified with serogroup 19). An alternative American typing scheme, which 
numbered serotypes in order of their discovery, has lost favour to the Danish system (13, 
14). 
Table 1. Pneumococcal serotyping using pool and type antisera 
Pool Vaccine groups/types Non-vaccine groups/types 
P Q R S T 
A 18* 4 5 2 
B 19* 6* 3 8 
C 7* 20 24*,31,40 
D 9* 11* 16*,36,37 
E 12* 10* 33* 21,39 
F 17* 22* 27,32*,41 * 
G 29,34,35*,42,47* 
H 14 23* 15* 13,28* 
I 25*,38,43,44,45,46,48 
*Indicates that there are> 1 serotypes within the serogroup 
Table 2. Resolution of serogroup 19 into distinct serotypes using factor antisera 
Serotype Factor antisera 
19b 19c 19f 7h 
19F + 
19A + 
19B + 
19C + + 
Observation of capsular swelling by microscopy (the Quellung reaction) has been 
the preferred method of typing pneumococci since its description by Neufeld at the 
beginning of the 20th century (15). However, this method of typing is costly and time 
consuming. Alternative methods, including counterimmunoelectrophoresis (16), dot blot 
(17), and slide or latex agglutination techniques (18-21), have been developed to improve 
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the ease of typing pneumococci. A recent review of European pneumococcal reference 
laboratories found an overall serotyping error rate of 5% and concluded that there was no 
association between typing method (Quellung vs. non-Quellung) and error rate (22). 
Sequencing of the capsule biosynthesis locus (cps) for all known pneumococcal 
serotypes opened the door for the development of molecular serotyping tools (11). 
Methods to identify up to 40 serotypes by either conventional or real-time polymerase 
chain reaction (peR) have been described (23-25). peR of the entire cps locus, followed 
by RFLP (restriction fragment length polymorphism) analysis and comparison to a 
database of serotype-specific band patterns, or peR and sequencing of the regulatory cpsB 
gene may also be used to determine pneumococcal serotypes (26, 27). A combination of 
multiplexed immunoassay and peR, with a Luminex microsphere-based detection system, 
has been developed to detect all known pneumococcal serotypes and non-typeable 
pneumococci (28). However, to date, microarray-based typing has been the only molecular 
tool to be able to detect all known pneumococcal serotypes in a single reaction (29). These 
methods are discussed further in the section on multiple serotype colonisation (section 
1.8.1). 
1.2.2. Genotyping 
Due to the organism's ability to undergo genetic recombination, genotyping offers 
increased resolution over serotyping to study pneumococcal population structures and 
strain specific characteristics. Multi-locus sequence typing (MLST) is currently the 
standard genotyping technique for S. pneumoniae, although this will inevitably change as 
the cost of whole genome sequencing falls (30). MLST involves peR amplification and 
sequencing of seven pneumococcal housekeeping genes and subsequent assignment of a 
numeric "sequence type" (ST) based on these sequences using the MLST website 
<http;llspneumoniae.mlst.netl). The numeric nature of the sequence type, coupled with the 
non-ambiguity of sequence data as compared with gel images used in alternative typing 
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schemes such as pulsed field gel electrophoresis (PFGE), pennits comparisons of MLST 
data globally. Relationships between STs can be detennined using computer algorithms 
such as eBURST (http://spneumoniae.mlst.netleburstJ) (31). As an example of the utility of 
characterisation of isolates by MLST compared to serotyping alone, an analysis of 
colonising pneumococci in Tanzanian children revealed nasopharyngeal co-colonisation by 
multiple genotypes of the same serotype (32). 
However, there are limitations to the current MLST scheme. Analysis of strain 
collections using either whole genome sequencing or an expanded 96-locus MLST scheme 
has revealed the considerable genetic diversity within single 7-locus STs (33, 34). Genetic 
recombination may result in the acquisition,loss or variation in key virulence determinants 
within a lineage (8). Croucher et al. identified >700 recombination events in a whole 
genome sequencing study of 240 isolates of the globally successful pneumococcal clone 
PMENI (ST81) collected over a 24 year period. Recombination resulted in capsule 
switches on ten occasions, leading to on-going success of the clone despite PCV7 
introduction (33). 
1.3. Antimicrobial resistance 
Resistant isolates of S. pneumoniae have become increasingly prevalent (35), with 
a number of drug-resistant clones having spread internationally (33, 36, 37). 
Beta-Iactam resistance in pneumococci occurs as a result of expression of mosaic 
pbp genes. These genes encode penicillin binding proteins (PBPs) with reduced affinity for 
beta-Iactam molecules. Mutations in PBPla, PBP2b, and PBP2x account for the majority 
of observed resistance. Point mutations occur in pbp genes in closely related streptococci 
and blocks of these genes may be subsequently acquired by pneumococci by horizontal 
gene transfer (38). Macrolide resistance is generally disseminated via transposons (33,38). 
Acquisition and expression of the erm(B) gene results in modification of the bacterial 23S 
ribosomal subunit with a reduction in macrolide binding affinity. Efflux pumps, coded by 
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me/genes, are an alternative macrolide resistance mechanism in pneumococci. Non-
typeable pneumococci may be a significant reservoir for antimicrobial resistance genes 
(39). 
A significant proportion of pneumococcal isolates from Asian children have been 
found to be antimicrobial resistant (40). Resistant organisms are largely confined to the 
types which commonly colonise children (serogroups 6, 14, 19, and 23). Residence in 
urban areas, day-care attendance, and previous history of otitis media have been shown to 
be risk factors for carriage of non-susceptible pneumococci by Asian children (40). Several 
studies have demonstrated significant levels of resistance in Thai pneumococcal isolates 
(41, 42). A recent six year review of 115 invasive pneumococcal isolates from Thai 
children demonstrated that 69.6% were non-susceptible to penicillin (26.1 % were 
intermediate and 43.5% were resistant) (43). Eighty nine percent of these non-susceptible 
isolates were of serotypes contained in the seven valent conjugate vaccine. 
A significant additional benefit associated with the widespread use of the 
pneumococcal conjugate vaccine is a reduction in the burden of invasive pneumococcal 
disease due to antimicrobial resistant strains, although over time this may be eroded by the 
increasing resistance in non-vaccine serotypes (44, 45). 
1.4. Pneumococcal colonisation and disease 
Colonisation of the nasopharynx by S. pneumoniae ("pneumococcal carriage") is 
believed to be essential for subsequent infection (46). A longitudinal study of infants from 
Alabama demonstrated that nasopharyngeal acquisition of a pneumococcal serotype was 
followed, within one month, by infection (mostly ADM) in 15% of cases (47). Invasive 
pneumococcal serotypes were found more frequently in nasal specimens at lower 
respiratory infection sampling points than at healthy sampling points in a cohort of Papua 
New Guinean children (48). Due to the inherent difficulties of obtaining invasive disease 
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isolates, nasopharyngeal colonisation data have been used to determine the likely serotypes 
and antimicrobial resistance of pneumococci causing invasive disease (49-52). 
Individual serotypes have different disease potentials, and this appears to be 
determined by both capsule and other genetic determinants. In Papua New Guinean 
children, Smith et al. found that invasion was more related to acquisition than persistence 
in the nasopharynx. Certain serotypes, notably 1, 5, and 46, were found to be highly 
invasive but rarely isolated from nasopharyngeal specimens (53). Brueggeman and 
colleagues compared invasive and carriage isolates in the UK and found that the most 
invasive serotypes (1, 5, and serogroup 7) were the least frequently carried and the least 
invasive serotypes (serogroups 6, 19, and 23) were the most frequently carried (54). The 
same group also determined that there was little variability in invasive potential amongst 
different clones (as defined by MLST) of the same serotype, but that there was 
considerable variability in the invasiveness of different serotypes of the same MLST 
genotype (55). Similar results were reported from Finland (56). Interestingly Sandgren et 
al. determined that Swedish pneumococcal strains of the same serotype, but different 
MLST genotype, had different invasive potentials suggesting that the capsule is not the 
sole determinant of invasiveness (57). 
There are also temporal and geographic trends in serotypes resulting in invasive 
infections (58). For example, invasive infections due to serotype 2 were noted to disappear 
from Boston in 1967 but this serotype has recently emerged as the commonest meningitis-
associated serotype in Bangladesh (59, 60). Feikin and Klugman reviewed several invasive 
pneumococcal disease datasets from the USA, covering the period 1928 - 1998. In both 
adults and children, they found a significant decline in the proportion of infections caused 
by the so-called "epidemic" serotypes (1 - 3 and 5) and a significant increase in infections 
by the PCV7 serogroup/types (4,6,9, 14, 18, 19, and 23). The authors concluded that 
changes in sampling (a trend towards lower thresholds for taking blood cultures over time), 
antimicrobial prescribing practices, socioeconomic conditions, and population-level 
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immunocompromise (due to an ageing population and the arrival ofHN infection) could 
account for this shift (61). Scott et al. reviewed over 7,000 episodes of invasive 
pneumococcal infection from 13 existing datasets and determined that disease due to 
serotypes 1 and 5 was more common in South America compared with the other 
geographic regions included in the analysis. Clear differences in the age distribution of 
disease caused by individual serotypes were found: risk of serotype 1 disease declined 
progressively through life and the opposite was true for serotype 3 (62). Similar results 
were described by Hausdorff and colleagues in an analysis of global vaccine coverage (63). 
The proportion of invasive pneumococcal disease caused by PCV7 serogroups was found 
to vary by geographic area (significantly lower in South America and Asia) and age group 
(lower coverage in older children and adults). This paper highlighted the relatively small 
dataset from the Asian region from which conclusions regarding invasive pneumococcal 
disease could be made. This point has been reinforced in several subsequent reviews (2, 
64, 65). In the most recent summary of South East Asian data, Jauneikaite et al. concluded 
that the most common serotypes associated with invasive disease were 19F, 23F, 14,68, 1, 
19 A, and 3. Of note, several of the poorest countries from the region contributed either 
limited or no data, for example Laos, Cambodia, or Myanmar (66). 
PCVs reduce colonisation by serotypes covered by the vaccine (67). Non-vaccine 
serotype colonisation increases as a result of this, leading to an increase in NVT invasive 
disease (68). Therefore, studies of nasopharyngeal colonisation are an important 
component of surveillance, both pre- and post-pneumococcal vaccine introduction (69). 
1.5. Pneumococcal colonisation dynamics in early childhood 
Streptococcus pneumoniae is considered part of the normal human nasopharyngeal 
flora and colonisation is particularly common in the young. There have been many studies 
of pneumococcal colonisation (summarised in (70) and (46), and the following discussion 
focuses on studies from World Bank defined low-income countries from Asia and Africa, 
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comparing with studies from other countries and regions where appropriate. Cross-
sectional studies including serotype prevalence meeting these criteria and all longitudinal 
carriage studies commencing at or around birth are summarised in Table 3 and Table 4. 
1.5.1. Acquisitions 
In developing world populations nasopharyngeal acquisition of pneumococci 
occurs very early in life. Studies in Papua New Guinea have documented a median age at 
acquisition of 19 days and universal colonisation by three months of age (71, 72). Similar 
studies in The Gambia found a median age of acquisition of 24 days and universal 
colonisation within the first year oflife (73). A recent intensive study of 1,404 Kenyan 
infants over the first three months of life showed a median time to acquisition of 38.5 days, 
with a pneumococcal acquisition rate of 0.0189 (95% CI 0.0177 - 0.0202) per day (74). In 
the past, similar pneumococcal acquisition rates were observed in high-income country 
infants. For example, 15.2% ofa cohort of99 Glaswegian infants born in 1950 were 
colonised within the first week oflife and 62.6% had been colonised at least once by 47 
weeks of age (75). In the 1970s, Gray and co-workers demonstrated a mean age at 
pneumococcal acquisition of six months and near universal colonisation within the first 
two years of life in a cohort of 82 Alabaman infants (47). More recent studies have shown 
more modest acquisition rates. In the Finnish infant cohort study, 11 % of infants had been 
colonised by two months, rising to 56% by 12 months and 87% by 24 months (76). 
Following primary acquisition in infancy, frequent re-acquisition of pneumococci 
may occur. In a longitudinal study of children aged six weeks to six years in a US day-care 
centre, children followed for more than 24 months carried between two and 12 
pneumococcal serotypes. Re-acquisition of the same serotype was not uncommon, and up 
to four reacquisitions of an individual serotype were documented (77). Hill et al. 
documented 1,145 episodes of carriage in 236 Gambian infants followed over the first year 
oflife: 909 episodes occurred after clearance ofthe first acquired pneumococcus (73). 
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1.5.2. Carriage duration 
Carriage duration varies by both serotype and age, although methodological 
differences between studies including definitions of a serotype "carriage episode" can 
make direct comparison difficult. However, some consistent observations have been made. 
Certain serotypes, notably 1 and 5, are carried for very short durations and are therefore 
rarely isolated from the nasopharynx despite being responsible for a significant proportion 
of invasive disease (53, 78, 79). Others, notably serogroups 6, 19, and 23, may be carried 
for long periods (47, 53, 72, 73, 77, 78). Capsule size has been found to correlate with 
carriage prevalence (80). Larger capsules are more resistant to neutrophil phagocytosis, 
which may result in prolonged carriage duration (81). 
1.5.3. Risk factors for colonisation 
Several factors have been associated with increased rates of pneumococcal carriage 
in children: age <2 years, overcrowding, antibiotic use, day-care attendance, and parental 
smoking (51, 82, 83). Pneumococci are transmitted primarily via respiratory droplets, 
which is likely to be particularly effective in crowded home~ or day-care centres and may 
be enhanced by coryza (74, 79, 84). A study of carriage in Southern Vietnam determined 
that children living in rural areas were more likely to be carriers than those living in urban 
and suburban areas (85). Interestingly, a study from Hong Kong found that the carriage 
rate of S. pneumoniae was significantly higher in ethnic Vietnamese compared to Chinese 
children (86). Traditional risk factors for colonisation, namely age, overcrowding, and 
parental smoking, could not explain this difference. Differences in carriage prevalence by 
ethnic group were not found in The Gambia or Nigeria (87, 88). In Western Australia, 
Aboriginal children were colonised by pneumococci considerably earlier than non-
Aboriginal children living in the same geographic area. By six months, 76% of Aboriginal 
and 47% of non-Aboriginal children had been colonised (89). 
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Table 3. Cross-sectional studies of pneumococcal colonisation and serotype distribution in children from World Bank defined low-income 
0 
African and Asian countries M 
Country Year Location N Age Health status Specimen % %PCV7 Ill. non- Commonest five Reference 
group colonised serotypes typeable serotype/groups 
Bangladesh 1999- 2000 Mixed 2,839 <5y Healthy Nasal swab 46 ND ND 6,9, 15,23, 16 (90) 
CAR· 1997 Urban 630 2-59m Out-patient visits NPS 60 47 ND 19F, 6B, 6A, 14,23B (91) 
China 1999 Urban 269 <5y Out-patient visits Nasal swab 37 ND 21 19,6,14,23,17 (92) 
China 1999- 2005 Urban 2,425 <5y Unwell (URTI) NPS 27 ND ND 19,23,6,14,15 (93) 
Fiji 2003 -4 Mixed 774 3-13m Healthy NPS 44 31 4 6A, 23F, 19F, 6B (94) 
Gambia 1989- 91 Rural 113 <5y Healthy NPS 76 ND 0 19,6,23,9, 15 (95) 
India Pub. 2007 Urban 200 3m-3y Out-patient visits NPS 7 85 8 1,6, 14, 19, NT (96) 
Indonesia 1997 Mixed 484 0-25m Healthy NPS 48 61 11 6,23, NT, 15,33 (97) 
Kenyaa 2004 Mixed 349 0-4y Community - all NPS 57 47 1 19F, 6B, 6A, 23F, 14 (98) 
Malawi 1997 Rural 906 2-59m Out-patient visits NPS 84 43 0 6A, 19A, 23F, 19F (99) 
Mozambique 2003 Rural 285 <5y Out-patient visits NPS 87 49 5 19F, 19A, 23F, 6A, 6B (100) 
Nepal 2003 -4 Rural 1,100 I-36m Healthy & unwell (ARI) NPS 79 58 ND 6, 19,23, 15,9 (101) 
Nigeriaa Pub. 2012 Peri-urban 375 <5y Community - all NPS 71 46 3b 19F, 6A, 6B, 23F, 15B (88) 
Thailanda 2002-4 Rural -425 <5y Unwell (ILl/pneumonia) NPS 60 55 lIb ND (102) 
Vietnam· Pub. 2000 Mixed 389 <5y Community - all Nasal swab 49 ND 6b 14, 19, and 23 (103) 
Vietnama 2003 -4 Mixed 722 <5y Community - all Nasal swab 47 ND 20b 19, 23, NT, 6,14 (85) 
Zambia 1994 Rural 260 <6y Out-patient visits NPS 72 ND ND ND (104) 
·Central Asian Republics 
• Studies also included children ~5y and/or adults 
b Not restricted to isolates from children <5y 
Table 4. Longitudinal studies of pneumococcal colonisation from birth 
-Country Year Location N Follow-up Swabs Swab Pneumococcal Carriage %PCV7 % non- Commonest five Reference M 
~eriod {/infant} interval acguisition duration? serotypes typeable serotype/grou~s 
Australia 1992 - 3 Rural 50 0-270d ND 2-4w Median age 58d No ND ND ND (105) 
>90% by 120d 
(Aboriginal data) 
Bangladesh 2000-1 Rural 99 0-12m 16 Varied 50%by8w No ND 3 6, 19,15,23, 10 (106) 
90% by21w 
lOO% by 12m 
Costa Rica 1988 - 92 Mixed 440 0-12m 4or52 3m or lw 95 -100% by 1y No ND ND ND (107) 
Finland 1994- 5 Urban 329 2-24m lO Varied 11%by2m No 53 5 6B, 23F, 19F, 6A, 11 (76) 
56% by 12m 
87% by 24m 
Gambia Pub. 2008 Rural 236 0-12m 16 Varied Median age 24d Yes 46 ND 6B, 19F, 6A, 14, 23F (73) 
100% by 12m 
Gambia Pub. 2010 Rural 196 0-12m 4 Varied 98% by 12m Yes 43 ND 19F, 6A, 6B, 14, 23F (l08) 
India 1994- 5 Not 100 0-18m 7 Varied Median age 11 w Yes ND ND 6,19,14,15,23 (109) 
stated 81% by 18m 
India 1998 - 9 Rural 464 0-6m 3 2m 54% by 2m No ND ND 23, 19,6,15,14 (110) 
86% by6m 
Kenya 2006-9 Mixed 1404 0-13w ::::15 Varied Median age 38.5d No 36 0 19F, 6A, 6B, 23F, 23B (74) 
Rate 0.01891 day 
Papua New Pub. 1986 Rural 25 O-::::lOm ND 5-14d 60% by 15d Yes ND ND ND (72) 
Guinea 100% by 3m 
Philippines Pub. 2006 Not 173 0-10m 6 Varied 50% by lOw No ND ND ND (111) 
stated 90% by 10m 
Country Year Location N Follow-up Swabs Swab Pneumococcal Carriage 0/. PCV7 0/. non- Commonest five Reference 
~eriod {/infant} interval acguisition duration? serotypes typeable serotype/grou~s 
Sweden 1985 - 8 Urban 468 0-10 or 30r4 4m 11% by 2m No ND ND ND (112) N M 
18m 34%by4m 
48% by 10m 
UK Pub. 1999 Urban 72 0-6/18m 7 1m ND No ND ND ND (113) 
UK 1999- Not 213 0-24w 9 Varied 15% by4w Yes 56 0 6B,19F,23F,14,6A (78,114) 
2001 stated 48% by 12w 
54% by 24w 
USA 1974- 5 Urban 82 0-24m 12 Varied Mean age 6m Yes ND 1 6, 19,23, 14,9 (47) 
96% by 24m 
Zambia 2003-4 Peri- 128 0-18m 7 3m No acquisition data No 44 6 19F, 6B, 23F, 15, 14 (115) 
urban 26% swabs positive 
1.6. Colonisation in older individuals 
Cross-sectional studies have documented a fall in pneumococcal colonisation 
prevalence with increasing age. In Kenya, pneumococcal carriage prevalence was 57% for 
0-4 year olds, 41 % for 5 - 9 year oIds, and 6.4% for 10- 85 year olds (98). Similar 
trends were seen in Nigeria and The Gambia, although adult carriage prevalence was 
significantly higher (87,88). In Sa Kaeo province on the Eastern border of Thailand, 
carriage prevalence fell from 60% in children under five years to 16% in adults fifty years 
or older (102). In the UK, colonisation prevalence was 52% in children under two years 
and 8% in adults (~18 years) in a longitudinal household study (116). 
Carriage duration has also been shown to decrease with increasing age. In the 
Gambian village study, the mean duration of carriage decreased from 27.9 weeks for 
children aged <1 year to 2.9 weeks in adults aged ~40 years (79). Similar findings were 
documented in studies of carriage of penicillin-resistant pneumococci in Sweden (117, 
118). 
The development of mucosal immunity and less frequent exposure are potential 
contributors to this age-related decline in colonisation and carriage duration (119-121). 
1.7. Non-typeable pneumococci and colonisation 
Pneumococci that fail to type with anti-sera may be either non-encapsulated 
"rough" strains as a result of deletion or disruption of the cps locus, encapsulated strains 
with intermittent or low level capsule expression, or encapsulated strains of a novel 
capsular type (122). Early in the 20th century Griffiths demonstrated that encapsulated 
pneumococci could become rough on prolonged or repeated sub-culture on solid media 
(123). 
A detailed description of rough pneumococci was given by Paul in 1927 (124). At 
this time, it had already been recognised that these organisms were non-encapsulated 
pneumococcal forms of low virulence, although they could be isolated from the sputum of 
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pneumonia cases (125). More recent publications have found that these organisms can be 
associated with outbreaks of mucosal disease, especially conjunctivitis (126-132). 
However, it has recently be confIrmed that non-typeable (NT) pneumococci, either due to 
absent or down-regulated capsular biosynthesis genes, can also cause invasive infection 
(133). 
Several studies have determined that non-typeable pneumococci may be either 
genetically "typical" pneumococci or more "atypical" organisms, clustering outside of the 
S. pneumoniae group and closer to S. mitis (9, 134). Isolates of the recently described 
species S. pseudopneumoniae may also be misidentifIed as NT pneumococci (135). As has 
been the case for typical encapsulated pneumococci, globally successful NT lineages have 
been identifIed (e.g. ST344 and ST448) (131, 136). 
The cps locus in NT pneumococci may be disrupted by the presence of either an 
aliB-type locus (referred to as aUe / aUD in reference (137» or the presence of a novel 
surface protein gene (nspA / pspK) (137-139). On the basis o,fpredicted structure and 
murine colonisation model data, the novel surface protein gene may be required for 
successful colonisation of the nasopharynx. 
It is hard to fully assess the prevalence of these organisms from carriage studies, 
since they are not consistently identifIed or reported. Additionally, with the increasing 
reliance on molecular serotyping tools which mostly cannot identify all known serotypes, 
the reported prevalence of PCR non-typeable pneumococci may not equate to the 
prevalence of antisera non-typeable pneumococci. The percentage of pneumococci that 
were non-typeable ranged from 0 - 21 % in the studies described in Table 3 and a study of 
Spanish primary school children found 44.5% of carried pneumococci were non-typeable 
(140). Simoes et al. showed that the detection of NT pneumococcal colonisation increased 
three-fold (from 2.9% to 8.6% of nasopharyngeal specimens), when a multiplex-PCR assay 
designed specifIcally to identify NT pneumococci was compared with culture of 
Portuguese nasopharyngeal specimens by the WHO (World Health Organisation) protocol 
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(141). Using a combination of multiplex PCR and micro array, Brugger et a1. detennined 
that NT pneumococci were more frequently identified in individuals as a co-coloniser 
, 
rather than as the only colonising pneumococcal "type" (142). Marsh et a1. determined that! 
non-typeable pneumococcal carriage rates were 5 - 20% in Indigenous Australian children, : 
and that these organisms were frequently drug resistant (39). It has been shown that NT 
pneumococci may act as a reservoir for drug resistance genes which may be transferred to 
encapsulated pneumococcal strains (143). 
1.S. Colonisation by multiple pneumococcal serotypes 
It has long been appreciated that multiple pneumococcal serotypes may co-exist in 
the nasopharynx. Using mouse inoculation, it was found that 14% of nasopharyngeal 
swabs from families of pneumonia cases contained> 1 pneumococcal serotype and that the 
prevalence of multiple serotype carriage was highest in children (144). Gratten et a1. 
serotyped up to six colonies from nasal swab culture plates and found multiple serotype 
carriage in 29.5% of Papua New Guinean children (145). Using multiplex PCR, a second 
serotype was found in 20% of pneumococcal colonised Waro'Amerindian Children (146). 
1.8.1. Detection of multiple serotype colonisation 
Detection of multiple pneumococcal serotype colonisation is challenging. Early 
work relied on mouse inoculation and was very labour intensive (144). Using agar-based 
culture, colony morphology rarely distinguishes between pneumococcal serotypes with a 
few exceptions (e.g. serotype 3 and NT pneumococci). Work from Papua New Guinea 
determined that multiple serotypes were not present in equal abundance in the 
nasopharynx. By serotyping 50 individual colonies from nasal swab cultures, Gratten and 
colleagues found that a minor serotype was present at a relative abundance of 4 - 27% in 
5/10 specimens (145). Brugger et a1. confirmed this result by ply PCR and tenninal-RFLP 
analysis. They found a median ratio ofserotypes of 1:3.8 (range 1:1 - 1:45) in 41 co-
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colonised individuals, i.e. the minority serotype was present at a median 26% (range 2 -
50%) relative abundance (142). 
It would not be practical, or cost-effective, to serotype large numbers of colonies to 
determine multiple serotype colonisation in a large carriage study. It has been estimated 
that, to reliably detect a minor serotype of 25% relative abundance, 11 colonies would need 
to be serotyped and this rises to 59 colonies in order to detect a serotype at a relative 
abundance of 5% (147). An Australian study concluded that picking four colonies for 
serotyping by random selection was more effective at identifying multiple serotype 
colonisation than picking colonies on the basis of morphological differences (17% vs. 14% 
of specimens) (148). 
Several techniques have been developed to improve the detection of mUltiple 
serotype carriage. A colony blot method was described by Bogaert et aI., which could 
detect multiple serotypes in the ratio of 1: 1000 (149). Bronsdon and colleagues described a 
similar method, but theirs was limited to the detection of a small number of serotypes 
(150). Researchers in The Gambia developed a latex agglutination technique where a 
sweep of colonies from the primary nasopharyngeal swab (NPS) culture plate were 
suspended in saline and serotyped by latex agglutination. Using this method in a 
longitudinal infant cohort study, up to 10.4% of pneumococcal acquisitions were found to 
be acquisitions of multiple serotypes (73). A broth enrichment step followed by either 
conventional Quellung typing or multiplex PCR improved both detection of pneumococci 
and multiple serotype carriage in studies from Denmark and the USA (25, 151). However, 
recent data from CDC suggest that the molecular approach may have flawed specificity 
due to the presence of pneumococcal cps locus homo logs in closely related streptococcal 
species including S. oraUs (152). A combined Luminex-based multiplex immunoassay and 
PCR has been demonstrated to be able to correctly identify multiple serotypes in laboratory 
generated mixed cultures, down to a relative abundance of 10% and perhaps lower (28). 
Recently, progress has been made in the detection of multiple serotype colonisation 
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directly from the NPS specimen. When restricted to the 29 PCR-detectable serotypes, 
Antonio et al. found that multiplex-PCR directly from the NPS-STGG specimen detected 
more serotypes per NPS than culture and sweep serotyping using the latex agglutination 
technique (153). PCR of the non-coding region of the pneumolysin (ply) gene followed by 
terminal-RFLP analysis improved detection of pneumococci and multiple serotype co-
colonisation directly from NPS specimens in a Swiss study: this method could detect 
multiple serotypes down to a ratio of 1:100 (154). A pneumococcal micro array developed 
by the Bacterial Microarray Group (BIlG@S) at St George's London correctly identified 
serotypes at a relative abundance of 1 % in mixed NPS specimens or cultures (29). 
I.S.2. Rationale for study of multiple serotype colonisation 
Understanding the prevalence and dynamics of carriage of multiple pneumococcal 
serotypes is of considerable importance now that there is widespread deployment of 
pneumococcal conjugate vaccine and reports of increasing numbers of cases of invasive 
pneumococcal disease due to non-vaccine types (69). Immunisation with a vaccine 
covering only a few of the >90 serotypes may result in replacement disease by less 
commonly carried pneumococcal types (155). Pneumococcal serotypes compete within the 
nasopharynx, as evidenced by the increased colonisation by non-vaccine serotypes 
following introduction of PCV (156). This intra-species competition may be mediated by 
bacteriocins (157) or antimicrobial pep tides of the innate immune system (158). In a 
murine model, resident pneumococci could prevent establishment of a new serotype 
introduced into the nasopharynx. This could be overcome by introducing a larger inoculum 
of the challenge serotype without affecting the growth of the resident serotype (159). 
However, in a rat model, pneumococcal strains of two serotypes 4 and 6B were able to co-
exist in the nasopharynx, with the invading serotype becoming 25 - 90% of the total 
pneumococcal population over 96 hours (160). Competition between serotypes in the 
human nasopharynx has been mathematically modelled using Markov models and data 
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from longitudinal carriage studies perfonned in the UK and Kenya. In the UK, Melegaro 
and colleagues studied five serotypes (6A, 6B, 14, 19F, and 23F) and detennined the 
"challenge strengthn and "resistance" for each. Both of these competition parameters were 
lower for serotypes 19F and 23F than for 6A and 6B (161). Using the Kenyan dataset, 
Lipsitch et al. studied 27 serotypes and detennined that serotype 19F was the serotype 
most resistant to competition (i.e. its presence in the nasopharynx resulted in lower rates of 
acquisition of other serotypes compared with non-colonised individuals) (162). Molecular 
approaches may clarify some of the contradictions noted when analysing datasets by 
serotype. 
1.9. Transmission of pneumococci within the household 
In the 1930-40s, it was demonstrated that family members of pneumococcal 
pneumonia patients were often colonised by the same pneumococcal serotype (144, 163). 
The detailed longitudinal studies on respiratory infections and upper respiratory tract 
colonisation perfonned in Paddington families in the 1950s identified that school aged 
children were most often associated with introduction and spread of pneumococci within 
the household (164, 165). Transmission occurred more frequently in crowded dwellings. 
The proportion of individuals in whom pneumococci could be detected increased in the 
days following the onset of coryzal symptoms, suggesting coryza enhanced pneumococcal 
transmission. Interestingly, studies of a cohort of 3 8 families in Syracuse, New York state 
did not find an association between crowding and transmission of pneumococci (166, 167). 
Hendley et al. detennined that young children were more commonly colonised than older 
children or adults in a study of Virginian families (168). They found higher carriage rates 
in adults from households including young children compared with adults from households 
with older children or no children. Transmission within the family was common and often 
associated with upper respiratory tract infection (84). As part of the FinOM infant cohort, 
100 families were also swabbed at the same time points as the study infant. After the age of 
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six months, carriage of the same pneumococcal type in another family member was the 
strongest predictor of carriage in the study infant (169). One hundred and twenty one 
complete UK families were swabbed monthly for 10 months in 2001-2. Young children 
were found to be important introducers of pneumococci into the household. Carriage in 
older family members was strongly associated with carriage in other household members 
(OR for carriage in the :::5y age group if another family member colonised: 2.25 (95% CI 
1.65 - 3.08» (116). Subsequent modelling of this dataset confirmed that children are more 
likely to acquire pneumococci from the community than adults. Adults were found to be 
more infectious but less susceptible to infection than children. Transmission within the 
family was associated with larger households, i.e. the proportion of household-acquired 
colonisations increased as the number of people in the household increased (170). 
Pneumococcal colonisation and transmission has also been documented to be frequent in 
other crowded settings, such as day care centres (171, 172), orphanages (173), schools 
(174), and prisons (175). 
Data regarding transmission of pneumococci in developinp country settings are 
scarce. Darboe and colleagues modelled transmission of pneumococci within 196 Gambian . 
mother-infant pairs. They concluded that there was a nine-fold increase in the odds of 
identifying a particular serotype in an infant if the same serotype was carried by the 
mother. However, they determined that only 9.5% of infant carriage could be attributed to 
carriage in the mothers (108). Nineteen complete Gambian households were studied bi-
weekly for a year by Hill and colleagues. Their findings were in agreement with the UK 
study, in that individuals were more likely to be colonised if there were other colonised 
household members. A detailed molecular study of serotype 6B confirmed that children 
tended to initiate transmission of the strain within a household (79). Clustering of 
pneumococcal genotypes within households was also documented in a study of a Brazilian 
urban slum community (176). 
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1.10. Immune responses to pneumococcal colonisation 
The immune response to pneumococcal colonisation is complex, most likely 
involving both B-cell and T-cell pathways, and remains incompletely understood. Some 
experimental murine models have suggested a relatively limited role for antibody in the 
clearance of nasopharyngeal colonisation and that a CD-4+ T-cell pathway mediated by IL-
17 A is the dominant mechanism involved in immunity to pneumococcal colonisation (177, 
178). In support of this are the results of a recent study which found greater IL-17 A 
responses to pneumococcal antigens in adults and children from Bangladesh compared 
with those from Sweden, perhaps reflecting their greater exposure to pneumococci (179). 
Using a mathematical modelling approach, Cobey and Lipsitch have demonstrated 
that a combination of weak serotype-specific immune responses (anti-capsular antibody 
. mediated) and non-specific immunity (e.g. IL-17 A or anti-protein antibody mediated) 
permit the on-going coexistence of>90 pneumococcal serotypes (180). The serotype-
specific antibody responses act to stabilise competition, and non-specific immunity reduces 
fitness differences, between the serotypes. 
1.10.1. Anti-capsular polysaccharide antibodies 
Anti-capsular antibodies are an important defence against pneumococcal infection, 
and the capsular polysaccharides of 7 - 23 pneumococcal serotypes are included in current 
pneumococcal vaccines (3-6, 181, 182). 
Colonisation in adult humans does result in a rise in serum serotype-specific anti-
capsular polysaccharide immunoglobulin G (IgG) (183, 184), although these antibodies 
may not protect against nasopharyngeal acquisition (185). Nasopharyngeal exposure to 
pneumococci, in the absence of subsequent colonisation, did not induce a serum serotype-
specific IgG response in an experimental colonisation model in adult humans (186). 
Pneumococcal conjugate vaccine studies in young children have shown that serum anti-
capsular IgG protects against nasopharyngeal acquisition by, and may reduce colonisation 
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density of, pneumococcal serotypes covered by the vaccine (67, 156). Dagan and co-
workers observed reduced nasopharyngeal acquisition of serotypes 14 and 19F in Israeli 
toddlers aged 12 - 35 months following administration ofa nine-valent PCV: the 
probability of acquisition was inversely correlated with serum anti-capsular IgG 
concentration (187). In the control group of this study, previous nasopharyngeal exposure 
to a serotype protected against subsequent colonisation by the homologous serotype and, 
for serotypes 14 and 23F (but not the other serotypes studied), this was related to the 
production of specific anti-capsular serum IgG (120). In children aged less than two years, 
infant cohort studies and PCV vaccine studies have demonstrated the generally limited 
development of serotype-specific serum anti-capsular antibodies in the absence of PCV 
immunisation (67, 182, 188-192). However, these previous studies of pneumococcal 
colonisation and immune responses in the under two year-olds included relatively 
infrequent sampling points which restricted potential for the study of immune responses to 
individual pneumococcal serotype acquisitions. 
1.10.2. Anti-protein antibodies 
The next generation of pneumococcal vaccines would ideally protect against all 
serotypes by targeting conserved cell surface or virulence proteins, to avoid that issue of 
serotype replacement disease observed following the introduction of PC V (69, 193). 
Vaccines to several protein antigens have been demonstrated to provide protection against 
invasive pneumococcal disease in mouse models. These proteins include the pneumococcal 
pilus (PI-I, comprising three subunits RrgA, RrgB, and RrgC), pneumococcal surface 
adhesin A (PsaA), pneumococcal surface protein A (PspA), pneumococcal surface protein 
C / choline binding protein A (PspC/CbpA), pneumolysin (Ply), histidine triad proteins 
(PhtA-E), neuraminidase (NanA), iron transport proteins (PiuA, PiaA) and also novel 
proteins, such as a protein required for cell wall separation of group B streptococcus 
(PesB) and serine/threonine protein kinase (StkP), discovered by ANTI GENome scanning 
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(194, 195). Many of these proteins are important for successful pneumococcal colonisation 
and/or disease (196). 
Anti-protein antibody development in response to pneumococcal colonisation has 
been studied in by several groups in a variety of settings. Whilst many of these proteins are 
well-conserved, some are not found in all pneumococci. This factor, coupled with the 
difference in immunogenicity between the various proteins, may explain some of the 
variation in antibody response seen (8, 197). 
1.10.2.1. Finland infant cohort 
Serum IgG concentrations to a variety of pneumococcal proteins were studied in up 
to 329 infants and their mothers. In this cohort, 87% of infants had been colonised by 
pneumococci by 24 months. 
Development of antibodies to Ply, PsaA, and PspA was correlated with 
pneumococcal exposure. At 24 months the infant antibody geometric mean concentration 
(GMC) was greater than the mother GMC for anti-PsaA, similar'to the mother GMC for 
anti-Ply, and less than the mother GMC for anti-PspA IgG (198). Most infants developed 
higher concentrations of IgG to the PspA family (family-lor -2) they were exposed to but 
mothers had high serum concentrations of IgG to both PspA families (199). A higher 
serum anti-PspA IgG concentration at each time point predicted a greater risk of 
colonisation in the subsequent six months (200). 
Serum IgG concentrations to Eno (a-enolase), Iga (immunoglobulin Al protease), 
SlrA (streptococcal lipoprotein rotamase A), and PpmA (putative proteinase maturation 
protein A) were measured in infants with ADM. There were no differences in GMC when 
stratified by previous pneumococcal exposure, suggesting that the stimulus for antibody 
production was probably exposure to cross-reactive epitopes on other nasopharyngeal 
commensal organisms (201). Higher anti-PpmA antibody titres at 18 months of age 
reduced the risk of ADM in the subsequent six months (202). 
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Exposure to pneumococci resulted in higher serum IgG concentrations to PhtB, 
PhtE and CbpA, but at 24 months infant GMCs were lower than mother GMCs. For anti-
PhtB and anti-PhtE, higher IgG concentrations were associated with increased risk of 
pneumococcal colonisation in the subsequent six months but there was no association with 
ADM risk (203). Higher anti-CbpA titres were associated with decreased risk of ADM in 
the subsequent 6 months (204). 
Infant serum IgG concentrations to NanA were similar to adult levels by 24 
months. There was no association found between anti-NanA antibodies and risk of 
subsequent pneumococcal colonisation or ADM (205). 
1.10.2.2. Netherlands infant cohorts 
The Netherlands Generation R study included a longitudinal analysis of antibody 
responses to 17 pneumococcal proteins, measured by Luminex assay, and pneumococcal 
carriage over the first two years oflife in 57 infants (206). Four paired serum and NPS 
samples were collected between birth and 24 months of age. 17.5% of infants were 
colonised by 1.5 months of age. There was no evidence of protection against colonisation 
by maternal serum IgG to any of the proteins. Higher titres of antibodies to BVH-3, NanA, ~ 
PpmA, PsaA, SlrA, SPOI89, and SPlO03 were associated with a decreased number of 
respiratory infections in the third year of life but none were associated with a reduction in 
pneumococcal colonisation. Another study from The Netherlands looked at colonisation 
and serum IgG to 18 pneumococcal proteins in infants followed from birth until 24 months . 
of age as part ofa PCV trial. Sera collected from infants at 12 and 24 months of age were 
analysed. Previous pneumococcal colonisation was associated with higher serum IgG titres . 
but there was no evidence of protection from subsequent colonisation (207). 
1.10.2.3. UK children 
The relationship between pneumococcal carriage and antibodies to CbpA, Ply, 
PsaA, and PspA was assessed in a cross-sectional study of healthy children and those 
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undergoing adenoidectomy (aged 2 - 12 years). Serum JgG antibody concentrations to all 
but PsaA increased with age: anti-PsaA JgG concentration was static after five months of 
age. Serum JgG concentrations were higher in children non-colonised compared with 
pneumococcus colonised children over the age of two years, suggesting that pre-existing -
antibodies may have a protective effect against colonisation (208). Although these results 
agree with a similar study in younger Gambian children (209), the cross-sectional nature of 
the study invites caution when interpreting this rmding: higher antibody levels in non-
colonised children might reflect recent immune mediated clearance of colonisation and not 
protection per se. In the Finland studies described above, higher antibody levels at 24 
months were generally positively correlated with pneumococcal exposure over the study 
period (198, 204). 
1.10.2.4. Papua New Guinea infant cohort 
Eighty nine mother-infant pairs were studied in the first four weeks of life to 
determine the relationship between mother and cord serum anti-Ply and anti-PspA 
(families 1 and 2) JgG titres on the timing of infant pneumococcal acquisition in an area 
where all infants are colonised by pneumococcus at a very early age (71). Three quarters 
(76%) of infants were colonised within four weeks of birth (median age 19 days). Maternal 
carriage at birth (30%, commoner in younger mothers) was associated with earlier infant 
colonisation and there was a trend to later colonisation in infants of older mothers. There 
was good correlation between mother and cord IgG titres, but cord titres were lower 
(median 7.2-fold for anti-Ply; 1.8-fold of anti-PspA family 1; 1.7-fold for anti-PspA family 
2). There was good correlation between JgG titres to PspA family 1 and PspA family 2 
titres, but not between anti-PspA1I2 and anti-Ply. There was no association between 
maternal antibody titres and carriage status at birth. In a multivariate model including all 
antibodies, and adjusting for maternal age and delivery carriage status, a higher 
maternaVcord anti-Ply titre was associated with delayed acquisition in the infant and a 
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higher maternal/cord anti-PspA family 1 (but not anti-PspA family 2) titre was associated 
with earlier acquisition. 
1.10.2.5. Philippines infant cohort 
Antibodies to various pneumococcal proteins were studied as part of the MATER 
cohort. Infants were followed during the first year of life and 90% had been colonised by 
pneumococci by six months. 
Mother and cord blood antibody GMCs were similar for all three proteins. Infant 
antibody GMCs to Ply and PspA increased from 18 - 20 weeks but were still lower than 
mother-cord levels at 48 weeks. Anti-PsaA development was different: there was a rapid 
increase in GMC from the first infant sampling point (seven weeks) and the infant 14 week; 
GMC was already greater than the mother GMC. Infants exposed to pneumococci had 
higher GMCs than non-exposed infants and this was significant for anti-PsaA and anti-Ply, ~ 
, 
but not for anti-PspA. A higher seven week anti-Ply concentration (i.e. maternally-derived I 
I 
l 
, 
antibodies) resulted in decreased risk of pneumococcal acquisition in the first three months i 
oflife (111). 
Development of serum IgG antibodies to PhtD, CbpA, and LytC (an autolysin) in 
infants was correlated with pneumococcal colonisation. Anti-LytC antibody development 
was similar to that seen for antibodies to NanA (Finnish cohort) and PsaA (Philippines 
cohort): a more rapid increase in GMC in early infancy, reaching adults levels within the 
first two years of life. (210). 
1.10.2.6. Gambian infant study 
Forty Gambian infants were sampled between three and five months of age. The 
serum IgG anti-PsaA GMC was significantly lower in pneumococcal carriers than in non· 
carriers, suggesting a protective effect of anti-PsaA antibodies on carriage acquisition in 
early infancy. (209). 
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1.10.2.7. Kenyan cross-sectional study 
A cross-sectional population survey of anti-PsaA, -PspA, and -Ply IgG was done in 
Kilifi. Serum anti-PspA and -Ply IgG concentrations increased in infancy and then levelled 
out with no decline observed in the elderly. Concentrations of serum anti-PsaA IgG were 
level throughout, indicating very early development in infancy (211). 
1.10.2.8. Experimental human carriage studies 
McCool and co-workers found that serum IgG to the N-terminal region of PspA 
prevented colonisation in adult humans and this molecule was immunogenic in those who 
became colonised (212). Analysis of serum IgG development in response to colonisation 
by 6B or 23F in human adults found that colonisation induced a significant serum IgG 
response to CbpA and PspA, but not to other proteins (PsaA, PpmA, Ply, IgAI protease, 
and lipotechoic acid) (213). 
1.11. Potential modifiers of pneumococcal colonisation dynamics 
1.11.1. Pneumococcal pilus 
Various cell-surface components, including pneumococcal surface adhesin A (PsaA), 
choline-binding protein A (CbpA), pneumococcal serine-rich repeat protein (PsrP) and 
pneumococcal adherence-virulence factor A (PavA) have been demonstrated to contribute 
to nasopharyngeal adherence and colonisation, but their mechanisms of action remain 
incompletely understood (46, 214-217). The RrgA subunit of the surface exposed pilus-l 
filamentous structure also enhances pneumococcal adherence to respiratory epithelial cells 
in vitro (218, 219). Pneumococcal pilus-l is encoded by the pilus islet-l (PI-I; rlrA islet) 
and is composed of three subunits, RrgA, RrgB, and RrgC (219-221). Since immunisation 
with pilus antigens is protective against lethal intraperitoneal challenge in a mouse model, 
pilus subunits are regarded as potential candidates for inclusion in a protein-based 
pneumococcal vaccine (222). However, PI-l presence is not universal: studies of 
46 
predominantly invasive pneumococci have found that PI-1 is present in isolates from a 
limited number ofserotypes (particularly those included in the 7-valent conjugate vaccine, 
peV7) and that its presence correlates with genotype by MLST (8, 197, 223-226). Given 
the prevalence of asymptomatic colonisation, and that serotype/genotype structure of 
invasive pneumococci is not stable (58), further work to describe the prevalence and 
function of the pilus-l in pneumococcal carriage strains is warranted. 
1.11.2. Bacterial and viral nasopharyngeal colonisers 
1.11.2.1. Bacteria 
Bacterial colonisation of the nasopharynx is a dynamic and interactive process. The 
nasopharynx is colonised with non-pathogenic (predominantly a-haemolytic streptococci) 
and potentially pathogenic micro-organisms (Haemophilus injluenzae, Moraxella 
catarrhalis, Staphylococcus aureus, and S. pneumoniae) (227). Non-pathogenic members 
of the upper respiratory tract flora may inhibit the growth of potential pathogens (228). 
Johanson et al. found that 82% of oropharyngeal cultures from 101 healthy adults 
contained organisms, predominantly a-haemolytic streptococci, capable of inhibiting S. 
pneumoniae (229). Brook and Gober showed that a wide range of organisms could inhibit 
common respiratory pathogens. These "protective" organisms were found significantly less 
frequently in the nasopharynges of otitis media (OM) prone children compared with 
healthy controls (230). Faden et al. discovered that carriage of S. pneumoniae, H. 
injluenzae, and M. catarrhalis increased significantly during episodes of otitis media, 
whilst the carriage of non-pathogens decreased (231). Pneumococcal vaccination has been 
associated with an increased incidence of acute otitis media caused by S. aureus (232). 
Several studies of children, from geographically diverse locations including The Gambia, 
Israel, The Netherlands and Papua New Guinea, have demonstrated a negative correlation 
between colonisation with S. aureus and S. pneumoniae, particularly those serotypes of 
pneumococcus covered by the seven valent conjugate vaccine (48, 233-235). Hydrogen 
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peroxide produced by pneumococcal strains may be responsible for this interference (236, 
237), although a recent study has also implicated the pneumococcal pilus as a mechanism 
by which pneumococci inhibit co-colonisation with S. aureus (238). Interestingly, there 
was absence of a negative association between colonisation by S. pneumoniae and S. 
aureus in HIV positive South African infants suggesting the mucosal immune system may 
be important in the regulation of co-colonisation by these species (239). However, 
development of serum antibodies to S. aureus or S. pneumoniae does not appear to mediate 
this phenomenon (240). Previous studies have generally documented positive correlations 
between nasopharyngeal colonisation by S. pneumoniae, H injluenzae, and M catarrhalis 
(105,235,241-243). In a rat model of colonisation, Margolis et al. determined that 
colonisation by either S. aureus or S. pneumoniae enhanced subsequent colonisation by H. 
injluenzae. Multiple strains of S. aureus were not able to co-exist: the resident strain was 
able to resist invasion by a newly introduced strain. Multiple strains of S. pneumoniae or 
H injluenzae were able to co-exist in the nasopharynx, although occasionally an immune 
response to H injluenzae colonisation limited nasopharyngeal acquisition of S. 
pneumoniae (160). Lysenko and colleagues also found that colonisation by H injluenzae 
could enhance clearance of S. pneumoniae from the nasopharynx by complement-
dependent neutrophil killing (244). Increasing use of metagenomic sequencing techniques 
directly on nasopharyngeal specimens is likely to lead to a greater understanding of 
between-species colonisation dynamics (245,246). 
1.11.2.2. Viruses 
The important role of viral infections as precursors of pneumococcal disease is well 
recognised. Infection by influenza viruses, respiratory syncytial virus, and rhinoviruses has 
been temporally linked to pneumococcal disease in both historical and contemporary 
studies (247-253). 
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Co-infection with bacteria is common in "viral" ARI, occurring in 3 - 30% of cases i 
(254). Madhi et al. recently reported the results of a PCV9 vaccine study involving nearly ; 
40,000 South African infants (255). They demonstrated that, in addition to a 20% reduction; 
in total number of episodes of pneumonia, a 31 % reduction in the number of cases of 
virus-associated pneumonia was seen in infants receiving the vaccine compared to the 
control group. Pneumonias associated with RSV decreased by 22% and those associated 
with influenza A decreased by 45%, suggesting that S. pneumoniae super-infection occurs 
in a significant proportion of virus-associated pneumonias. 
Viral infection of the respiratory tract predisposes to bacterial colonisation/super-
infection by several mechanisms (256, 257). Non-specific mechanisms include viral-
induced damage to the respiratory epithelium, resulting in impairment of ciliary function. 
Influenza neuraminidase may expose pneumococcal receptors on the upper respiratory 
tract epithelium, thus increasing adherence of S. pneumoniae (258). Also, in a murine 
model, influenza A infection increases type I interferon production resulting in decreased 
macrophage-mediated clearance of colonising pneumococci from the.nasopharynx (259). 
Virus-mediated up-regulation of the platelet activating factor receptor may also enhance 
adhesion of pneumococci to the respiratory epithelium (260). Similarly, RSV infection 
increases pneumococcal adherence to the upper respiratory tract epithelium and this is 
mediated by the RSV G glycoprotein (261,262). 
1.12. Study rationale and objectives 
1.12.1. Rationale for the study 
As stated previously, S. pneumoniae is estimated to be responsible for -10% of 
deaths in children aged <5 years (2). Since almost a third of the world's children live in 
Southeast Asia, this pathogen is likely to be of considerable importance but there is a 
paucity of data on pneumococcal colonisation and disease in the region (2, 63, 65). 
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Infant immunisation with pneumococcal conjugate vaccines is now routine in many 
countries including those that are GA VI eligible (263). In addition to the prevention of 
invasive disease, pneumonia, otitis media and aU-cause mortality, PCVs have been shown 
to reduce colonisation by the serotypes covered by the vaccine which has led to adaptive 
alterations in the serotypes colonising the nasopharynx and causing disease (67,68). 
Surveillance of colonisation is an important component of the vaccination monitoring 
process and robust pre-vaccine era data are important in the planning of introduction and 
assessment of impact (69). 
Given the large number of serotypes and many potential modifying agents, 
including other nasopharyngeal colonisers, respiratory virus infection, infant immune 
system maturation and antibiotic use, pneumococcal colonisation dynamics are best 
understood from longitudinal data (47, 72, 73, 76, 89, 105-110, 112-116). Such studies are 
difficult to perform so few have been comprehensive with regard to follow-up duration, 
consistency of sampling intervals, and clinical data collection to permit assessment of 
potential modifiers of pneumococcal carriage. Various sampling and culture methods have 
been described, adding to the heterogeneity between studies and prompting the 
development of a WHO standard protocol for pneumococcal nasopharyngeal colonisation 
detection (70). 
1.12.2. Research question 
What is the natural history and outcome of Streptococcus pneumoniae colonisation 
in infancy in the presence or absence of specific maternal and infant immunity and 
simultaneous colonisation/infection with other bacteria and viruses? 
1.12.3. Hypotheses to be tested 
• Early nasopharyngeal colonisation with S. pneumoniae leads either to an immune 
response to the bacterium, with subsequent protection from disease and eradication, 
or to carriage, or to an episode of clinical disease. 
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• Current methods of estimating nasopharyngeal pneumococcal carriage lack 
sensitivity, and improved methods, particularly focussed on identifying 
simultaneous multiple carriage, would significantly add to our understanding of 
nasopharyngeal carriage acquisition, duration and disease. 
• Pneumococcal acquisition can be profoundly influenced by simultaneous viral 
infection or colonisation of the nasopharynx. 
1.12.4. Additional aims and objectives 
• Determine the frequency of transmission of pneumococcal strains between mother 
and infant. 
• Assess the contribution of maternally-derived antibodies to the timing of first 
pneumococcal colonisation in infants. 
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2 Methods 
2.1. Study site 
Maela is a camp for displaced persons from Myanmar (Burma), located 
approximately 500 Ian from Bangkok in Tak province on the North-western border of 
Thailand (Figure 2). The camp covers an area of 4 km2 and is situated in forested hills 
approximately five kilometres from the border with Myanmar (Figure 3 & 
Figure 4). The climate is tropical, with three defmed seasons: hot (March - May), wet 
(June - October), and cool (November - February) (Figure 5). 
Figure 2. Map of Thailand and Myanmar 
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Figure 3. Satellite image of Maela camp 
Figure 4. Photograph of Maela camp 
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Figure 5. Meteorological data for Mae Sot, 2007 - 2010 
(Data provided by Mae Sot Meteorological Station, Thai Meteorological Department) 
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2.1.1. Camp population 
Refugees from Myanmar began arriving at Maela in 1984. In September 2007 the 
official population was 42,652, accounting for 30.1 % of all Burmese officially registered 
refugees in Thailand (figures from http://www.tbbc.org/camps/populations.htm). The 
Karen are the predominant ethnic group living in Maela. 
2.1.2. Health in Maela 
At the commencement of the study, only aggregate health statistics were available 
for the refugee population on the Thailand-Myanmar border: camp-specific data were not 
published in the annual CCSDPT (Committee for Coordination of Services to Displaced 
Persons in Thailand) report (264). Comparing these data with WHO figures for Myanmar 
and Thailand demonstrates that neonatal, infant, and <5 year mortality figures fell between 
those for Myanmar and Thailand (Table 5) (265). 
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Table 5. Key health statistics for border refugee camps, Myanmar, and Thailand 
Health indicator Myanmar (265) Thailand (265) Border camps (264) 
Infant Mortality Rate 50 (2010) 11 (2010) 20 (2006) 
(/1000 live births) 
Neonatal Mortality Rate 32 (2010) 8 (2010) 11 (2006) 
(/1000 live births) 
<5yr Mortality Rate 66 (2010) 13 (2010) 28 (2006) 
(/1000 population) 
Deaths <5 due to 19 (2004) 11 (2004) 9a (2006) 
pneumonia (%) (266) 
'Reported as deaths due to LRTI and not specifically pneumonia 
In 2006, 15% of the refugee population were less than five years of age and only 
9% were 45 years or older. Lower respiratory tract infections (LRTI) were the cause of 9% .. 
of deaths, and were responsible for 25% of all reported morbidity, in the under-5 age group 
(264). 
General healthcare is provided to the camp population by the NGO Premiere 
Urgence-Aide Medicale Intemationale (PU-AMI), who have both in-patient and out-
patient facilities staffed by a combination of local medical staff and expatriate physicians. 
PU-AMI is also responsible for public health activities, including infant immunisations. 
WHO Expanded Program on Immunisation (EPI) recommended immunisations are offered· 
to camp residents, and in 2006 CCSDPT reported >90% coverage for all infant 
immunisations in the refugee population (264). Pneumococcal conjugate, Hib, and 
influenza vaccines are not available in the camp. 
Antenatal care and malaria treatment has been provided by Shoklo Malaria 
Research Unit (SMRU) since 1986. Approximately one hundred locally trained medics, 
nurses, and home visitors run the SMRU clinic in Maela, under the supervision of 
expatriate physicians. 
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2.2. Study design 
The work contained in this thesis formed part of a larger cohort study of infant 
pneumonia epidemiology carried out at Maela between 2007 and 2010. 
2.2.1. Sample size calculation 
For the overall cohort, the sample size calculation was based on observation of 
clinical pneumonia episodes. Using the published estimated incidence of clinical 
pneumonia in developing world children «5y) of 0.28 episodes/child-year (267), a sample 
size of 1,000 infants followed for two years would be expected to result in the observation 
of 560 (95% CI 520 - 600) pneumonia episodes. Assuming a 1 % per month dropout rate, 
this would result in 886 infants being followed for 12 months and 786 being followed for 
the entire 24 months, potentially permitting the observation of approximately 520 clinical 
pneumonia episodes. 
For the pneumococcal carriage study, a 1 in 4 randomisation at recruitment would 
result in 250 mother-infant pairs being included. Assuming an overall carriage prevalence 
of 80% in infants and a 1 % per month dropout rate, approximately 4,500 pneumococci 
would be isolated. Assuming a carriage prevalence of 20% in the mother, approximately 
1,100 pneumococci would be isolated. These figures would permit detection of serotypes 
present at 1 % of the total carried pneumococcal population. Given that its prevalence is 
likely to be underestimated by standard culture methodology, the detection of multiple 
pneumococcal serotype colonisation was not included as a factor in the sample size 
calculation (70, 145). 
2.2.2. Recruitment 
Between October 2007 and November 2008, all pregnant women attending the 
SMRU antenatal clinic at 28 - 30 weeks gestation were invited to consent to their infant's 
participation in the cohort study. One thousand allocation codes were generated by Dr 
Verena Carrara, SMRU epidemiologist: 750 for participation in the "routine" follow-up 
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group and 250 for participation in the "immunology" follow-up group. Using sealed 
opaque envelopes containing an allocation code, women were randomly allocated to either 
the "routine" or "immunology" follow-up groups (Figure 6). 
The only exclusion criterion was related to likely departure from Maela during the 
study follow-up period: women who were actively planning resettlement to a third country 
were not eligible for study enrolment. 
Figure 6. Cohort design and follow-up 
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Women were encouraged to deliver at the SMRU clinic and all were reviewed 
around the time of delivery. Mothers were asked to bring their infant to monthly follow-up 
visits until the infant reached 24 months of age. Specimen collection varied by follow-up 
group (Figure 6). Mothers were also requested to bring their infant for review at the SMRU 
clinic when unwell for whatever reason. All study activities occurring in Maela were 
supervised by Dr Claudia Turner, SMRU consultant paediatrician. 
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2.2.3. Study visits 
2.2.3.1. Delivery visit 
All women had a NPS collected around the time of delivery to determine 
pneumococcal colonisation status. Additional specimens were collected from mothers 
randomised to the "immunology" follow-up group: 5 mL venous blood was taken from 
both mother and umbilical cord. Details regarding the woman's health, pregnancy history, 
and household structure were recorded (Appendix 1). Following delivery, study infants 
underwent a full newborn examination (Appendix 1). 
In the event of a home delivery, women were requested to attend the SMRU clinic 
with their infant for review as soon as possible after delivery. 
2.2.3.2. Monthly visits 
At each monthly visit, a health questionnaire was completed to document illnesses 
occurring in the previous month. Anthropometric measurements, including weight, height, 
and arm circumference, were taken at these visits (Appendix 1). A nasopharyngeal swab 
(NPS) was taken from all infants. Mothers in the "immunology" follow-up group also had 
a NPS taken. Immunology follow-up group infants had a 0.5 mL venous blood specimen 
collected at each visit, with larger volumes of blood (5 mL) being collected at the 6, 12, 18, 
and 24 month visit. 
In the event of a missed monthly visit, home visitors made contact with the family 
at home to reschedule the appointment. 
2.2.3.3. Illness visits 
Infants were reviewed at the SMRU clinic during illness episodes. Clinical 
pneumonia was diagnosed following the WHO Integrated Management of Childhood 
Illnesses (lMCI) criteria (Table 6) (268) , and included the ''very severe" pneumonia 
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category as specified in the WHO Pocket Book of Hospital Care for Children (269). 
Clinical data were recorded on a standard illness CRF (Appendix 1). 
All children diagnosed with pneumonia had a chest x-ray (Mae Ramat hospital, 
Mae Ramat, Thailand), nasopharyngeal aspirate (NPA), NPS, and venous blood taken. 
Chest x-rays were interpreted in accordance with the WHO standardised criteria (270). 
Treatment followed SMRU Paediatric Guidelines. 
Table 6. Clinical pneumonia diagnostic criteria 
Pneumonia severity 
Pneumonia 
Severe pneumonia 
Definition 
Cough OR difficulty breathing 
AND 
Fast respiratory rate-
Cough OR difficulty breathing 
AND 
Lower chest wall indrawing 
Very severe pneumonia Cough OR difficulty breathing 
AND 
• Measured over one minute 
Central cyanosis OR severe respiratory distress 
OR inability to drink 
2.2.4. Specimen collection 
2.2.4.1. Nasopharyngeal swabs 
Notes 
Fast RR definition: 
<2 months: ~60 
2 - 11 months: ~50 
12 - 59 months: ~40 
Fast RR may not be present 
Fast RR may not be present' 
Nasopharyngeal swabs were collected in accordance with the WHO standard 
protocol for detection of pneumococcal nasopharyngeal colonisation (70). A Dacron-tipped 
flexible shaft swab (MW15ID; Medical Wire & Equipment, Corsham, UK) was inserted 
into the nasopharynx, rotated, and withdrawn. If significant resistance was encountered the , 
other nostril was used. The swab tip was excised immediately into a cryovial containing 1 
mL STGG medium (skimmed milk, tryptone, glucose, glycerol medium; prepared in-
59 
house) using 70% ethanol-cleaned scissors. NPS-STGG specimens were transferred to the 
SMRU laboratory in Mae Sot in a cool box, within eight hours of collection, and frozen at 
-80°C until culture. All specimens were vortexed for 15 seconds prior to freezing. 
2.2.4.2. Nasopharyngeal aspirates 
A sterile 8-French infant feeding tube was inserted into the nasopharynx and then 
withdrawn while suction was applied with a 20 mL syringe attached to the feeding tube. 
The nasopharyngeal secretions and the tip of the feeding tube were transferred to a cryovial 
containing I mL viral transport medium (VTM, MEM-Hanks' with 0.5% gelatin, 
amphotericin B, penicillin, streptomycin; prepared in-house) and were transferred daily to 
the Mae Sot laboratory in a cool box and frozen at -80°C until analysis by rRT-PCR. 
2.2.4.3. Serum specimens 
Venous blood was collected into plain blood tubes (Teklab, Sakriston, UK). Serum 
was separated by centrifugation at 3,000 rpm for 10 minutes in the Mael,a clinic laboratory. 
Serum specimens were transferred daily to the Mae Sot laboratory in a cool box and frozen 
at -80°C until analysis. 
2.2.5. Specimen processing 
All core bacteriology and molecular work was done in the SMRU microbiology 
laboratory (Mae Sot, Thailand). Additional work was performed in collaborating 
laboratories as described below and in the subsequent chapters. 
2.2.5.1. Nasopharyngeal swabs 
2.2.5.1.1. General comments 
Nasopharyngeal swabs were cultured in batches of between 50 and 150 per week. 
Prior to culture, the NPS-STGG specimens were fully thawed and vortexed for 15 seconds. 
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2.2.5.1.2. Detection of Streptococcus pneumoniae 
Using disposable calibrated loops (Sterilin, Newport, UK), 10 ilL of thawed NPS-
STGG was streaked onto 5% sheep blood-CNA agar (bioMerieux, Marcy L'Etoile, France) 
and incubated overnight at 36°C in 5% CO2• In the absence of growth, plates were 
incubated for a further 24 hours before being discarded. All morphologically distinct 
alpha-haemolytic colonies were sub-cultured onto plain 5% sheep blood agar (Clinical 
Diagnostics, Bangkok, Thailand). In the absence of morphologic variation, two 
representative colonies were sub-cultured. S. pneumoniae was identified by colonial 
morphology and optochin disc susceptibility (5 Ilg / 6 mm optochin disc; Oxoid, 
Basingstoke, UK), defined as zone diameter of~14 mm. Isolates with reduced optochin 
disc zone diameters (7 - 13 mm) were confirmed as pneumococci by the tube bile 
solubility test (271). Where colonial morphology and optochin zone diameter was identical ! 
in both sub-cultured colonies, only one of the isolates was followed further. Whilst this 
colony selection methodology might underestimate multiple serotype colonisation, it is 
likely to identify the dominant serotype in each specimen as well as correctly identify the 
most common serotypes in a study population (148, 272). The standardised WHO ProtOcol 
permits direct comparison with other datasets using the same methodology. 
2.2.5.1.3. Detection of other bacterial species 
For infant specimens only, a further 10 ilL of thawed NPS-STGG was streaked 
onto a chocolate agar plate (Clinical Diagnostics, Bangkok, Thailand), a 10 unit bacitracin 
disc (Oxoid, Basingstoke, UK) applied to the first streak, and the plate incubated overnight 
at 36°C in 5% C02. In the absence of growth, plates were incubated for a further 24 hours 
before being discarded. 
Target organisms were Haemophilus injluenzae, Moraxella catarrhalis, and 
Staphylococcus aureus. These organisms were identified using standard microbiological 
techniques as outlined in Table 7. 
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Table 7. Identification of non-pneumococcal nasopharyngeal colonisers 
Organism Identification tests 
Haemophilus injluenzae Bacitracina resistant 
Gram stain 
Moraxella catarrhalis 
Staphylococcus aureus 
a Oxoid, Basingstoke, UK 
X + Va factor dependent growth 
Typical colony characteristics 
Gram stain 
Trybutyrin positivec 
Gram stain 
Catalase positive 
Coagulase 
DNase 
b Becton Dickinson, Franklin Lakes NJ, USA 
C Rosco Diatabs, Taastrup, Denmark 
Notes 
Serotyping by slide agglutinationS 
Growth on both CNA-blood and chocolate 
plates 
S. aureus: coagulase and DNase positive 
CoNS: coagulase and DNase negative 
2.2.5.2. Further work on Streptococcus pneumoniae isolates 
2.2.5.2.1. Serotyping 
All pneumococcal isolates were serotyped by latex agglutination (19, 273). Latex 
serotyping reagents were prepared in-house, using a protocol kindly supplied by Prof 
Richard Adegbola (MRC Laboratories, The Gambia). Briefly, a 0.5 McFarland suspension 
of pure overnight culture of pneumococci was made in 0.85% saline. This suspension was 
first tested with latex antisera pools A - I, followed by all appropriate group, type, and 
factor latex antisera. Ten microliters of pneumococcal suspension was mixed with the 
same volume of latex antiserum on a clean glass slide. The slide was rocked on an orbital 
shaker for up to two minutes. A positive result was indicated by clear agglutination with 
clearing of the background. Traditional serotyping, using the Quellung reaction, was 
performed on isolates with equivocal latex serotype results (274). Serotype 6A isolates 
were confirmed as either serotype 6A or 6C by PCR, as described elsewhere (275). 
Non-typeable pneumococci, either morphologically typical pneumococcal colonies 
(likely encapsulated organisms) or rough colonies (likely non-encapsulated organisms) 
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were provisionally identified when weak agglutination with pool Band serogroup 19 latex 
antisera, but no agglutination with group 19 factor antisera (19b, 19c, 19f, 7h), was 
observed. These isolates, along with those completely non-reactive with typing antisera, 
were confirmed by bile solubility and absent capsular swelling with Omniserum (SSI 
Diagnostica, Statens Serum Institute, Hillerod, Denmark) (274). To avoid over-estimation 
of the prevalence of NT pneumococci as a result of capsule locus loss during prolonged or 
multiple sub-culture, serotyping was performed on colonies picked from overnight cultures 
only (123). Ifrepeat serotyping was subsequently required, it was performed on colonies 
picked from overnight culture of isolates stored at -80°C in STGG since primary isolation. 
2.2.5.2.2. Antimicrobial susceptibility testing 
Antimicrobial susceptibilities were determined for all S. pneumoniae isolates. The 
modified Kirby-Bauer disk diffusion method was used and zone diameter were interpreted 
using CLSI guidelines (2007 version, Table 8) (276, 277). Minimum inhibitory 
concentrations for benzyl penicillin and ceftriaxone were determined by the Etest method 
(AB Biodisk, Solna, Sweden) for isolates with an oxacillin disc zone diameter of <20 mm 
(Table 9) (276). Etests were performed in accordance with manufacturer's instructions 
with the exception that organism suspensions were made in 0.85% saline solution rather 
than broth, following confirmation from AB Biodisk that this was an acceptable 
alternative. 
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Table 8. Zone diameter interpretive criteria for Streptococcus pneumoniae 
Drug Disc (J.lg)8 
Zone diameter (mm) 
Resistant Intermediate Susceptible 
Oxacillinb ~20 
Erythromycin 15 :::;15 16 - 20 ~21 
Clindamycin 2 :::;15 16 - 18 ~19 
Tetracycline 30 :::;18 19 - 22 ~23 
Chloramphenicol 30 :::;20 ~21 
Co-trimoxazole 1.25/23.75 :::;15 16 - 18 ~19 
a Oxoid, Basingstoke, UK 
bTo determine penicillin susceptibility 
Table 9. MIC interpretive criteria for Streptococcus pneumoniae 
Drug 
Resistant 
Benzyl penicillin ~2 
Ceftriaxone ~4 
MIC (Jlg/mL) 
Intermediate 
0.12 - 1 
2 
2.2.5.3. N asopbaryngeal aspirates 
Susceptible 
:::;0.06 
:::;1 
NPA specimens were processed in weekly batches. Viral nucleic acid was extracted 
from the thawed NPA-VTM specimens using the QIAamp viral RNA mini kit (Qiagen, 
Hilden, Germany), following the manufacturer's instructions. Extracts were analysed by 
rRT-PCR for adenoviruses, human metapneumovirus, influenza viruses (influenza A 
(seasonal HINI, seasonal H3N2 and pandemic HINI) and influenza B), and respiratory 
syncytial virus, as described elsewhere (278, 279). A human RNaseP PCR was used to 
detect the presence of inhibitors in the NPA-VIM specimens (280). A Rotorgene 6000 
real-time PCR thermocycler (Corbett Life Science, Sydney, Australia) and SuperScript III 
One-Step RI-PCR kits (Invitrogen, Carlsbad CA, USA) were used throughout. Positive 
and negative controls were included in every PCR run. 
Specimens were considered positive if a virus PCR cT value was <40 with 
appropriate run control results. Specimens with low positive PCR results (cT values of35 
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- 39) were repeated: only if the cT was <40 in both runs was the virus PCR considered 
positive. 
2.2.5.4. Quality control in the SMRU microbiology laboratory 
Written SOPs were developed for all laboratory activities (Appendix 2). 
All new batches of culture media (commercial or in-house prepared) were tested for 
sterility, the ability to support growth of target organisms, and, where appropriate, the 
ability to inhibit non-target organisms. Antimicrobial discs were quality controlled on a 
weekly basis according to CLSI guidelines (276). Similarly, Etests were tested on a 
monthly basis. All bacterial identification tests were performed with appropriate positive 
and negative controls. 
The molecular laboratory workflow was strictly controlled to avoid contamination: 
master mix preparation, nucleic acid extraction, amplification, and gel electrophoresis took 
place in separate laboratory rooms. 
The laboratory participated in the Thailand national external quality assurance 
scheme (DMSc unit code MI 1158). In 2008, the laboratory passed a one-off US-CDC 
organised quality assurance exercise for respiratory virus detection. 
2.2.5.5. Serum specimens 
All serology work was performed by staff at the WHO reference laboratory for 
pneumococcal serology in the Institute of Child Health (London, UK), under the 
supervision of Prof David Goldblatt. This work is described in sections 5.1.4.3 and 5.2.4.3. 
2.2.6. Data management and analysis 
Clinical data were double-entered into an Access 2003 database (Microsoft, 
Richmond WA, USA) and the databases merged to identify data entry errors. Laboratory 
data were single-entered into the database and all entries were checked against the original 
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laboratory CRFs at the completion of the study. Statistical analyses were performed in 
StatalIC 12.1 (StataCorp, College Station TX, USA). 
2.2.7. Ethical considerations 
Written informed consent was obtained from the women prior to study enrolment. 
Participant information sheets and consent forms were translated into both Karen and 
Burmese languages. In the event of a woman being unable to read or write, the information 
sheet was read out loud by one of the consent team, her thumbprint used in place of a 
written signature, and the consent form counter-signed by a witness. 
Ethical approval was granted by the ethics committees of the Faculty of Tropical 
Medicine, Mahidol University, Thailand (MUTM-2007-014 / MUTM-2009-306) and 
Oxford Tropical Research Ethics Committee, Oxford University, UK (OXTREC-031-06). 
66 
3 Pneumococcal colonisation dynamics in infants and mothers 
3.1. A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants 
and their mothers on the Thailand-Myanmar border 
3.1.1. Summary 
Background 
Pneumococcal disease is a major cause of childhood death. Almost a third of the world's 
children live in Southeast Asia, but there are few data from the region on pneumococcal 
colonisation or disease. The study aim was to document the characteristics of 
pneumococcal carriage in an isolated SE Asian birth cohort. 
Methods 
Two hundred and thirty four Karen mother-infant pairs were studied. Infants were 
followed from birth and nasopharyngeal swabs were taken from mother and infant at 
monthly intervals until the infant was 24 months old. NPS were cultured following WHO 
methodology and all cultured pneumococci were serotyped by latex agglutination and had 
antimicrobial susceptibilities determined by disc diffusion testing. 
Results 
8,386 swabs were cultured and 4,396 pneumococci characterised. Infants became 
colonised early (median 46 days; 95% CI 45 - 46) and by 24 months had a median of seven 
(range 0 - 15) carriage episodes. Maternal smoking and additional young children in the 
house were associated with earlier colonisation (HR 1.5 (95% CI 1.1 - 2.1) and 1.4 (95% 
ClI.O - 1.9)). For the four commonest serotypes and non-typeable pneumococci, previous 
exposure to homologous or heterologous serotypes resulted in an extended interval to 
reacquisition of the same serotype. Previous colonisation by serotypes 14 and 19F was also 1 
[ 
associated with reduced carriage duration if subsequently reacquired (HR for first 
reacquisition 4.1 (95% CI 1.4 - 12.6) and 2.6 (1.5 - 4.7)). Mothers acquired pneumococci 
less frequently, and carried them for shorter periods, than their infants (acquisition rate 0.5 
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vs. 1.1 1100 person-days, P < 0.001; median duration 31 vs. 61 days, P = .001). 55.8% of 
pneumococci from infants were vaccine serotypes (I3-valent pneumococcal conjugate 
vaccine, PCV13), compared with 27.5% from mothers (P < 0.001). Non-typeable 
pneumococcal carriage was common, being carried at least once by 55.1 % of infants and 
32.0% of mothers. 34.6% and 26.9% of pneumococci from infants and mothers, 
respectively, were multi-drug resistant. Infants co-habiting with other young children were 
at greater risk of being colonised by drug resistant pneumococci (OR 1.2 (95% CI 1.2 -
1.8». 
Conclusions 
Pneumococcal carriage frequency and duration are influenced by previous exposure to 
both homologous and heterologous serotypes. These data will inform vaccination strategies 
in this population. 
3.1.2. Introduction 
Streptococcus pneumoniae is estimated to be responsible for -10% of deaths in 
children aged <5 years (2). Since almost a third of the world's children live in Southeast 
Asia, this pathogen is likely to be of considerable importance but there is a paucity of data 
on pneumococcal disease in the region (2, 63, 65). Infant immunisation with pneumococcal 
conjugate vaccines is now routine in many countries including those that are GA VI eligible 
(263). In addition to the prevention of invasive disease, pneumonia, otitis media and all-
cause mortality, PCV s have been shown to reduce colonisation by the serotypes covered by 
the vaccine which has led to adaptive alterations in the serotypes colonising the 
nasopharynx and causing disease (67, 68). Surveillance of colonisation is an important 
component of the vaccination monitoring process and robust pre-vaccine era data are 
important in planning and assessment of impact (69). Given the large number of serotypes 
and many potential modifying agents, including other nasopharyngeal colonisers, 
respiratory virus infection, infant immune system maturation and antibiotic use, 
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pneumococcal colonisation dynamics are best understood from longitudinal data (47, 72, 
73, 76, 89, 105-110, 112-116). Such studies are complicated to perform so few have been 
comprehensive with regard to follow-up duration, consistency of sampling intervals, and 
clinical data collection to permit assessment of potential modifiers of pneumococcal 
carriage. Various sampling and culture methods have been described, adding to the 
heterogeneity between studies and prompting the development of a World Health 
Organisation standard protocol for pneumococcal nasopharyngeal colonisation detection 
(70). 
3.1.3. Aims and objectives 
The objectives of this study were to explore pneumococcal colonisation dynamics 
and modifiers in mother-infant pairs followed from birth for 24 months. The study was 
nested within a longitudinal study designed to establish the epidemiology and aetiology of 
pneumonia in a cohort of refugee children aged <2 years. The behaviour of serotypes 
included in the current conjugate vaccines was of particular interest, as they are the most 
prevalent serotypes causing disease and conjugate vaccines are known to interfere with 
pneumococcal transmission by perturbing nasopharyngeal colonisation. 
3.1.4. Methods 
3.1.4.1. Study site and population 
Between October 2007 and November 2008, all pregnant women attending the 
SMRU antenatal clinic in Maela camp were invited to consent to their infant's 
participation in the pneumonia cohort study. Using sealed opaque envelopes containing an 
allocation code, women were randomly allocated to the "immunology" (pneumococcal 
carriage) follow-up group at enrolment. Women enrolled into this "immunology" follow-
up group had an NPS taken at delivery and both infant and mother had a NPS taken at 
monthly surveillance visits from 1 - 24 months of age. 
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3.1.4.2. Sampling and laboratory procedures 
NPS were collected according to the WHO pneumococcal colonisation detection 
protocol and processed as described in sections 2.2.4.1 and 2.2.5.1 (70). Briefly, 
nasopharyngeal secretions were sampled using Dacron-tipped swabs (Medical Wire & 
Equipment, Corsham, UK) and the tip was immediately stored in a cryovial containing Iml 
STGG medium. NPS-STGG specimens were transferred to the laboratory in a cool box 
within eight hours of collection and were frozen at -80°C until culture. Ten microliters of 
thawed STGG was cultured onto sheep blood-CNA agar (bioMerieux, Marcy L'Etoile, 
France) and incubated overnight at 36°C in 5% CO2• All morphologically distinct alpha-
haemolytic colonies were sub-cultured onto plain sheep blood agar. S. pneumoniae was 
identified by colonial morphology, optochin disc susceptibility +1- bile solubility testing 
(271). Pneumococci were serotyped by latex agglutination and confirmed by Quellung 
typing if equivocal (19, 273). Serotype 6C was identified by PCR (275). Non-typeable 
isolates were confirmed by bile solubility and absence of capsular swelling with 
Omniserum (SSI Diagnostica Statens Serum Institute, Hillerod, Denmark) (274). 
Antimicrobial susceptibilities were determined by disk diffusion, following 2007 CLSI 
guidelines (276, 277). Etests (AB Biodisk, Solna, Sweden) were used to determine MICs 
to benzyl penicillin and ceftriaxone for all isolates with a growth inhibition zone diameter 
of <20 mm around the 1 Jlg oxacillin disc. 
3.1.4.3. Definition of carriage 
A carriage episode was defined as the period of time between acquisition and 
clearance of a pneumococcal serotype. Acquisition was identified when a pneumococcal 
serotype was cultured from a swab for the first time or when a serotype was re-cultured 
following clearance as defined below. Carriage episodes commenced at the midpoint 
between the last negative swab and the first positive swab for the serotype. Following 
acquisition, clearance of the serotype from the nasopharynx was considered to have 
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occurred when two consecutive swabs were culture negative for that serotype. Termination 
of the carriage episode was defined as the midpoint between the last positive swab and the 
first negative swab for the serotype (Figure 7) (73). Given the lability of their capsules, 
serotypes 15B and 15C were considered as a single serotype, labelled 15B/C (281). 
Figure 7. Definition of pneumococcal serotype carriage episode 
In thi s example, the individual first carries 6B and subsequently acquires 19F. Fol lowing 
clearance, there is reacquisition of serotype 6B. A = acquisition; B = clearance; C = 
carriage duration . 
A c B 
3.1.4.4. Data analysis 
Non-normally distributed continuous data were described by median and inter-
quartile range. Comparisons were made using the Wilcoxon rank-sum test. Categorical 
data were analysed by the chi-squared test. Logistic regression models, with either study 
participant identifier included as a random-effect or robust standard errors to control for 
repeated observations within individuals, were used to determine temporal changes in 
serotype distributions, multiple serotype detection, and transmission. Odds ratios, adjusted 
for the number ofNPS specimens per individual, were calculated to determine the 
likelihood of carriage of serotypes in infants or mothers. Generalised Estimating Equations 
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(GEE), with a logistic link and exchangeable correlation structure to account for repeated 
observations per individual, were used to identify the risks of reacquisition of commonly 
carried serotypes and to detennine the risks of acquisition of drug resistant pneumococci in 
infants (120). Assessments of GEE model fit were made using a modification to the 
Akaike infonnation criterion (AIC) (282). Time to pneumococcal acquisition and carriage 
duration were estimated by survival analysis, since some carriage episodes were censored. 
The log-rank test was used to compare groups. Survival models (Cox proportional hazards 
or parametric models using exponential or Weibull distributions) were used to assess 
potential predictors of acquisition and carriage duration (283). Model fit was assessed by 
examination of predicted Cox-Snell residuals, the AIC, and log-likelihood values. 
3.1.5. Results 
Of999 pregnant women recruited into the pneumonia cohort study, 250 were 
randomly allocated to the immunology follow-up group. Nineteen women and their babies 
did not attend the first follow-up visit (14 lost to follow-up, four neonatal deaths, and one 
stillbirth) resulting in 231 mothers and 234 infants (three sets of twins) who had at least 
one surveillance NPS collected. These 234 mother-infant pairs are included in the 
subsequent analyses. 
8,386 NPS were collected (73.6% of expected): 4,195 from mothers and 4,191 from 
infants (median 23 per individual; range 1- 24 for infants, 2 - 25 for mothers). The 
median mother-infant pair follow-up duration was 23.9 months post-delivery (728 days; 
range 28 -760). Overall there were 2,188 pneumococcal carriage episodes identified 
(1,504 infant; 684 mother): infants had a median of seven (range 0 - 15) carriage episodes, 
compared with a median of two (range 0 - 16) in mothers (P < .001). 
3.1.5.1. Acquisition dynamics in infants 
Infant acquisition was extremely rapid: by the three month visit 75.7% of infants 
had been colonised, increasing to 97.0% by six months. All but one infant remaining in the 
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study had acquired pneumococci at least once by the eleven month visit. The median age 
of fIrst acquisition was 46 days (95% CI 45 - 46), with an observed and modelled 
acquisition rate of 0.018 per day (Figure 8). 
Figure 8. Observed and modelled age at first pneumococcal acquisition in the cohort 
of infants 
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Carriage stabilised after seven months and point-prevalence remained between 67.6 
and 83.6% (Figure 9, top panel). Tw~nty percent of mothers were colonised by 
pneumococcus at delivery (+1- 7 days). This proportion increased after birth, peaking at 
30.6% at the four month visit and subsequently stabilising with monthly colonisation 
point-prevalence of 16.8 - 29.6% (Figure 9, bottom panel). 
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Figure 9. Cross-sectional pneumococcal carriage prevalence in infants and mothers 
by month of infant age 
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Potential associations between age at first acquisition and household size, presence 
of other young children in the house, ethnic group, prematurity (delivery <37 weeks 
gestation), home delivery, season of birth, maternal pneumococcal colonisation at birth, 
maternal smoking, or antibiotic consumption in the neonatal period were explored (Table 
10). The impact of feeding differences on colonisation age could not be assessed since 
breast feeding was almost universal. By univariate analysis, large households (>5 people), 
other children <5y in the house, mothers who smoked, and home delivery were all 
associated significantly with earlier acquisition age. In a multivariate Cox model, the 
presence of other children <5y in the house and maternal smoking remained associated 
significantly with an earlier age at first colonisation (children <5y: HR 1.47, P = .01; 
maternal smoking: HR 1.53, P = .01). Premature birth was associated with delayed 
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colonisation (HR 0.54, P = .04). There was a trend for female infants to become colonised 
at an earlier age than males (HR 1.34, P = .05). 
Table 10. Univariate and multivariate Cox regression analyses of potential factors 
influencing age at first pneumococcal acquisition in infants 
A Hazard Ratio> 1 indicates earlier age at first acquisition. All factors were included in the 
multivariate model. 
Factor Univariate model Multivariate model 
Hazard Ratio P Hazard Ratio P 
(95% CI) (95% CI) 
Household size >5 people 1.34 (1.02 - 1.76) .04 1.20 (0.89 - 1.62) .2 
Children <5y in the house 1.53 (1.17 -2.01) .002 1.47 (1.09 - 2.01) .01 
Mother smoker 1.63 (1.21 - 2.19) .001 1.53 (1.10 - 2.14) .01 
Ethnic group: 
SgawKaren 
-
PwoKaren 0.79 (0.51 - 1.24) .3 0.89 (0.55 - 1.44) .6 
Muslim 1.12 (0.78 - 1.75) .5 1.29 (0.84 - 1.98) .3 
Other 1.38 (0.56 - 3.36) .5 1.94 (0.77 -4.90) .2 
Season of birth: 
Hot (March - May) 
-
Wet (June - October) 0.75 (0.52 - 1.06) .1 0.85 (0.58 - 1.24) .4 
Cool (November - February) 1.08 (0.75 - 1.54) .7 1.13 (0.77 - 1.66) .5 
Horne delivery 1.56 (1.13 - 2.16) .007 1.23 (0.86 - 1.78) .3 
Prematurity 0.61 (0.38 -1.00) .05 0.54 (0.29 - 0.97) .04 
Female gender 1.20 (0.92 - 1.56) .2 1.34 (1.00 - 1.79) .05 
Mother colonised at birth 1.28 (0.92 - 1.77) .1 1.21 (0.86 - 1.72) .3 
Antibiotics in neonatal period 0.79 (0.52 - 1.22) .3 0.95 (0.58 - 1.55) .8 
Age at first acquisition was not significantly different between the commonest eight 
serotypes or between grouped vaccine (PCV13) serotypes, non-vaccine serotypes (NVT), 
and non-typeable (NT) pneumococci (Table 11). Estimates of individual serotype 
acquisition rates, excluding serotype reacquisitions, over the entire cohort follow-up period 
are summarised in Table 12 and Figure 10. 
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3.1.5.2. Pneumococcal carriage kinetics 
The median duration of the infants' first ever carriage episode was 63 days (95% CI 
61 - 90). Duration of carriage of serotypes 19F and 23F was longer (P < .001 and .008 
respectively), and NT pneumococci shorter (P = .01), than for the other serotypes (Table 
11). Following the first carriage episode, infants had 1,279 subsequent pneumococcal 
acquisitions: 620 in the first year oflife and 659 in the second. NT pneumococci, 19F, 23F, 
and 6B remained the most commonly carried serotypes (Table 11). Median age at second 
pneumococcal serotype acquisition was 111 days (95% CI 107 - 13 7), with no significant 
differences between PCVl3 serotypes, NVT, and NT pneumococci. The median interval 
between acquisitions was 62 days (95% CI 61 - 63). Considering all subsequent carriage 
episodes, PCV13 serotypes were carried for longer than NVT and NT pneumococci 
(medians 62, 46, and 34 days; P < .001), although there was substantial variation between 
individual serotypes (Table 11). Estimates of serotype specific clearance rates following 
primary acquisitions of the serotype are summarised in Table 12 and Figure 10. For 
serotypes with at least ten primary acquisitions, acquisition rates were correlated with 
prevalence (r = 0.99, P < .001) and log rates of acquisition and clearance were negatively 
correlated (r = -0.69, P < .001) (Figure 11). 
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Table 11. Age at acquisition and duration of pneumococcal carriage 
f' 
Ten commonest serotypes, ranked by number of carriage episodes. f' 
Infant: first episode Infant: aU subsequent episodes Mother: aU episodes 
Serotype N Acquisition age, d Carriage duration, d Serotype N Carriage duration, d Serotype N Carriage duration, d 
Median (95% CI) Median (95% CI) Median (95% CI) Median (95% CI)-
NT 35 46 (16 - 48) 31 (31 - 61) NT 160 34 (32 - 60) . NT 145 32 (31 - 51) 
19F 23 47 (16 - 80) 213 (78 - 243) 19F 146 92 (62 -120) 19F 50 31 (30 - 31) 
23F 21 45 (15 - 47) 184 (62 - 241) 23F 114 90 (62 - 94) 23F 31 31 (30 - 32) 
6B 14 44 (16 - 48) 120 (61 - 153) 6B 105 62 (58 - 91) 34 25 31 (30 - 59) 
35F 9 46b 121 (30 - 180) 14 72 87 (61 - 92) 3 23 46 (31 - 90) 
llA 8 46 (16 - 77) 60 (30 - 90) 15B/C 68 61 (49 - 91) 6B 23 31 (30 - 32) 
14 8 16 (13 - 83) 62 (30 - 151) 6A 60 63 (48 - 121) 14 22 32 (31 - 60) 
28F 8 46 (14 - 138) 61 (30 - 63) 6C 46 62 (33 - 94) llA 18 33 (30 - 48) 
4 7 16 (13 - 20) 84b 19A 43 59 (31- 63) 35C 18 32 (30 - 33) 
34 5 16b 123b 34 38 63 (32 - 134) 15B/C 16 32 (29 - 32) 
PCV13 95 44 (16 - 47) 116 (88 - 127) PCV13 611 62 (61 -76) PCV13 223 31 (31 - 32) 
NVT" 95 46 (44 - 46) 61 (57 - 87) NVT' 508 46 (33 - 58) NVT' 316 31 (31- 32) 
All 225 46 (44 - 46) 63 (61 - 90) AU 1,279 60 (57 - 61) AU 684 31 (31 - 32) 
& Duration calculated for 602 carriage episodes (acquisition date could not be calculated for carriage episodes including the first or second swab) 
bUnable to estimate 95% CI 
C Excluding non-typeable pneumococci 
Table 12. Pneumococcal acquisition and clearance rates in infants 
Time to first acquisition and subsequent clearance of the serotype (includes each infant's 
first episode of carriage for each serotype). Results for all serotypes with> 1 0 acquisitions. 
Serotype Episodes Acquisition Clearance 
(N) Rate (/day) 95% CI Rate (/day) 95%CI 
NT 129 0.00164 (0.00138 - 0.00195) 0.01351 (0.01124 - 0.01623) 
19F 111 0.00133 (0.00110 - 0.00160) 0.00608 (0.00497 - 0.00744) 
23F 101 0.00110 (0.00091 - 0.00134) 0.00666 (0.00535 - 0.00829) 
6B 85 0.00087 (0.00071 - 0.00108) 0.01007 (0.00808 - 0.01255) 
14 71 0.00067 (0.00053 - 0.00085) 0.00932 (0.00716 - 0.01214) 
15B/C 65 0.00058 (0.00046 - 0.00075) 0.01058 (0.00799 - 0.01399) 
6A 55 0.00049 (0.00037 - 0.00063) 0.00747 (0.00536 - 0.01040) 
6C 43 0.00038 (0.00028 - 0.00051) 0.01099 (0.00796 - 0.01516) 
19A 42 0.00036 (0.00027 - 0.00049) 0.01040 (0.00743 - 0.01456) 
34 38 0.00032 (0.00024 - 0.00044) 0.00843 (0.00574 - 0.01239) 
15A 28 0.00023 (0.00016 - 0.00034) 0.01284 (0.00846 - 0.01950) 
13 25 0.00021 (0.00014 - 0.00030) 0.01588 (0.01001 - 0.02521) 
38 23 0.00019 (0.00012 - 0.00028) 0.01744 (0.01068 - 0.02847) 
lOB 22 0.00018 (0.00012 - 0.00028) 0.01726 (0.01126 - 0.02648) 
35C 22 0.00018 (0.00012 - 0.00028) 0.01367 (0.00882 - 0.02120) 
18C 20 0.00016 (0.00011 - 0.00025) 0.02093 (0.01335 - 0.03281) 
llA 19 0.00016 (0.00010 - 0.00025) 0.01976 (0.01245 - 0.03136) 
9V 18 0.00015 (0.00009 - 0.00023) 0.01309 (0.00802 - 0.02137) 
21 18 0.00015 (0.00009 - 0.00023) 0.01319 (0.00820 - 0.02122) 
23A 18 0.00015 (0.00009 - 0.00024) 0.01264 (0.00775 - 0.02064) 
33B 17 0.00014 (0.00009 - 0.00022) 0.01009 (0.00608 - 0.01674) 
9N 16 0.00013 (0.00008 - 0.00021) 0.01742 (0.01050 - 0.02890) 
28F 16 0.00013 (0.00008 - 0.00021) 0.01693 (0.00983 - 0.02915) 
35F 16 0.00013 (0.00008 - 0.00022) 0.01021 (0.00616 - 0.01694) 
19B 15 0.00012 (0.00007 - 0.00020) 0.01563 (0.00908 - 0.02693) 
3 14 0.00011 (0.00007 - 0.00019) 0.01829 (0.01039 - 0.03221) 
lOA 14 0.00011 (0.00007 - 0.00019) 0.00989 (0.00548 - 0.01785) 
4 13 0.00011 (0.00006 - 0.00018) 0.01662 (0.00920 - 0.03000) 
17F 13 0.00011 (0.00006 - 0.00018) 0.01844 (0.01071 - 0.03176) 
22A 12 0.00010 (0.00006 - 0.00017) 0.01789 (0.00991 - 0.03230) 
16F 11 0.00009 (0.00005 - 0.00016) 0.02356 (0.01268 - 0.04378) 
PCV13 204 0.00607 (0.00530 - 0.00697) 0.00805 (0.00696 - 0.00932) 
NVTa 191 0.00465 (0.00404 - 0.00536) 0.01288 (0.01110 - 0.01495) 
AU6 221 0.01837 (0.01610 - 0.02096) 0.00962 (0.00839 - 0.01104) 
a Excluding non-typeable pneumococci 
b 2111234 infants acquired pneumococci during follow-up: acquisition and clearance of first pneumococcus 
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Figure 10. Serotype-specific acquisition and clearance rates in infants over the entire 
follow-up period 
Serotype reacquisitions were excluded. Results for all serotypes with> I 0 acquisitions. 
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There were 272 instances of re-acquisition of a previously carried serotype. NT 
pneumococci, 19F, 23F, 6B and 14 accounted for -75% of these re-acquisitions. 
A Generalised Estimating Equation (GEE), with a logistic link and exchangeable 
correlation structure, was used to identify the risks of reacquisition of the ten most 
commonly carried serotypes (6A, 6B, 6C, 14, 15B/C, 19F, 19A, 23F, 34, and NT) 
following previous carriage of the homologous or heterologous serotypes. Infants were 
considered to be at-risk of acquisition of a serotype if this serotype was not present in 
either of the two preceding NPS specimens. In the first instance, crude odds ratios were 
calculated for the risk of reacquiring a previously carried serotype. Subsequently, a full 
model was fitted which included previous carriage of all of these serotypes, presence of 
any other pneumococcal serotype in the preceding NPS, antimicrobial use in the preceding 
30 days, plus household factors (large household (>5 people) and presence of other 
children <5y in the house). In the crude assessment, a protective effect was not observed 
for any of the serotypes assessed. Conversely, infants with previous carriage of serotypes 
6AIBIC, 19F, 23F, or 34 had a significantly greater risk of subsequent reacquisition than 
those who had not been colonised (Table 13). With the exception of previous carriage of 
19F resulting in a reduced risk of acquisition of 6C (OR 0.45, P = .046), no serotype-
specific protective effects of previous colonisation were found. The presence of a 
pneumococcus of any other serotype in the preceding NPS was protective against 
acquisition of6B (OR 0.66, P = .048), 6C (OR 0.32, P < .001), 19A (OR 0.47, P = .02), 
and 23F (OR 0.66, P = .04). As in the crude analysis, infants with previous colonisation by 
6B (OR 3.00, P < .00 I), 19F (OR 2.65, P < .001), 23F (OR 2.65, P < .001), and 34 (OR 
3.85, P = .002) had significantly higher risk of subsequent colonisation by the homologous 
serotype than non-colonised infants (Table 14). For serotypes 6B, 6C, and 19F the 
presence of additional young children in the house was a risk factor for acquisition (6B: 
OR 1.55, 95% CI 1.04 - 2.32, P = .03; 6C: OR 2.21, 95% CI 1.16 - 4.21, P = .02; 19F: OR 
1.47,95% CI 1.03 - 2.10, P = .03). Antimicrobial consumption in the preceding 30 days 
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was protective against colonisation by 6A (OR 0.12, 95% CI 0.02 - 0.89, P = .04) and a 
risk factor for 19F acquisition (OR 1.69, 95% CI 1.09 - 2.63, P = .02). 
The effect of previous colonisation by homologous and heterologous serotypes on 
timing and duration ofreacquisitions ofserotypes 6B, 14, 19F, 23F, and NT pneumococci 
was examined. Controlling for age and carriage of heterologous serotypes, previous 
carriage of serotype 14 or 19F was associated with significantly reduced duration (HR > I) 
of subsequent carriage episodes of the same serotype, and there was a trend in the same 
direction for serotype 23F. Previous carriage was also associated with an increased interval 
to reacquisition (HR <1) of the same serotype (Table 15). Previous colonisation by 
heterologous serotypes also impacted on time to reacquisition of these five serotypes (HR 
<1, P < .05 for all serotypes), but only for 19F could a reduction of carriage duration be 
demonstrated (HR 2.01, P = .01). 
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Table 13. Crude risk of pneumococcal serotype acquisition if previous colonisation by the homologous serotype 
N 
Serotype 00 
6A 6B 6C 14 15B/C 19F 19A 23F 34 NT 
OR (95% CI) for 2.28 2.09 2.60 l.33 1.65 1.56 1.59 1.59 3.07 0.97 
acquisition following 
previous colonisation by (1.11 - 4.67) (1.36 - 3.21) (1.22 - 5.62) (0.72 - 2.45) (0.84 - 3.21) (1.08 - 2.26) (0.61 - 4.17) (1.04 - 2.43) (1.32 -7.10) (0.68 - 1.37) 
the homologous serotype 
P 0.03 0.001 0.01 0.4 0.1 0.02 0.3 0.03 0.009 0.8 
% of at-risk specimens 
positive for new acquisition 
(no. at-risk specimens): 
o previous acquisitions 1.48 (3,713) 2.66 (3,198) 1.14 (3,756) 2.04 (3,474) 1.78 (3,643) 4.01 (2,766) 1.11 (3,790) 3.34 (3,028) 0.99 (3,844) 4.94 (2,612) 
~1 previous acquisitions 3.09 (259) 6.00 (567) 2.56 (273) 1.97 (458) 1.81 (332) 7.99 (713) 1.5 (253) 5.67 (600) 2.39 (209) 6.20 (1,048) 
Table 14. Adjusted anal!sis of the effect of~revious serotype colonisation on new acguisitions of heterologous or homologous serotypes 
Newly Previously carried serotype M 
acquired 6A 6B 6C 14 1SB/C 19F 19A 23F 34 NT Prev.swab 00 
serotype grewPncb 
6A 1.44 0.97 2.04 1.99- 2.49- 1.73 0.91 1.20 1.17 1.48 0.69 
(0.62 - 3.31) (0.51 - 1.86) (0.96 - 4.33) (1.05 - 3.77) (1.24 - 4.99) (0.94 - 3.15) (0.37 - 2.23) (0.64 - 2.24) (0.48 - 2.87) (0.84 - 2.61) (0.39 - 1.22) 
6B 2.03- 3.00- 2.19- 0.70 2.37- 1.78- 0.80 1.36 0.59 0.89 0.66a 
(1.11 - 3.71) (1.82 - 4.93) (1.17-4.12) (0.38 - 1.28) (1.37 - 4.09) (1.12 - 2.84)" (0.37 - 1.71) (0.84 - 2.19) (0.25 - 1.39) (0.57 - 1.38) (0.44 - 0.99) 
6C 0.35 0.71 1.49 1.23 0.71 0.45- 0.99 1.90 1.48 2.58 0.32a 
(0.08 - 1.50) (0.32 - 1.59) (0.59 - 3.76) (0.55 - 2.76) (0.26 - 1.95) (0.21 - 0.99) (0.36 - 2.74) (0.94 - 3.84) (0.54 - 4.03) (1.35 - 4.92) (0.18 - 0.58) 
14 2.52· 1.99· 1.13 0.53 0.54 1.42 1.16 1.66 0.86 1.04 0.86 
(1.29 - 4.94) (1.13 - 3.48) (0.50 - 2.54) (0.23 - 1.21) (0.22 - 1.34) (0.81 - 2.49) (0.50 - 2.65) (0.95 - 2.90) (0.33 - 2.23) (0.62 - 1.73) (0.51- 1.45) 
1SB/C 0.90 0.96 1.15 0.75 0.52 1.06 1.80 0.89 1.53 1.44 1.23 
(0.40 - 2.05) (0.52 - 1.75) (0.55 - 2.40) (0.36 - 1.53) (0.20 - 1.34) (0.60 - 1.89) (0.88 - 3.65) (0.49 - 1.62) (0.70 - 3.37) (0.86 - 2.42) (0.68 - 2.21) 
19F 1.10 1.65- 1.51 0.92 0.68 2.65- 0.50 1.58- 1.15 1.17 0.82 
(0.60 - 2.01) (1.07 - 2.56) (0.85 - 2.68) (0.55 - 1.54) (0.35 - 1.32) (1.69 - 4.14) (0.21 - 1.17) (1.04 - 2.40) (0.59 - 2.25) (0.80 - 1.70) (0.58 - 1.17) 
19A 1.35 1.36 1.49 1.50 1.37 1.13 0.60 2.45- 1.95 1.01 0.47-
(0.52 - 3.52) (0.62 - 2.95) (0.52 - 4.28) (0.65 - 3.47) (0.54 - 3.45) (0.54 - 2.37) (0.14 - 2.55) (1.19 - 5.04) (0.76 - 5.02) (0.51 - 2.03) (0.25 - 0.87) 
23F 1.05 1.35 1.04 1.11 0.71 1.741 1.55 2.65- 0.67 1.16 0.66a 
(0.55 - 2.02) (0.84 - 2.18) (0.52 - 2.10) (0.65 - 1.90) (0.35 - 1.42) (1.11 - 2.74) (0.82 - 2.94) (1.67 - 4.21) (0.27 - 1.67) (0.77 - 1.74) (0.45 - 0.97) 
34 2.38· 0.88 1.05 1.74 2.02 1.26 0.91 2.01- 3.85- 1.44 0.53 
(1.06 - 5.30) (0.40 - 1.94) (0.36 - 3.04) (0.79 - 3.86) (0.89 - 4.61) (0.61 - 2.60) (0.31 - 2.67) (1.03 - 4.08) (1.64 - 9.06) (0.77 - 2.87) (0.27 - 1.05) 
NT 0.71 1.26 1.19 1.09 1.44 1.28 1.48 1.12 0.62 0.90 1.05 
(0.37 - 1.38) (0.82 - 1.92) (0.66 - 2.13) (0.67 - 1.75) (0.85 - 2.44) (0.85 - 1.94) (0.84 - 2.59) (0.73 - 1.71) (0.28 - 1.37) (0.60 - 1.34) (0.75 -1.46) 
Results summarised as odds ratios and 95% confidence intervals; boldface values represent homologous serotype comparisons 
a P < .05; bNasopharyngeal swab from the preceding month grew any other pneumococcal serotype 
Table 15. Effect of previous carriage on reacquisition and carriage duration of 
common pneumococcal serotypes 
First episodes of serotype carriage, not necessarily the infant's first ever carriage episode, 
were compared with subsequent episodes of carriage of the same serotype, controlling for 
age and carriage of heterologous serotypes. 
Serotype No. carriage Reacquisition Carriage Time to 
episodes number duration reacquisitionb 
(first 1 reacq.) HR(95% CIt P HR (95% CIl" P 
NT 195 (129/66) 1 sl 1.13 (0.79 - 1.63) .5 0.18 (0.1 0 - 0.35) <.001 
2nd 0.75 (0.33 - 1.71) .5 0.22 (0.07 - 0.63) .005 
3rd 0.31 (0.04 - 2.46) .3 0.40 (0.12 - 1.38) .1 
19F 169 (112/57) 181 2.64 (1.50 - 4.67) .001 0.39 (0.14 - 1.08) .07 
2nd 2.81 (1.09 - 7.22) .03 0.35 (0.09 - 1.32) .1 
3rd 1.39 (0.90 - 2.16) .1 1.00 (0.19 - 5.16) 1.0 
23F 135 (101134) 1st 1.56 (0.94 - 2.60) .08 0.50 (0.19 -1.31) .2 
2nd 3.20 (1.93 - 5.28) <.001 0.19 (0.04 - 0.95) .04 
3rd 0.76 (0.51 - 1.11) .2 0.79 (0.08 -7.99) .8 
68 119 (85/34) 18t 1.18 (0.62 - 2.23) .6 0.30 (0.11 - 0.84) .02 
2nd 1.21 (0.59 - 2.46) .6 0.21 (0.05 - 0.84) .03 
3rd .. 
14 80 (71/9) 1st 4.12 (1.35 - 12.59) .01 0.04 (0.04 - 0.35) .004 
2nd 
3rd 
a Cox proportional hazards model 
b Time from clearance of a serotype to subsequent reacquisition 
C Parametric survival model (Weibull distribution) 
The pneumococcal nasopharyngeal acquisition rate was significantly lower in 
mothers compared with infants (0.5 vs. 1.1 per 100 person-days; P < .001). Mothers 
carried pneumococci for a shorter duration than infants (median 31 vs. 61 days; P < .00 I) 
(Table II). 
There were 3,963 mother-infant swab pairs (swabs taken from both mother and 
infant on the same day), and in 233 (5.9%) a common serotype was identified. Forty six of 
the mothers were colonised by pneumococci at delivery and only ten (21.7%) ofthe infants 
acquired the mother's serotype as their first colonising pneumococcus. Identification of a 
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common serotype in a mother-infant pair became less common as the infant's age 
increased (for each one month increase: OR 0.98, 95% CI 0.96 - 0.99, P = .02) which, 
along with an increasing proportion of colonised mothers in the four months following 
delivery, suggests transmission occurred more frequently in the early months of life 
(Figure 12). 
Figure 12. Proportion of mother-infant NPS pairs in which a common pneumococcal 
serotype was identified, by infant age 
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3.1.5.3. Pneumococcal serotype distribution 
A total of 4,396 pneumococci were isolated from all swabs taken, comprising 67 
serotypes (3,363 from infants; 1,033 from mothers). In infants, eight serotypes (19F, 23F, 
NT, 6B, 14, 6A, 15B/C, 6C) accounted for 67.0% of the isolates (Figure 13(a». In 
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mothers, 29.6% of isolates were non-typeable with no other predominant serotypes (Figure 
13 (b)). 
Figure 13. Pneumococcal serotype distribution in infants and mothers 
The bars indicate the number of isolates of each serotype and the dashed lines indicate the 
cumulative frequency, with a cumulative frequency of 67% is indicated by the vertical 
arrows. Dark grey bars highlight PCV13 serotypes. 
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Over half (55.8%) of pneumococci from infants were PCV13 serotypes, compared 
with 27.5% from mothers (P < .001) (Table 16). The proportion of pneumococci that were 
PCV13 serotypes increased significantly over the first year oflife in infants (from 46.2% at 
1 month to 64.4% at 12 months; P < .001) and then decreased over the second year (Figure 
14). Infants carried a median of five (range 0 - 13), and mothers a median of two (range 0 
- 11), serotypes over the 24 month observation period. Considering serotype carriage over 
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the entire follow-up period (as binary "yes/no" variables for carriage of each serotype in an 
individual), all of the most common serotypes were more likely to be carried by infants 
than mothers, controlling for the number ofNPS collected per individual in a logistic 
regression model (OR> 1, Table 16). In swabs where pneumococci were cultured, mUltiple 
serotypes were identified in 5.1 % of infant swabs and 2.6% of mother swabs. Detection of 
more than one carried serotype became more common as age increased (infants P < .001; 
mothers P = .001). 
Table 16. Pneumococcal serotypes most commonly carried in infants and their 
mothers 
Serotypes ranked by overall isolation frequency. 
Serotype Overall Infant Mother Carriage in infants 
N (%; rank) N (%; rank) N (%; rank) vs. mothers 
OR (95% CIt 
NT 660 (15.0; 1) 354 (10.5; 3) 306 (29.6; 1) 2.8 (1.9 - 4.2) 
19F 604 (13.7; 2) 545 (16.2; I) 59 (5.7; 2) 4.5 (2.9 - 7.0) 
23F 471 (10.7; 3) 432 (12.9; 2) 39 (3.8; 3) 6.3 (3.8 - 10.2) 
68 337 (7.7; 4) 308 (9.2; 4) 29 (2.8; 5) .7.3 (4.2 - 12.8) 
14 216 (4.9; 5) 188 (5.6; 5) 28 (2.7; 6) 4.7 (2.7 - 8.0) 
6A 184 (4.2; 6) 167 (5.0; 6) 17 (1.7; 10) 5.2 (2.8 - 9.7) 
IS8/e 171 (3.9; 7) 152 (4.5; 7) 19 (1.8; 9) 5.7 (3.2 - 10.4) 
34 138 (3.1; 8) 99 (2.9; 10) 39 (3.8; 3) 1.8 (1.0 - 3.2) 
6C 117 (2.7; 9) 108 (3.2; 8) 9 (0.9; 18) 6.7 (3.0 - 14.7) 
19A 114 (2.6; 10) 100 (3.0; 9) 14 (1.4; 13) 3.9 (2.0 - 7.6) 
PCV13 serotypes 2,162 (49.2%) 1,878 (55.8%) 284 (27.5%) 9.0 (5.1 - 15.7) 
NVT serotypesb 1,574 (35.8%) 1,131 (33.6%) 443 (42.9%) 8.3 (4.4 - 15.6) 
Total 4,396 3,363 1,033 4.9 (2.3 - 10.2) 
·OR for the serotype being carried at any time point (adjusted for number of swabs per individual; all P <: 
.05) 
b Excluding non-typeable pneumococci 
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Figure 14. Pneumococcal isolates by serotype category in infants and mothers, by 
infant age 
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3.1.5.4. Antimicrobial resistance in carried pneumococcal isolates 
Antimicrobial resistance data were summarised by acquisitions: the first isolate of 
each serotype carriage episode was selected to represent the entire carriage episode. 
Therefore, 1,504 pneumococci from infant carriage episodes and 546 pneumococci from 
mother carriage episodes were analysed. Pneumococci were determined to be multi-drug 
resistant if they were resistant to three of more of chloramphenicol, erythromycin, 
penicillin (MIC ~0.12 JlglmL), tetracycline, or trimethoprim-sulphamethoxazole (co-
trimoxazole ). 
Forty percent of infant isolates were penicillin non-susceptible and 34.6% were 
MDR. PCV13 serotypes were significantly more likely to be MDR (P < .001). Over 75% 
of infant isolates were fully susceptible to chloramphenicol, clindamycin, and 
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erythromycin whereas only 21.3% and 40.5% of isolates were fully susceptible to co-
trimoxazole and tetracycline, respectively (Table 17). Of the MDR isolates, over two-thirds 
were from four PCV13 serotypes (6B, 19F, 19A, and 23F). Whilst serotype 14 and NT 
isolates were frequently penicillin non-susceptible, they were less likely to be MDR (Table 
18). 
A quarter of pneumococci from mothers were MDR and, as for infant isolates, 
PCV 13 serotypes were more likely to be resistant (P < .001) (Table 19 & Table 20). 
Table 17. Antimicrobial resistance in carried pneumococcal isolates from infants 
Drug Isolates tested· Susceptible Intermediate Resistant 
N N(%) N(%) N(%) 
Penicillin 1,504 903 (60.0) 580 (38.6) 21 (1.4) 
Ceftriaxoneb 695 693 (99.7) 2 (0.3) 0 
Chloramphenicol 1,504 1,406 (93.5) NN 98 (6.5) 
Clindamycin 1,504 1,307 (86.9) 47 (3.1) 150 (10.0) 
Erythromycin 1,504 1,171 (77.8) 10 (0.7) 323 (21.5) 
Co-trimoxazole 1,504 320 (21.3) 197(13.1) 987 (65.6) 
Tetracycline 1,504 609 (40.5) 69 (4.6) 826 (54.9) 
a Reporting a single isolate per pneumococcal serotype carriage episode 
b Tested if oxacillin screening disc <20 mm 
C There is no intermediate susceptibility category for chloramphenicol 
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Table 18. Antimicrobial resistance in the most commonly carried pneumococcal 
serotypes from infants 
Serotype MDR Penicillin non-susceptible- Total 
N 0/0 N 0/0 
NT 75 38.5 157 80.5 195 
19F 161 95.3 162 95.9 169 
23F 104 77.0 98 72.6 135 
6B 63 52.9 33 27.7 119 
14 13 16.3 58 72.5 80 
15B/C 4 5.6 9 12.7 71 
6A 13 20.6 3 4.8 63 
6C 20 40.0 0 0 50 
19A 39 84.8 43 93.5 46 
34 2 4.7 8 18.6 43 
PCV13 398 56.4 407 57.6 706 
NVTb 47 7.8 37 6.1 603 
Total 520 34.6 601 40.0 1,504 
a MIC 2:0.12 JlglmL; 6 Excluding non-typeable pneumococci 
Table 19. Antimicrobial resistance in carried pneumococcal isolates from mothers 
Drug Isolates tested· Susceptible Intermediate Resistant 
N N(%) N(%) N(%) 
Penicillin 546 359 (65.8) 182 (33.3) 5 (0.9) 
Ceftriaxoneb 231 229 (99.1) 2 (0.9) 0 
Chloramphenicol 546 514 (94.1) NAc 32 (5.9) 
Clindamycin 546 492 (90.1) 17(3.1) 37 (6.8) 
Erythromycin 546 464 (85.0) 5 (0.9) 77(14.1) 
Co-trimoxazole 546 163 (29.8) 73 (13.4) 310 (56.8) 
Tetracycline 546 232 (42.5) 43 (7.9) 271 (49.6) 
a Reporting a single isolate per pneumococcal serotype carriage episode 
b Tested if oxacillin screening disc <20 mm 
C There is no intermediate susceptibility category for chloramphenicol 
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Table 20. Antimicrobial resistance in the ten most commonly carried pneumococcal 
serotypes from mothers 
Serotype MDR Penicillin non-susceptible· Total 
N 0/0 N % 
NT 45 43.7 77 74.8 103 
19F 40 90.9 42 95.5 44 
23F 20 71.4 19 67.9 28 
34 1 4.3 1 4.3 23 
3 0 0 0 0 20 
68 11 55.0 7 35.0 20 
14 5 25.0 18 90.0 20 
llA 0 0 0 0 17 
35C 1 6.3 6.3 16 
19A 10 90.9 11 100.0 11 
PCV13 89 46.6 101 52.9 191 
NVTb 13 5.2 9 3.6 252 
Total 147 26.9 187 34.3 546 
a MIC2:0.121!g1mL 
b Excluding non-typeable pneumococci 
The proportion of antimicrobial resistant isolates was greater in infants compared to 
mothers (MDR: 34.6% vs. 26.9%, P = .001; penicillin non-susceptible 40.0% vs. 34.3%, P 
= .02). This finding was also true when restricted to PCV13 ser~types: 56.4% of infant 
isolates were MDR compared to 46.6% of mother isolates (P = .02). There were no 
significant differences in resistance between infant and mother isolates for non-vaccine 
serotypes and non-typeable pneumococci. 
Risk factors for acquisition of drug resistant pneumococci were explored using a 
generalised estimating equation with a logistic link. Correcting for the number of swabs 
collected per individual, only the presence of other young children in the house was 
associated significantly with a greater risk of acquisition of both multi-drug resistant and 
penicillin non-susceptible pneumococci (P < .001). Female infants were more likely to 
acquire penicillin non-susceptible, but not MDR, pneumococci than males (P = .005). 
, 
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Acquisition of another pneumococcal serotype at the preceding NPS was protective against 
acquisition of a drug resistant pneumococcus (P < .001) (Table 21). 
Table 21. Risk factors for acquisition of drug-resistant pneumococci in infants 
Risk factor for acquisition MDR Penicillin non-susceptible 
OR (95% CI) P OR (95% CI) P 
Female gender 1.15 (0.94 - lAO) .2 1.32 (1.09 - 1.60) .005 
Large household size (>5) 0.99 (0.81 - 1.22) .9 1.09 (0.90 - 1.33) .4 
Children <5 y in house 1.59 (1.29 - 1.97) < .001 1.47 (1.21 - 1.80) <.001 
Adults >60 y in house 1.18 (0.88 - 1.57) .3 1.14 (0.87 - 1.50) .3 
Mother smokes 1.06 (0.86 - 1.31) .6 1.01 (0.82 - 1.23) 1.0 
One month age increase 1.00 (0.99 - 1.01) 1.0 1.00 (0.99 - 1.02) .7 
Pneumococcal serotype 0.69 (0.56 - 0.85) <.001 0.69 (0.57 - 0.84) <.001 
acquisition at preceding NPS 
Antibiotics in previous 30 d: 
Any class 1.13 (0.85 - 1.50) .4 
Beta-Iactam 
-
1.24 (0.94 - 1.64) .1 
3.1.6. Discussion 
To date, this is the largest longitudinal pneumococcal carriage study in children 
under two years, in terms of the number studied and the sampling frequency/duration of 
follow-up. Adherence to the WHO detection protocol enables direct comparison with other 
similar studies. The high level of follow-up and the uniformity of swab frequency over the 
follow-up period permitted confident assessment of carriage prevalence and dynamics. The 
inclusion of consistent follow-up in the second year of life was important since the risk of 
invasive disease remains high (119, 284), but there are few detailed data on pneumococcal 
carriage dynamics in children aged 12 - 24 months. Over 40% of all observed 
pneumococcal acquisitions occurred in the second year of life and there were significantly 
more re-acquisitions of previously carried serotypes in the second 12 months compared to 
the first 12 months of life, perhaps as a result of waning immunity. 
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In this crowded refugee camp, infants were colonised frequently by pneumococci 
and the fIrst acquisition occurred early in life. The median age of acquisition (46 days) is 
similar to published studies from Asia and Africa, although in individual studies from 
Papua New Guinea and The Gambia, infants were colonised even earlier (60% by 15 days 
and 50% by 33 days respectively) (72, 73). The observed and modelled acquisition rate of 
0.018 per day was identical to that found in a contemporary Kenyan birth cohort which 
used very short sampling intervals in the fIrst weeks of life (74). In contrast, studies from 
the USA and Europe document older age at first pneumococcal acquisition, and lower 
overall carriage prevalence: the mean age at fIrst acquisition was six months in the USA 
(47), and 56% of Finnish infants were colonised by 12 months with an overall carriage 
prevalence of21 % in the fIrst two years oflife (76). In agreement with recent data from 
Kenya, serotype-specifIc acquisition rates were strongly correlated with serotype carriage 
prevalence (285). This study also documented a negative correlation between serotype-
specifIc acquisition and clearance rates, which was also seen in the Maela cohort. In the 
current cohort, having a mother who smoked or other young children in the household Was 
associated with an earlier age at fIrst pneumococcal colonisation. Siblings have been ! 
I previously recognised as a risk factor for pneumococcal acquisition (107). The presence of ' I 
pneumococcal carriage, although infants in India who were exposed to ~20 cigarettes per I , smokers in the household has not been consistently identifIed as a risk factor for infant 
day were at increased risk of colonisation at two months of age (110). 
Carriage duration varied by serotype, with serotypes 19F and 23F being carried for 
the longest periods in infants. For serotypes 14 and 19F, previous carriage of the serotyPe 
was associated with signifIcantly increased interval to reacquisition and shorter duration of 
subsequent carriage of the same serotype. This trend was observed for 23F, although the 
reduction in carriage duration did not reach signifIcance. These findings suggest that 
nasopharyngeal exposure to serotypes with immunogenic capsular polysaccharides (l4/I 9F 
> 23F > 6B) result in an immune response capable of enhancing clearance if reacquisition 
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occurs. The fact that NT carriage was also associated with delayed reacquisition of NT 
pneumococci implies that other factors, such as antibody responses to common surface 
proteins, are also involved in the regulation of pneumococcal nasopharyngeal colonisation. 
Modelling of data from previous longitudinal carriage studies has demonstrated evidence 
for both serotype-dependent and independent effects on pneumococcal serotype 
acquisitions in young children, but not both in the same study population. Carriage of eight 
serotypes was modelled in Israeli infants aged 12 - 35 months, and a significantly lower 
risk of acquisition of serotypes 6A, 14, and 23F in those previously colonised was found 
(120). Serotype-independent protection against reacquisition of four serotypes was shown 
in Bangladeshi infants aged <1 year (121). In univariate and multivariate models, there was 
no evidence of serotype-specific protection from colonisation in Maela infants. For several 
serotypes, previously colonised infants had a significantly greater risk of acquisition of the 
homologous serotype most likely as a result of intense exposure to pneumococci in the 
household and community. Colonisation by another serotype in the preceding month 
reduced the risk of acquisition of 6B, 6C, 19A, and 23F, and previous colonisation by 19F 
protected against subsequent colonisation by 6C. These observations provide some 
evidence for the occurrence of intra-species competition and serotype-independent 
protection against colonisation in children aged <2 years. 
Eight serotypes accounted for two-thirds of the pneumococcal isolates from infants. 
Serogroups 6, 19, 23 and serotype 14 have been the most prevalent pneumococci in the 
majority of previous infant/childhood carriage studies, regardless of geographical location 
(73, 76, 110, 114). As expected, the proportion ofPCV13 serotype carriage was greater in 
infants than in their mothers (87, 98, 116). An unexpected finding was the high prevalence 
of non-typeable pneumococcal carriage. These organisms have limited disease potential, 
but may act as an important reservoir of antimicrobial resistance genes (39). They are not 
consistently reported in carriage studies: they may not be identified because of atypical 
colony morphology or they may be actively excluded because of lack of association with 
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invasive disease. When included, prevalence has varied from 0.7% of pneumococci in a 
Kenyan survey of adults and children to 44.5% in Spanish primary school children (98, 
140). In the current study, these organisms were carried at least once by 55.1% of infants 
and 32.0% of mothers. The vast majority of isolates appeared non-encapsulated, rather 
than being pneumococci of a novel capsular type (data not shown). While it is possible that 
these organisms were misidentified non-pneumococcal streptococci or the result of poor 
quality serotyping quality control this is unlikely as all were confirmed by optochin 
susceptibility and bile solubility, and serotype was rechecked by Quellung. In addition 168 
NT pneumococci from this collection have been genotyped by MLST and 96.4% were 
typed successfully, confIrming their identity (134, 286). Further characterisation of a small 
sample of isolates by microarray-based comparative genomic hybridisation and subsequent 
sequencing of the cps locus, confirmed their pneumococcal identity and demonstrated 
deletion or disruption of the capsule biosynthesis genes in 17/18 (94.4%) isolates (139). 
Antimicrobial resistant pneumococci were frequently carried by infants and their 
mothers, with PCV13 serotypes predominating. Serotypes 6B, 19F, 19A, and 23F 
accounted for around two-thirds of all MDR pneumococcal acquisitions, a fInding in 
agreement with previously published data (45). Interestingly, recent antimicrobial 
consumption was associated with an increased risk of an infant becoming colonised by 
serotype 19F. It would be expected that introduction of a pneumococcal conjugate vaccine 
into the community would result in a reduction in carriage and disease caused by drug-
resistant pneumococci. However, non-typeable pneumococci were also frequently drug 
resistant: 80.5% of infant isolates were penicillin non-susceptible and 38.5% were MDR. 
As previously noted, these frequently carried organisms may represent a signifIcant 
reservoir of anti-microbial resistance genes for exchange with encapsulated pneumococci 
(39). 
There are some limitations to the study. Firstly, the WHO culture protocol I 
underestimates the prevalence of multiple serotype carriage (see section 4). This may result 
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in an underestimation of carriage duration. It may also explain the emergence of 
"replacement" serotypes seen when pev is used and the predominant carriage serotypes 
decline (69). Secondly, the sampling strategy employed means that there were only limited 
data regarding adult pneumococcal carriage prevalence and transmission of serotypes 
within the household. The carriage prevalence in the mothers (24.0%) was higher than that 
documented in Kenyan adults (5.3%), similar to Papua New Guinean mothers (-30%), but 
lower than Gambian adults (>50%) (72,87,98). Mothers were selected for inclusion since 
they were likely to have the greatest contact with the infants and therefore offered a 
reasonable opportunity to study pneumococcal transmission. However, the large household 
sizes and the crowded nature of the camp inevitably resulted in the majority of 
pneumococcal transmission being unobserved. In spite of this a trend in concordance of 
serotypes between mothers and their infants could be documented, suggesting that 
transmission was more frequent in the early months of life. The monthly interval between 
nasopharyngeal swabs will have resulted in the under detection of serotypes carried for 
short durations. This is particularly relevant to the estimation of carriage prevalence in 
adults, as median carriage duration was only 31 days (Le. a serotype detected at a single 
swabbing point only) in the study mothers. This swabbing interval is also likely to 
generally overestimate serotype carriage episode durations (285). Although antimicrobial 
consumption data were collected for each individual child, this was likely to be inaccurate 
in many cases. Antimicrobial prescriptions from the SMRU clinic and PU-AMI hospital 
were documented but, as is the case with many parts of SE Asia, antimicrobials may be 
purchased in Maela without prescription from local pharmacies or markets (287). In many 
circumstances an antimicrobial agent is included in an over-the-counter mixed medication 
bag to treat fever (288). Measurement of urinary antimicrobial activity at swabbing visits 
may have permitted a more accurate assessment of the influence of recent antimicrobial 
consumption on pneumococcal acquisitions and colonisation (289). However, not all 
antimicrobials are excreted in the urine and only very recent consumption could be 
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captured in this way. Camp-level antimicrobial consumption/purchase data would have 
provided a useful indication of the antimicrobial pressures that colonising pneumococci 
were exposed to. However, given the nature of the camp and the porosity of its borders, 
these data were not available. 
In conclusion, the characteristics of pneumococcal carriage in mothers and infants 
in an isolated SE Asian community have been comprehensively documented. These data 
will inform vaccination strategies in this population. Determination of timing of 
transmission of pneumococci between mother and infant, and the impact of early 
colonisation by a serotype on subsequent acquisitions, improves understanding of the 
complex process of early pneumococcal nasopharyngeal colonisation. 
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4 Detection of multiple pneumococcal serotype colonisation 
4.1. Improved detection of nasopharyngeal co-colonisation by multiple pneumococcal 
serotypes using latex agglutination or molecular serotyping by micro array 
4.1.1. Summary 
Background 
Identification of S. pneumoniae in the nasopharynx. is critical for the understanding of 
transmission, estimates of vaccine efficacy and possible replacement disease. Conventional 
nasopharyngeal swab culture and serotyping following the WHO protocol is likely to 
underestimate multiple serotype carriage. In this study, the WHO protocol was compared 
with methods aimed at improving co-colonisation detection. 
Methods 
125 NPS from infants in the Maela pneumococcal carriage study, containing ~1 serotype 
by WHO culture, were re-cultured in duplicate. A sweep of colonies from one plate culture 
was serotyped by latex agglutination. DNA extracted from the second plate was analysed 
by S. pneumoniae molecular serotyping microarray. 
Results 
Multiple serotypes were detected in 11.2% swabs by WHO culture, 43.2% by sweep 
serotyping, and 48.8% by microarray. Sweep and micro array were more likely to detect 
multiple serotypes than WHO culture (P < .001). Co-colonisation detection rates were 
similar between microarray and sweep but microarray identified the greatest number of 
serotypes. A common serogroup-type was identified in 95.2% swabs by all methods. 
Conclusions 
WHO methodology significantly underestimates mUltiple serotype carriage compared to 
these alternative methods. Sweep serotyping is cost-effective and field-deployable but may 
fail to detect serotypes at low abundance whereas microarray is more costly and 
technology-dependent but may detect these additional minor carried serotypes. 
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4.1.2. Introduction 
The introduction of pneumococcal conjugate vaccines has resulted in a profound 
reduction in invasive disease caused by serotypes covered by the vaccines, but increases in 
the numbers of cases due to non-vaccine serotypes have been observed (193). Conjugate 
vaccines have also been shown to prevent nasopharyngeal carriage of the vaccine 
serotypes, although an increase in the carriage of non-vaccine serotypes has also been 
documented (67). To plan future vaccine strategy there is a need to better understand the I 
" i 
dynamics of pneumococcal colonisation of the nasopharynx (a critical early step in the I, 
pathogenesis of invasive pneumococcal disease, IPD (46», particularly in relation to I t 
! 
carriage of, and competition between, multiple serotypes. Non-vaccine serotypes carried at f 
low density may become important disease-causing serotypes once vaccine serotypes are 
removed from, or suppressed within, the nasopharyngeal niche by immunisation (155). 
Longitudinal studies of pneumococcal colonisation allow detailed exploration of carriage 
dynamics but standard approaches based on agar plate culture and conventional serotyping 
techniques may not be optimal for the detection of multiple serotype carriage (70). 
Published studies have reported multiple colonisation prevalence inconsistently and, when 
this has been reported, laboratory methods have varied considerably making direct inter-
study comparisons difficult. Gratten et al. serotyped up to six colonies from nasal swab 
culture plates and found multiple serotype carriage in 29.5% of Papua New Guinean 
children (145). They went on to serotype at least 50 colonies from ten selected nasal swab 
cultures and concluded that the minor carried serotype accounted for 4 - 27% of the total 
pneumococcal population. In a study of Tanzanian children, Charalambous and colleagues 
confirmed that single colony selection was a reasonable approach for determination of 
serotype/group colonisation prevalence at a population level but that multiple colony 
selection/serotyping would be necessary to accurately define multiple colonisation 
prevalence and total serotype diversity (272). Hare et al. concluded that random colony 
selection was superior to selection by morphological difference for determination of 
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multiple colonisation Australian Aboriginal children (148). A review of published 
literature on multiple carriage concluded that, to detect a minor carried serotype, it would 
be necessary to serotype at least five colonies to have a 95% chance of detecting the 
serotype if it accounted for 50% of the total pneumococcal population and one would need 
to examine 299 colonies if the serotype was present at a relative abundance of 1 % (147). 
Given the time and financial implications of the study of multiple serotype colonisation by 
Quellung serotyping of more than a single colony, several alternative approaches for 
multiple serotype detection have been described. Researchers in The Gambia have 
developed a latex agglutination technique where colonies from the primary culture plate 
are suspended in saline and serotyped by latex agglutination. Using this extremely cost-
effective method up to 10.4% of pneumococcal acquisitions were found to be of multiple 
serotypes in a longitudinal infant cohort study (73). However, there are no published 
studies comparing this technique with conventional pneumococcal serotyping 
methodologies for detection of multiple serotype colonisation. Several other methods have 
demonstrated increased detection of multiple carriage compared to standard culture, 
including swab enrichment culture followed by either Quellung typing (151) or multiplex 
PCR (25) from the broth; immunoblotting (150) or multiplex PCR (146) from the primary 
culture plate; mUltiplex PCR direct from the nasopharyngeal swab - STGG transport 
medium specimen (NPS-STGG) (153); plyNCR PCR followed by terminal RFLP direct 
from the swab (154); and microarray based detection and serotyping (29, 142). However, 
in general these methods are either expensive, time-consuming, limited in number of 
serotypes detected, or a combination of these factors and therefore are not well suited for 
use in large scale carriage studies, particularly those carried out in less developed countries 
where the largest burden of pneumococcal disease resides (2). 
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4.1.3. Aims and objectives 
The objectives for this study were firstly to determine the amount by which the 
standard WHO culture method for detection of pneumococcal nasopharyngeal carriage 
underestimates co-colonisation by multiple serotypes and secondly to assess the utility of 
the two alternative methods, one molecular (for reference laboratory use) and the other 
culture-based (for field laboratory use), for detection of pneumococcal co-colonisation in 
an infant carriage study. Micro-array was selected as the reference laboratory method since ! 
• 
it had previously been demonstrated to be able to detect extremely low abundance 
pneumococci of any known serotype (29). The latex agglutination-sweep method 
developed in The Gambia was selected for the SMRU laboratory since it was cheap, rapid, 
suited to high-volume studies, technically undemanding, and could theoretically detect all 
known pneumococcal serotypes (73). 
4.1.4. Methods 
Nasopharyngeal swabs collected from cohort infants during the Maela 
pneumococcal carriage study were used in the current study. 
4.1.4.1. Detection of pneumococcal colonisation by the WHO culture protocol 
Swabs were collected and processed according to the current WHO pneumococcal 
carriage detection protocol, as desc~bed in sections 2.2.4.1 and 2.2.5.1 (70). 
4.1.4.2. Detection of pneumococcal colonisation by sweep serotyping or microarray 
One hundred and twenty five NPS-STGG specimens known to contain at least One 
pneumococcal serotype by the WHO culture method were selected from the entire swab 
collection. Laboratory personnel were blinded to the original WHO culture result. 
The specimens were thawed, mixed, and 10 JlL aliquots of STGG were re-cultured 
on to two CNA-blood agar plates. Both plates were incubated overnight at 36°C in 5% 
C02. Growth was assessed after overnight culture and those with growth only in the 
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primary streak were re-incubated for a further twenty four hours. If growth was still poor at 
48 hours, the specimen was re-cultured using 50 ilL aliquots ofSTGG. The entire growth 
from each plate was removed using a sterile cotton swab (Medical Wire & Equipment, 
Corsham, UK) and suspended into aliquots of sterile saline. The first aliquot (0.5 - 2 mL 
saline, adjusted to make an organism density of 0.5 McFarland) was used for sweep 
serotyping and genomic DNA was extracted from the second aliquot using a Gram positive 
bacteria protocol (QIAamp mini kit, Qiagen, Hilden, Gennany). Briefly, the organism 
suspension was centrifuged to pellet the bacteria; this pellet was resuspended in 180 ilL of 
an enzyme lysis solution (20 mglmL lysozyme; 20 mM Tris-HCI, pH 8.0; 2 mM EDTA; 
1.2% Triton) and incubated at 37°C for 30 minutes. Two hundred microlitres of Qiagen 
buffer AL and 20 ilL proteinase K were added and the mixture incubated for 30 minutes at 
56°C followed by 15 minutes at 95 DC. Following these lysis steps, the standard 
manufacturer's extraction protocol was followed and DNA was eluted into 200 ilL Qiagen 
buffer AE. The DNA extract was stored at -80°C prior to testing by the Bacterial 
Microarray Group (Drs Jason Hinds and Kate Gould) at St. George's Hospital, University 
of London, UK (BIlG@S; http://bugs.sgul.ac.uk). 
Sweep serotyping by latex agglutination was perfonned on the saline suspension: 
the suspension was first tested with antisera pools A-I, followed by all appropriate group, 
type, and factor antisera (described in section 12.3 & reference (73». Non-typeable 
pneumococci were provisionally identified by the latex agglutination reactions described 
previously. 
Molecular serotyping was perfonned on the DNA extracts using the BIlG@S SP-
CPSv1.4.0 microarray and the output analysed using a Bayesian hierarchical model as 
described elsewhere (142). In addition to serotype detection, the array was used to 
detennine the relative serotype proportions in specimens containing multiple serotypes 
(29). 
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To confinn a single highly discrepant result, a swab in which sweep serotyping 
identified two serotypes but microarray detected nine serotypes, intensive study of the 
NPS-STGG specimen by conventional culture and serotyping was undertaken. To ensure 
single colonies would be well separated, five 2 J.lL aliquots of the thawed STGG were re-
cultured onto CNA-blood agar plates and incubated overnight as described previously. A 
total of 300 randomly selected alpha-haemolytic colonies were sub-cultured onto plain 
blood agar plates (with optochin discs to identify S. pneumoniae) and subsequently 
serotyped by latex agglutination. Finally, sequential multiplex PCR was attempted on the 
DNA extract from this specimen culture to provide a second confinnatory molecular 
serotyping result (23). 
4.1.4.3. Statistical analysis 
Continuous variables were analysed by the Wilcoxon matched-pairs signed-rank 
test and proportions were compared by the chi-squared test. Comparisons of multiple 
serotype carriage detection by method were done using McNemar's test. Statistical 
significance was inferred by two-sided P-values of < .05. 
At the time of this study it was not possible to resolve serotypes 6A and 6C using 
antisera, therefore these serotypes were considered identical and labelled 6A1C. In a small 
number of specimens microarray testing identified multiple non-typeable pneumococci, 
based on variation of the cps locus components, however these were considered to be a 
single serotype when comparing methods. 
4.1.5. Results 
4.1.5.1. Swabs and study participants 
One hundred and twenty five nasopharyngeal swabs from 42 infants, aged between 
26 and 516 days, were included. Swabs from up to 12 different sampling time points per 
infant were examined. 
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4.1.5.2. Detection of multiple serotype colonisation 
Multiple pneumococcal serotypes were identified in 141125 (11.2%) of the NPS by 
the WHO culture method. A single serotype was identified in the other 1111125 (88.8%) 
swabs. The proportion of swabs in which multiple serotype carriage was identified 
increased using either sweep (541125; 43.2%) or microarray serotyping (61/125; 48.8%). 
Sweep serotyping was 3.9 times (95% CI 2.4 - 6.2) and microarray serotyping 4.4 times 
(95% CI 2.8 - 6.9) more likely to detect multiple pneumococcal serotype colonisation than 
the WHO culture method (P < .001). 
Considering all 125 swabs together, microarray identified significantly more 
pneumococci (222 pneumococci /47 serotypes) than either sweep serotyping (195 
pneumococci /39 serotypes) or WHO culture (139 pneumococci / 35 serotypes) (P < .001) 
(Figure 15). The number ofserotypes identified per swab ranged from one to nine, and is 
summarised in Table 22. 
Figure 15. Distribution of serotypes identified by each detection method 
·Unable to r€!solv(! ~erogrolJP 
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Table 22. Number of pneumococcal serotypes identified per nasopharyngeal swab by 
each of the three detection methods 
Total number of WHO culture Sweep serotype Microarray 
serotypes detected IN (%)] IN (%)] IN (%)] 
1 III (88.8) 71 (56.8) 64 (51.2) 
2 14 (11.2) 41 (32.8) 36 (28.8) 
3 0(0) 10 (8.0) 20 (16.0) 
4 0(0) 3 (2.4) 3 (2.4) 
~S 0(0) 0(0) 2 (1.6) 
Sweep serotyping detected significantly fewer serotypes per swab than microarray 
(P = .04) although this difference became non-significant (P = .06) if a single outlying 
swab was excluded. In this particular swab, nine serotypes were identified by microarray 
but only two serotypes by sweep serotyping and by further examination of 300 discrete 
alpha-haemolytic colonies by conventional culture (246/300 colonies were identified as S. 
pneumoniae and only these were serotyped), although multiplex. peR also indicated the 
presence of at least four serotypes which included those identified by sweep serotyping 
plus others detected by microarray. In two instances, the sweep and microarray serotyping 
methods could not resolve a serogroup (i.e. could not serotype to the "type" level). By all 
three methods, a common six serotypes accounted for 56.9 - 60.0% of the total but the 
rank order of these serotypes varied by method (Table 23). 
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Table 23. Pneumococcal serotypes most frequently identified by each detection 
method 
Serotype WHO culture Sweep serotype Microarray 
[N (%») [N (%») [N (0/0») 
19F 23 (16.6) 26 (13.3) 26 (11.7) 
NT 15 (10.8) 41 (21.0) 49 (22.1) 
6B 14(10.1) 16 (8.2) 17 (7.7) 
35F 12 (8.6) 15 (7.7) 19 (8.6) 
23F 8 (5.8) 9 (4.6) 8 (3.6) 
14 7 (5.0) 10 (5.1) 10 (4.5) 
Proportion of total 79/139 (56.9) 1171195 (60.0) 129/222 (58.2) 
serotypes identified 
Both sweep and microarray serotyping identified a significantly larger proportion 
of NT pneumococci compared to WHO culture (22.1 % by microarray / 21.0% by sweep 
vs. 10.8% by WHO, P = .007). However, even when these NT pneumococci were 
excluded from the analyses, sweep or microarray serotyping still identified a significantly 
greater number of pneumococci and multiple serotype co-colonisation episodes than the 
WHO culture method. Microarray detected 173 typeable pneumococci (46 serotypes) and 
multiple serotype carriage in 411125 (32.8%) NPS; sweep serotyping detected 154 typeable 
pneumococci (38 serotypes) and multiple serotype carriage in 311125 (24.8%) NPS; and 
WHO culture detected 124 typeable pneumococci (34 serotypes) and multiple serotype 
carriage in 111125 (8.8%) NPS (P < .001). 
There was a non-significant trend in the proportion ofPCV13 serotypes versus non-
vaccine serotypes detected by the three methods: PCV13 serotypes accounted for 46.8% 
(WHO culture), 39.5% (sweep serotyping), and 38.3% (microarray serotyping) of all of the 
serotypes detected (P = .25). Considering only the microarray data, in swabs where a 
single serotype was identified (i.e. completely "dominant"), the serotype was a PCV13 
type in 35/64 (54.7%) but in swabs where multiple serotypes were detected, the 
"dominant" serotype was a PCV13 type in only 21161 (34.4%, P = .02). The ability of the 
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microarray to determine the relative abundance of each serotype allowed detailed 
exploration of the temporal flux of relative serotype levels in two representative infants, in 
whom a total of 24 swabs were examined (Figure 16). 
Figure 16. Dynamics of pneumococcal carriage over the first year of life in two 
infants 
The figure summarises microarray data of serotypes detected and their relative abundance. 
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4.1.5.3. Serotype result agreement between detection methods 
Overall, at least one common serotype was found by all three detection methods in 
109/125 specimens (87.2%; 95% CI 81.1 - 93.1%). Relaxing agreement to the serogroup-
type (SaT) level, there was at least one common saT identified by all three methods in 
119/125 specimens (95.2%; 95% CI 91.4 - 99.0%) and SaT agreement between two of the 
three methods in the remaining six specimens. 
In 44 specimens a single pneumococcal serotype was identified by all three 
detection methods. In 42/44 (95.5%; 95% CI 89.0 - 100%) all three methods identified the 
same serotype. In one swab WHO and microarray both identified a type 9V pneumococcus 
but sweep serotyping determined the serotype to be 9A. In the other non-congruent 
107 
speCImen, both WHO culture and sweep serotyping identified a non-typeable 
pneumococcus but the microarray detected type 6B capsule genes. 
4.1.5.4. Limits of detection of sweep serotyping and microarray 
In order to assess the limits of the sweep serotyping assay, serial dilutions of 
overnight cultures of S. pneumoniae (six clinical isolates; serotypes 6A, 6B, 14, 19F, 19A, 
and 23F) were made in normal saline and these were serotyped using latex antisera as 
described previously. Organism density in the saline suspensions was determined by the 
plate count technique (290). Reproducible serotype results could be obtained at organism 
densities of 107 - 108 CFU/mL (Le. 0.5 McFarland). In vitro mixtures of these suspensions 
confirmed that, at an overall organism density of 0.5 McFarland (visual), serotypes present 
at ~25% of the total pneumococcal population could reliably be detected by latex 
agglutination (data not shown). 
In the 61 swabs in which multiple serotypes were detected by micro array, the 
relative proportion of the minority serotype (defined as the least abundant serotype 
detected) ranged from 1 % to 46% (median 7%, IQR 3 - 14%) (Table 24). Microarray 
serotyping detected additional serotypes compared to sweep serotyping in 38 specimens, in 
30/38 (78.9%) the predominant additional serotype detected was NT and in 21138 (55.3%) 
the only additional serotype was NT. In the 17/38 specimens in which microarray detected 
additional typeable pneumococci, 9/17 (53.0%) serotypes were present at <10%,5/17 
(29.4%) were present at 10 - 19%, and only 3/17 (17.6%) were present at ~20% of the total 
pneumococcal population. 
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Table 24. Relative proportion of minority serotypes detected by microarray 
compared with the total number of pneumococcal serotypes detected 
Relative proportion of Total number of serotypes detected Total 
minority serotype 
2 3 4 5 9 
<10% 12 15 3 1 32 
10-19% 11 5 0 0 0 16 
20-29% 6 0 0 0 0 6 
30-39% 3 0 0 0 0 3 
40-49% 4 0 0 0 0 4 
Total 36 20 3 61 
4.1.6. Discussion 
This study has demonstrated that culture and serotyping of nasopharyngeal swab 
specimens using the current WHO protocol significantly underestimates the frequency of 
multiple pneumococcal serotype carriage. Sweep serotyping identified 1.4 times, and 
microarray 1.6 times, as many pneumococci compared to this standard culture method. 
These alternative methods also revealed greater diversity of carriage serotypes, reflected by 
the greater proportion of non-vaccine serotypes identified by eac~ method. As expected, 
microarray identified the largest number of carried serotypes and was able to detected 
minor serotypes present at very low relative abundance. The microarray data confirmed the 
previously described fmding that the minority serotype in a multiple carriage episode is 
present at low abundance: we documented a median relative abundance of7% (range 1 -
46%) for the minority serotype, compared with 4 - 27% found in the Papua New Guinea 
study using Quellung typing of multiple colonies (145). The ability of micro array and 
sweep serotyping to confidently document the frequency of non-typeable pneumococcal 
carriage is also useful since these organisms are suspected of being an important reservoir 
of antimicrobial resistance although they are, as yet, not an important cause of invasive 
disease (39). Identification of non-typeable pneumococci can be problematic given the 
phenotypic and genetic similarities to closely related streptococcal species such as S. mitis 
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and S. pseudopneumoniae. However, characterisation of 168 NT isolates from the Maela 
study population by MLST concluded that 162/168 (96%) could be assigned a sequence 
type and only six isolates were found to be non-pneumococcal streptococci by eMLSA 
analysis (286). This result gives confidence to the finding of frequent NT pneumococcal 
detections in the current evaluation. 
The agreement between the three methods, in terms of detection of a common 
serotype, was excellent with at least one common SOT identified in 95.2% of swabs. The 
two discrepancies observed in 44 swabs in which a single serotype was identified by all 
methods were minor: a factor discrepancy (9 A versus 9V) between methods in one and a 
potentially non-expressed capsule in the other (microarray identified 6B capsule genes but 
both WHO and sweep found a non-typeable pneumococcus). A single result was 
unsatisfactory: the swab in which microarray identified nine serotypes but sweep 
serotyping identified only two, and WHO culture one, serotypes. This specimen was re-
cultured and 246 discrete pneumococcal colonies individually serotyped by latex 
agglutination: the sweep serotyping result was confirmed by this approach and additional 
serotypes were not encountered. In spite of this, the microarray result may well be correct 
and is supported to some extent by multiplex peR results. It is likely that to detect several 
very low abundance serotypes it would be necessary to serotype even more than the 300 
colonies that was attempted here. Furthermore, the presence of conserved capsule 
polysaccharide genes in other non-alpha-haemolytic or optochin resistant alpha-haemolytic 
Streptococcus spp. in the primary plate DNA extract may have resulted in signal on the 
array, possibly considered a false positive but reflecting the total gene pool and capacity 
for capsule polysaccharide production in the sample (152). 
The WHO culture method will detect the predominant serotype but statistically 
cannot be expected to detect low abundant serotypes (147). Increasing the number of 
colonies serotyped by random selection from the primary culture plate has been shown to 
improve detection of multiple colonisation (148), but the cost and time required for the 
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additional serotyping renders this difficult to sustain in the setting of a large carriage study. 
These factors also limit the utility of immunoblotting or broth enrichment methods in such 
studies (150, 151). 
Sweep serotyping is cheap, quick, technically straightforward and was not 
significantly inferior to the microarray method in detecting multiple carriage episodes, 
although it was not efficient at detecting pneumococcal serotypes present at very low 
abundance «25% of the total). If this can be improved sweep serotyping may ultimately 
become a gold-standard method for detection, but not relative quantitation, of multiple 
serotypes in nasopharyngeal samples. 
Molecular techniques, especially when applied directly to the swab, reduce the cost 
and time of multiple serotype detection compared to Quellung typing but currently 
multiplex peR can only detect a limited number of serotypes (29 in the original multiplex 
(23» and may therefore miss serotypes ultimately important for replacement disease after 
vaccination (25, 46). The significant advantages of the microamlY method used in the 
current study are the ability to detect all known pneumococcal serotypes and estimate their 
relative abundance in a mixed population. In the setting of a longitudinal carriage study. 
these additional data will permit detailed observations of the interactions between 
pneumococcal serotypes, and indeed between pneumococci and other bacterial or viral 
species, over time. 
Both sweep and microarray serotyping enable researchers to better interrogate 
nasopharyngeal swab specimens with regard to detection of multiple pneumococcal 
serotype carriage. In the current study microarray was more sensitive than sweep 
serotyping and provided useful data regarding relative serotype abundance. However, 
microarray-based molecular serotyping is currently restricted to a small number of research 
laboratories and the cost-per-test is relatively high, although additional simultaneous 
analyses can be conducted. Sweep serotyping is extremely cost effective (lOJ,1L neat 
pneumococcal antiserum is used to produce 6mL oflatex reagent) and can be performed in 
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any microbiology laboratory capable of serotyping S. pneumoniae by Quellung, which 
makes it a highly useful technique for pneumococcal carriage studies, particularly in 
resource-poor settings. 
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4.2. Further evaluations of latex sweep serotyping for detection of multiple 
pneumococcal serotype colonisation 
4.2.1. Summary 
Background 
Standard culture of nasopharyngeal swabs using WHO methodology to detect 
pneumococcal colonisation underestimates the prevalence of mUltiple serotype 
colonisation. The impact of this on pneumococcal serotype distributions and colonisation 
dynamics in infancy are not clear. 
lit 
I· il Methods 
To further evaluate the utility oflatex sweep serotyping, 8,736 NPS collected from 364 
infants taking part in the Maela longitudinal infant pneumonia cohort study were cultured 
and serotyped using the latex sweep method. 1,107 of these swabs had previously been 
cultured using the standard WHO methodology. To assess the iI11pact of culture/serotyping 
methodology on estimation of serotype colonisation dynamics, a retrospective case-control . 
study was done comparing colonisation results on 100 matched pairs of infants. Swabs 
from each infant were cultured either by WHO or latex sweep method. 
Results 
In 1,107 swabs cultured by both WHO and latex sweep methods, latex sweep serotyping 
was three times more likely to detect colonisation with multiple pneumococcal serotypes, !" 
Ii 
excluding NT pneumococci, than WHO culture (9.3% vs. 3.1 % ofNPS; P < .001). At least 11 
!: 
one common serotype was identified in 91.2% of swabs from which pneumococci were 
detected by both methods. Agreement between methods improved with increasing 
colonisation density (P = .03). Estimates of age at first pneumococcal acquisition and 
duration of colonisation were not affected by culture/serotyping method. However, a 
greater number of serotype carriage episodes were detected in infants cultured by latex 
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sweep (P = .03). The overall rate ofNVT pneumococcal acquisition was also greater in 
infants cultured by latex sweep (P = .04). 
Conclusions 
Latex sweep serotyping was feasible to perfonn on a large specimen collection. As 
expected, detection of multiple serotype colonisation was significantly improved compared 
with WHO methodology. Further work to improve latex sweep serotype detection at low 
colonisation densities is required. 
4.2.2. Introduction 
The previous evaluation (section 4.1) demonstrated that standard WHO culture and 
serotyping was an inadequate tool for detecting and characterising multiple serotype 
colonisation. This rmding raised questions regarding studies of pneumococcal colonisation 
dynamics: 
• Do methodological differences (WHO culture/serotyping vs. culture plus latex 
sweep serotyping) significantly influence reported serotype distributions? 
• Is there a methodological effect on estimates of acquisition rates and carriage 
duration? 
4.2.3. Aims and objectives 
The objectives of this study were to perfonn culture plus latex sweep serotyping on 
nasopharyngeal swabs collected from cohort infants and to subsequently compare 
pneumococcal colonisation results both within infants (WHO vs. sweep method in 
"routine" follow-up group infants) and between groups of infants ("immunology" (WHO 
culture) vs. "routine" (sweep method) follow-up groups). 
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4.2.4. Methods 
4.2.4.1. Specimen selection and processing 
On completion of the Maela pneumonia cohort study follow-up, the specimen 
database was reviewed and all nasopharyngeal swabs from "routine" follow-up infants 
with a complete set of 24 monthly specimens were cultured and latex sweep serotyping 
done as described in section 4.1.4.2. A proportion of these NPS specimens had previously 
been cultured according to the WHO protocol as described in section 2.2.5.1. The 
laboratory staff that performed the latex sweep serotyping were blinded to the original 
WHO culture results. 
Colonisation density was assessed by estimating the number of pneumococcal 
colonies in each of the four agar plate quadrants: 1 + (growth in quadrant 1 (inoculation 
area/primary streak) but <10 colonies in quadrant 2), 2+ (> I 0 colonies in quadrant 2 but 
<10 colonies in quadrant 3),3+ (>10 colonies in quadrant 3 but <10 colonies in quadrant 
4), or 4+ (> 1 0 colonies in quadrant 4). 
To compare pneumococcal acquisition rates and carriage durations by . 
culture/serotype method, all "immunology" follow-up group infants with a complete 24 
monthly NPS specimen set were matched 1: 1 by gender and month of birth with a 
"routine" follow-up group infant using the "vmatch" command in Stata/IC 12.1 
(StataCorp, College Station TX, USA). 
4.2.4.2. Definitions of carriage 
The definitions of serotype acquisition, clearance, and duration employed were 
those used in the study of pneumococcal colonisation mother-infant pairs and described in 
section 3.1.4.3. 
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4.2.4.3. Data analysis 
Comparisons of serotype detections by WHO culture or sweep serotyping were 
made by McNemar's test. Continuous numerical variables were summarised by means and 
groups were compared by t-test. Serotype acquisition rates and carriage durations were 
calculated by survival analysis techniques, as described in section 3.1.4.4. Groups were 
compared using the log-rank test. 
As previously described, serotypes 15B and 15C were considered to be a single 
serotype (l5B/C). Serotypes 6A and 6C were also combined (serotype 6A1C), since, at the 
time of the study, latex sweep serotyping could not distinguish between the two. Non-
typeable pneumococci were excluded from these comparisons, since culture and serotyping 
by latex sweep has no confirmatory test of pneumococcal identity except the presence of 
capsule. 
4.2.5. Results 
4.2.5.1. "Routine" follow-up group infants 
Three hundred and sixty four infants from the "routine" follow-up group had a 
complete 24 month NPS specimen set. A total of8,736 swabs were cultured and latex 
sweep serotyping done. Typeable pneumococci were identified in 65.3% (5,699/8,736) of 
specimens. Multiple pneumococcal serotypes were found in 734 NPS specimens (12.9% of 
specimens from which pneumococci were cultured). In swabs with more than one serotype, 
the median number of serotypes detected was two and the maximum was four. 
4.2.5.1.1. Serotype distribution 
A total of62 serotypes were identified and eight of these (l9F, 23F, 6B, 6A1C, 14, 
15B/C, 35C, 19A) accounted for two-thirds of all pneumococci detected (Figure 17). 
Almost two thirds (61.8%; 3,999/6,471) of the pneumococci detected were PCV13 
serotypes and 42.4% (3,704/8,736) NPS contained at least one PCV13 serotype. 
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The ten serotypes most prevalent serotypes in these infants were identical to those 
in the 234 infants from the "immunology" follow-up group (excluding NT pneumococci; 
section 3.1.5.3 and Figure 13), although the rank: order varied. 
Figure 17. Infant carriage pneumococcal serotype distribution by latex sweep 
serotyping 
Results of culture of 8,736 swabs from 364 infants. 
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One thousand one hundred and seven (12.7%) of the NPS specimens from these 
364 infants had previously been cultured using the WHO protocol. At least one typeable 
pneumococcus was identified in 759 (68.6%) and 708 (64.0%) NPS specimens by WHO 
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proportion of specimens containing at least one PCV13 serotype or NVT pneumococcus by 
method (PCV13: 42.7% (sweep) vs. 44.0% (WHO), P = .1; NVT: 25.3% (sweep) vs. 
26.3% (WHO), P = .2). 
In swabs containing at least one typeable pneumococcus by the WHO method, an 
identical serotype was identified in 85.0% (645/759) by the sweep method. Relaxed to 
agreement at the serogroup/type level, this proportion increased only slightly to 86.4% 
(656/759). Where both methods identified at least a single typeable pneumococcus, 
agreement was 91.2% (645/707; serotype level) and 92.8% (565/707; serogroup/type 
level), perhaps indicating that low density pneumococcal colonisation was missed by the 
latex sweep method. Serotype agreement between methods was lowest in specimens when 
there was light colonisation (defined as 1 +) on the WHO culture plate (Table 25). 
Although not statistically significant at the serotype level, the likelihood of agreement at 
serogroup/type level was significantly higher if colonisation density was 2+ or greater (OR 
1.65, 95% CI 1.06 - 2.57, P = .03). 
Table 25. Relationship between colonisation density and agreement between WHO 
culture and latex sweep result 
Colonisation density Serotype agreement Total 
(WHO culture plate) N(%) 
1+ 311 (80.4) 387 
l+ 170 (89.5) 190 
3+ 96 (92.3) 104 
4+ 68 (87.2) 78 
Total 648 (85.0) 759 
4.2.5.2. Comparison of pneumococcal colonisation dynamics: infant swabs cultured 
by WHO or latex sweep methods 
One hundred "immunology" follow-up group infants whose NPS had been cultured 
by WHO method were matched 1: 1 with "routine" follow-up group infants whose swabs 
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were processed by the latex sweep method. All infants contributed 24 monthly swabs and 
all were colonised by pneumococci at least once. 
In both groups, the median age at fIrst pneumococcal acquisition was 46 days (P = 
.6; Figure 18). Considering individual serotype acquisition rates, there were no signifIcant 
differences in rates of acquisition of commonly carried PCV13 serotypes. However, non-
vaccine serotypes were acquired faster in infants whose swabs were processed by the latex 
sweep method (Table 26). Durations of fIrst carriage episodes, without stratifIcation by 
serotype, were similar in both groups ("immunology"IWHO: median 90 days (IQR 31 -
151); "routine"/sweep: 62 days (lQR 31 - 121); P = .2; Figure 19). 
Infants with swabs processed using the latex sweep method had a greater number of 
pneumococcal serotype carriage episodes than those whose swabs were cultured using 
WHO methodology (mean 8.4 vs. 7.5, P = .03). There were no differences in the number 
of PCV 13 or NVT serotype carriage episodes between the groups (PC V 13 serotypes 
accounted for 51.4% ("immunology"IWHO) and 54.0% ("routine"/sweep) carriage 
episodes, P = .3). 
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Figure 18. Age at first pneumococcal acquisition, by NPS culture/serotyping method 
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Table 26. Individual pneumococcal serotype acquisition rates, by culture/serotyping 
method 
100 infants were included in each group. 
Serotype Swabs cultured: WHO method Swabs cultured: sweep method P 
N Acq rate· 95%CI N Acq rate· 95%CI 
19F 56 0.0012 (0.0009 - 0.0016) 59 0.0012 (0.0010 - 0.0016) .9 
23F 51 0.0010 (0.0008 - 0.0013) 44 0.0008 (0.0006 - 0.0011) .3 
6B 49 0.0009 (0.0007 - 0.0012) 50 0.0009 (0.0007 - 0.0012) .9 
6A1C 47 0.0008 (0.0006 - 0.0011) 48 0.0009 (0.0007 - 0.0012) .6 
ISB/e 36 0.0006 (0.0004 - 0.0008) 51 0.0009 (0.0007 - 0.0012) .03 
14 35 0.0006 (0.0004 - 0.0008) 37 0.0006 (0.0004 - 0.0009) .8 
19A 25 0.0004 (0.0003 - 0.0006) 32 0.0005 (0.0004 - 0.0007) .3 
34 22 0.0003 (0.0002 - 0.0005) 32 0.0005 (0.0004 - 0.0008) .1 
ISA 15 0.0002 (0.0001 - 0.0004) 20 0.0003 (0.0002 - 0.0005) .4 
3SC 12 0.0002 (0.0001 - 0.0003) 29 0.0005 (0.0003 - 0.0007) .002 
PCV13 100 0.0058 (0.0048 - 0.0071) 100 0.0070 (0.0057 - 0.0085) .2 
NVTb 92 0.0047 (0.0038 - 0.0057) 98 0.0071 (0.0058 - 0.0086) .04 
Allb 100 0.0150 (0.0123 - 0.0183) 100 0.0165 (0.0135 - 0.0200) .6 
• Acquisition rate per day 
b Non-typeable pneumococcal colonisation excluded 
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Figure 19. Duration of first pneumococcal carriage episode, by culture/serotyping 
method 
100 infants were included in each group. 
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4.2.6. Discussion 
This study confinns the preliminary finding that the latex sweep serotyping method 
is significantly more sensitive than WHO culture followed by serotyping of 
morphologically distinct colonies for detection of multiple pneumococcal serotype 
colonisation. It also demonstrates the feasibility of processing large numbers ofNPS 
specimens using the latex sweep method: over 8,000 swabs were turned around in less than 
12 months. Alternative methods developed to improve multiple serotype colonisation are 
currently unlikely to be able to manage such numbers, especially when factoring in the 
costs of molecular assays or those phenotypic assays requiring significant volumes of 
pneumococcal antisera (150, 153, 154). Increased throughput did not negatively impact on 
serotype agreement between two methods: a common serotype was found in 92.8% swabs. 
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In the initial evaluation of serotyping methods, which included micro array, a common 
serogroup/type was identified in 95.2% specimens (291). This is an important finding, 
especially since recent work has determined that molecular serotyping directly from broth 
enrichment cultures may identify cps locus genes present in non-pneumococcal 
streptococci resulting in false positive "pneumococcal" serotype detections (152). 
Given the high prevalence of carriage of non-typeable pneumococci, improved 
confirmation of colonisation by these organisms would be helpful (39). Although non-
specific weak agglutination by latex can presumptively identify these organisms, without a 
confirmatory test of pneumococcal identity their carriage prevalence may be over-
estimated by the latex sweep method (unpublished data from the PneuCarriage study; 
personal communication from Catherine Satzke). The finding that the latex sweep method 
was significantly less sensitive at serotype detection from swabs with lower pneumococcal 
density is also a problem and further work to improve this is required, especially for the 
technique to be successfully employed in situations where low colonisation density may be 
anticipated (156, 292). This is relevant since studies of colonisation in immunised infants 
and also adults are of considerable importance in monitoring for changing in serotype 
carriage prevalence following introduction of conjugate vaccines (69). It may also explain 
why the overall prevalence of multiple serotype colonisation reported here (12.9% by 
sweep in the "routine" cohort infants) was lower than in some other studies, for example 
Papua New Guinea where Gratten et al. identified multiple serotypes in 29.5% of children 
carrying pneumococci (145). However, the three-fold increase in multiple serotype 
detection (9.3% vs. 3.1 %) when comparing sweep results to WHO culture/serotyping in 
the same specimen selection from Maela infants represents a reasonably impressive 
increase in detection. In the current study, WHO culture equated to serotyping all 
morphologically discrete pneumococci. Comparing this strategy to selection of four 
random colonies for characterisation, Hare et al. identified an additional 3% (14% vs. 17%) 
ofNPS specimens containing multiple pneumococcal serotypes in Australian Aboriginal 
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children: put another way, random colony selection resulted in a 1.2-fold increase in 
multiple colonisation detection over the WHO approach (148). 
Infant serotype distribution was not affected by culturelserotyping methodology in 
this study. Excluding non-typeable pneumococci, the top ten ranking serotypes in infant 
swabs processed by WHO method or latex sweep were identical, with a small number of 
serotypes accounting for the majority of pneumococci identified. This finding agrees with 
the work of Charalambous and colleagues, who demonstrated that population-level 
characteristics of colonising pneumococci could be adequately described by 
characterisation of a single colony per specimen (272). Age at first pneumococcal 
acquisition was identical, and durations of first pneumococcal carriage were similar, in 
infants whose swabs were processed by either method. Estimates for NVT acquisition rates 
were higher (both overall and for serotypes 15B/C and 35C individually) in infant whose 
swabs were processed by latex sweep. These infants were also detennined to have a greater 
number of discrete serotype colonisation episodes compare to infants whose swabs were 
cultured by the WHO method. Sweep serotyping was not significantly more likely detect 
NVT pneumococcal colonisation overall. However, a limitation of this study was that 
differences observed in colonisation dynamics in the case-control component may reflect 
unaccounted for, and potentially important, environmental factors (51). Infants were 
matched by gender and month of birth, but household differences were not measured. 
In conclusion, this study has demonstrated accuracy and feasibility of latex sweep 
serotyping for detection of pneumococcal colonisation in longitudinal infant studies. 
Further work to improve detection of colonisation by non-typeable organisms and 
pneumococci at low density is required. 
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5 Immunological aspects of pneumococcal colonisation in young children 
5.1. Serum antibody responses to pneumococcal capsular polysaccharides in children 
under two years 
5.1.1. Summary 
Background 
Antibodies against the pneumococcal capsule may protect against nasopharyngeal 
colonisation. However, detailed kinetics of anti-capsular IgG antibody development in 
relation to nasopharyngeal acquisitions over the first two years of life are poorly defined. 
Methods 
Monthly sera and nasopharyngeal swabs were collected from 36 infants from 1 - 24 
months of age. Swabs were cultured to detect pneumococcal colonisation and IgG to 
dominant serotypes (6B, 14, 19F, 19A, and 23F) were quantified. 
Results 
Pneumococcal colonisation occurred early in the cohort. Anti-capsular IgG declined until 
six months and failed to protect against colonisation. Increases in homologous anti-
capsular IgG were observed for all19A acquisitions but only to a proportion of others 
(from 23F - 29.2% to 14 - 76.9%). Older age at acquisition was associated with a greater 
increase in homologous anti-capsular IgG (P = 0.05; 95% CI 0.03 - 0.07; P < .001). Anti-
capsular IgG fold-change between six and 24 months to serotype 14 was greater in those 
infants who had been colonised compared with the non-colonised group (3.64 vs. 0.41, P < 
.001). 
Conclusions 
The relationship between serum IgG and the prevention of, or response to, pneumococcal 
nasopharyngeal colonisation remains complex. Mechanisms other than serum anti-capsular 
IgG are likely to have a role but are currently poorly understood. 
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5.1.2. Introduction 
The immune response to pneumococcal nasopharyngeal colonisation is complex 
and remains incompletely understood. Murine models have suggested a relatively limited 
role for antibody in the clearance of nasopharyngeal colonisation and that a CD-4+ T-cell 
pathway mediated by IL-17 A is the dominant mechanism involved in immunity to 
pneumococcal colonisation (177, 178). However, colonisation in adult humans does result 
in a rise in serum serotype-specific anti-capsular polysaccharide IgG (183, 184), although 
these antibodies may not protect against colonisation (185). Pneumococcal conjugate 
vaccine studies in young children have shown that serum anti-capsular IgG protects against 
nasopharyngeal acquisition by, and may reduce colonisation density of, pneumococcal 
serotypes covered by the vaccine (67, 120, 156, 187). It has been suggested that a serum 
anti-capsular IgG concentration of~0.35 JlglmL is protective against invasive disease of 
the homologous serotype (293, 294). Whilst mucosal IgA antibodies are produced in 
response to pneumococcal colonisation and infection, correlates of protection for either 
colonisation or invasive disease are not yet known (295-297). 
Previous studies of pneumococcal colonisation and immune responses in infants 
and young children have demonstrated the generally limited development of serotype-
specific serum anti-capsular antibodies in the absence of PCV immunisation, although 
these studies included relatively infrequent sampling points which restricted potential for 
study of the immune response to individual pneumococcal serotype acquisitions (188, 
190). Also, failure to pre-adsorb test sera with both pneumococcal cell wall polysaccharide 
and type 22F capsular polysaccharide has been demonstrated to result in sub-optimal 
quantitation of serotype-specific anti-capsular antibody responses in older generations of 
antibody detection assays (298, 299). 
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5.1.3. Aims and objectives 
The aims of the present study were to examine: (i) the effect of mat em ally derived 
serotype specific anti-capsular IgG antibodies on risk and timing of nasopharyngeal 
colonisation by the homologous serotype in infancy; (ii) the development of serum 
serotype-specific anti-capsular IgG in relation to nasopharyngeal acquisitions of 
pneumococci in the first two years of life. 
5.1.4. Methods 
5.1.4.1. Study site and population 
Thirty six infants from the "immunology" follow-up group of the Maela cohort, 
with complete sets of both nasopharyngeal swabs and serum specimens, were selected for 
further analysis. 
5.1.4.2. Pneumococcal nasopharyngeal colonisation 
Nasopharyngeal swabs were taken at scheduled monthly visits from one to 24 
months of age (section 2.2.3). Swabs were collected and processed according the standard 
WHO protocol, as described in sections 2.2.4.1 and 2.2.5.1 (70,291). All pneumococcal 
isolates were serotyped by latex agglutination with Quellung confirmation of equivocal 
results (273). 
5.1.4.3. Determination of pneumococcal capsular antibody concentrations 
At each monthly nasopharyngeal sampling point a venous blood specimen was 
collected into a 2 mL plain tube (Teklab, Sacriston, UK) and an aliquot of serum was 
stored at -80°C for subsequent antibody analyses. Serum IgG antibodies to capsular 
polysaccharides 6B, 14, 19F, 19A, and 23F were measured (subsequently referred to as 
"target" serotypes). These serotypes were selected since they are included in the 13-valent 
conjugate vaccine (PCV13) and were frequently carried by infants in the cohort 
(accounting for 1,573/3,363 (46.8%) ofall pneumococci cultured from nasopharyngeal 
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swabs) (300). Antibody concentrations were detennined by ELISA, after adsorption with 
both 22F polysaccharide and cell-wall polysaccharide, at the WHO reference laboratory for 
pneumococcal serology in the Institute of Child Health, London, UK (298). The assay limit 
of detection was 0.15 J-lg/mL and all results below this were reported as 0.075 J-lg/mL. 
5.1.4.4. Statistical analysis 
Antibody concentrations and fold-changes in antibody levels were nonnalised by 
log-transfonnation prior to analysis. Geometric mean concentrations and their 95% 
confidence intervals were calculated and comparisons between groups were made using t-
tests or ANOVA as appropriate. Pearson's correlation coefficients were used to examine 
correlations between antibody concentrations to the five capsular polysaccharides. The 
relationship between age at carriage acquisition and anti-capsular antibody response was 
assessed by linear regression. For this analysis, pneumococcal serotype acquisition was 
defined as the first ever identification of a serotype from a nasopharyngeal swab culture or 
when a serotype was re-cultured following clearance as dermed by the absence of the 
serotype from two consecutive swabs. Assessments of the effect of maternally derived 
serum anti-capsular IgG on risk and timing of homologous serotype acquisition in infants 
was made by logistic regression and survival analysis, respectively. 
5.1.5. Results 
Eight hundred and sixty four serum specimens were analysed. The demographic 
and pneumococcal colonisation characteristics of this sub-group of 36 infants were not 
significantly different to overall infant cohort (described in chapter 3). 
5.1.5.1. Pneumococcal colonisation 
The median age at first pneumococcal acquisition was 46 days and all 36 infants 
had been colonised by the seventh month visit (Figure 20). Over the first two year of life, 
pneumococci were detected in a median of20 swabs per infant (IQR 16 - 21; range 8-
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24). Infants were colonised by a median of seven individual pneumococcal serotypes (IQR 
6 - 8; range 2 - 11). There were 106 discrete nasopharyngeal acquisitions of the five target 
serotypes: almost all infants (35/36; 97.2%) carried at least one ofthe target serotypes and 
two-thirds (23/36; 63.8%) carried two or more (cumulative acquisitions of target serotypes 
are summarised in Figure 20). Serotype 19A was acquired later than the other serotypes: 
median age at first positive swab was 17 months (IQR 11 - 19) versus 9 months (lQR 5 -
14) for the other serotypes combined (P = .03; Figure 21). 
Figure 20. Cumulative proportion of infants colonised by pneumococci 
1.00 
"0 0.75 
(!) 
en 
c: 
o 
"0 
u 
c: 0.50 
o 
t 
o 
a. 
e 
n.. 0.25 
o 
/ 
• ! 
I 
I 
I 
I 
t 
• 
6 12 
Age (visit month) 
--.. -- All pneumococci • 68 
~ 19A • 19F 
18 
• 14 
- -4 • ...-- 23F 
128 
24 
Figure 21. Age at first acquisition of five target pneumococcal serotypes 
The graph summarises the monthly visit in which the serotype was detected in a 
nasopharyngeal swab for the fIrst time in an infant. 
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5.1.5.2. Antibody kinetics 
Serum IgG for all serotypes was highest in the fIrst sample taken from the infants 
reflecting maternally derived, transplacentally transported IgG. Serum IgG antibody 
concentrations to all fIve serotypes declined between one and six months of age, with 
antibodies to serotype 14 having a significantly greater fold-change than the other 
serotypes (P = .02) (Figure 22, Table 27 & Table 28). Following this nadir, IgG 
concentrations increased modestly until 24 months, although none of the GMCs at 24 
months were equal to the one month values (Figure 22 & Table 27). Between six and 24 
months of age, the greatest increase was seen in IgG antibodies to 19A (mean fold-change 
4.91 (95% CI 3.31 - 7.28) and the smallest in antibodies to serotype 14 (mean fold-change 
0.91 (95% CI 0.54 - 1.52) (P = .005). At 24 months, measurable anti-capsular IgG 
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antibodies (:::0.15 Ilg/mL) were found in the sera of 19.4% to 97.1% of infants, varying 
considerably by serotype (Table 27). 
Figure 22. Kinetics of serum IgG antibodies to five pneumococcal capsular 
polysaccharides in infants from 1 - 24 months of age 
The shows geometric mean concentrations with 95% confidence intervals. 
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Table 27. Geometric mean serum anti-capsular IgG antibody concentrations in 36 
infants during the first two years of life 
Serotype Sera GMC (95% CI), JlglmL Infants with 
(N). 1 month 6 months 12 months 18 months 24 months detectable IgG 
at 24m, N (%)b 
68 858 0.71 0.09 0.11 0.17 0.24 28/36 (77.8) 
(0.48 - 1.04) (0.07 - 0.1 0) (0.08 - 0.13) (0.13 - 0.22) (0.18 - 0.32) 
14 858 3.74 0.23 0.16 0.20 0.21 18/36 (50.0) 
(275 - 5.08) (0.16 - 0.33) (0.11 - 0.23) (0.14 - 0.30) (0.14 - 0.32) 
19F 857 0.90 0.10 0.13 0.20 0.21 16/36 (55.6) 
(0.63 - 1.27) (0.08 - 0.12) (0.09 - 0.18) (0.14 - 0.29) (0.14 - 0.31) 
19A 857 1.58 0.20 0.41 0.80 0.95 34/35 (97.1) 
(1.19-2.11) (0.15-0.26) (0.28 - 0.60) (0.54 - 1.17) (0.67 - 1.35) 
23F 859 0.52 0.08 0.09 0.11 0.10 7/36 (19.4) 
(0.36 - 0.74) (0.08 - 0.08) (0.07-0.11) (0.09 - 0.14) (0.08 - 0.12) 
• All time points combined (1 - 24 months); 864 sera were included but some were of insufficient volume for 
all anal yses 
bDefmed as a 24 month anti-capsular IgG concentration of?:0.15 Jlg/mL 
Table 28. The effect of nasopharyngeal colonisation in the first two years of life on 
fold changes of serotype-specific anti-capsular IgG in serum 
Serotype Exposure· Six months Twenty four months 
Infants IgG fold-changeb pd Infants IgG fold-thangeC 
(N) Mean (95% CI) (N) Mean (95% CI) 
68 Colonised 5 0.13 (0.04-0.46) .9 15 3.78 (2.07 - 6.90) 
Non-colonised 31 0.12 (0.09 - 0.17) 21 2.18 (1.50 - 3.1S) 
14 Colonised 2 0.03 (0.01 - O.lS) .3 13 3.64 (1.66 -7.97) 
Non-colonised 34 0.07 (0.05 - 0.10) 23 0.41 (0.27 - 0.64) 
19F Colonised 8 0.11 (0.06 - 0.19) .9 22 2.60 (1.56 - 4.33) 
Non-colonised 28 0.12 (0.07 - O.1S) 14 1.50 (0.68 - 3.32) 
19A Colonised 0 7 6.77 (2.93 - 15.63) 
Non-colonised 36 0.12 (0.09 - O.IS) 29 4.53 (2.85 -7.21) 
23F Colonised 7 0.18 (0.07 - 0.46) .5 18 1.46 (1.03 - 2.08) 
Non-colonised 29 0.14 (0.09 - 0.21) 18 1.14 (0.93 - 1.38) 
• Colonised: detection of the pneumococcal serotype in the nasopharynx from 1 month to either 6 or 24 
months 
b 6 month serum IgG concentration divided by the 1 month serum JgG 
c 24 month serum JgG concentration divided by the 6 month serum IgG concentration 
pd 
.09 
<: .001 
.2 
.4 
.2 
d Comparison of logged fold-changes in serum JgG concentration in colonised vs. non-colonised infants . 
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In the context of PCV administration, it has been suggested that a serum anti-
capsular IgG concentration of~0.35 J.lg/mL protects against invasive disease caused by the 
homologous serotype (293, 294). By 24 months of age the proportion of infants with anti-
capsular IgG concentrations above this threshold varied considerably by serotype: 5.6% 
(95% CI 0.1 - 18.7) for 23F, 30.6% (95% CI 16.3 - 48.1) for 19F, 33.3% (95% CI 18.6-
60.0) for 6B, 38.9% (95% CI 23.1 - 56.5) for 14, and 85.7% (95% CI 67.2 - 93.6) for 19A 
(P<.OOl). 
5.1.5.3. Relationship between maternally derived serum IgG anti-capsular antibodies 
and risk of colonisation by the homologous serotype in infancy 
Specimens collected from the infant at one month of age were used to assess the 
contribution of maternally derived antibodies to the risk and timing of nasopharyngeal 
acquisition by the homologous serotype in the first two years oflife. In univariate logistic 
regression and Cox proportion hazards models there were no significant associations 
between logged anti-capsular IgG concentrations at one month of age and subsequent 
acquisition of the homologous serotype (Table 29). Interestingly, the relationship between 
one month anti-19A antibodies and risk, and timing, of 19A acquisitions was the opposite 
of the other serotypes. A higher one month anti-19A IgG concentration was associated 
with higher risk, and earlier acquisition, of 19A although the numbers were small and 
statistical significance was not achieved. 
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Table 29. Assessment of the effect of maternally derived serum anti-capsular IgG 
antibodies on the risk and timing of nasopharyngeal acquisition of the homologous 
serotype in the infant over the first 24 months of life 
Logged serum anti-capsular IgG concentrations in the infant specimen collected at one 
month of age were compared with homologous serotype acquisition in univariate logistic 
regression and Cox proportional hazards models. An OR of <1 indicated a lower risk of 
nasopharyngeal acquisition with increasing concentrations of anti-capsular IgG. A HR of 
<1 indicated a longer interval to acquisition with increasing concentrations of anti-capsular 
IgG. 
Serotype Risk of acquisition P Timing of acquisition P 
OR (95% CI) HR(95% CI) 
68 1.06 (0.23 - 4.91) .9 0.99 (0.32 - 3.11) 1.0 
14 0.54 (0.07 - 3.85) .5 0.65 (0.14 - 3.00) .6 
19F 0.64 (0.11 - 3.63) .6 0.77 (0.32 -1.81) .5 
19A 9.86 (0.46 - 213.16) .1 6.49 (0.46 - 91.35) .2 
23F 1.91 (0.37 - 9.75) .4 1.41 (0.46 - 4.34) .5 
5.1.5.4. Relationship between colonisation and serum IgG anti-capsular antibodies 
Serum anti-capsular IgG concentration fold-changes (between one and six or six 
and 24 month specimens) were compared by grouping infants by colonisation status for the 
homologous serotype (Table 28). Colonisation by the sixth month visit was not associated 
with a significant increase in homologous serum anti-capsular IgG concentration over the 
same time period, compared with the non-colonised group. The mean anti-capsular IgG 
fold-change between six and 24 months was higher in the those infants who had been 
colonised at any time point compared with the non-colonised group for serotypes 6B, 19F, 
19A, and 23F, although the differences were not statistically significant. However, for 
serotype 14 a significant increase was observed in the colonised group (3.64 vs. 0.41 
J.1g/mL, P < .001). There were no significant differences between the proportions of infants 
with 24 month serum anti-capsular IgG concentrations ~.35 Jlg/mL by colonisation status, 
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with the exception of serotype 14. For this serotype, 76.9% (10/13) of colonised infants 
had "protective" levels of serum IgG compared with 17.4% (4/23) of non-colonised infants 
(p= .001). 
Within individuals, there was a significant correlation between 6 - 24 month fold-
changes for anti-19F and anti-19A (r = 0.47, 95% CI 0.17 - 0.70). These were also 
correlated with the fold-change for anti-6B (6B & 19F: r = 0.56,95% CI 0.28 - 0.75; 6B & 
19A: r = 0.54, 95% CI 0.25 - 0.74). 
5.1.5.5. Antibody responses to individual pneumococcal serotype acquisitions 
The development of serotype specific antibodies following individual 
nasopharyngeal acquisitions was explored. The fold-change in serum anti-capsular IgG 
concentration was calculated between the visit prior to the sampling time point where 
nasopharyngeal acquisition was identified and the visit three months following the 
acquisition time point (i.e. the antibody fold-change over a four month time span). This 
fold-change could be calculated for 94/106 (88.7%) of the target serotype acquisitions: 
those acquisitions occurring up to and including the 21-month nasopharyngeal sampling 
point. Seven acquisitions of serotype 23F (7/24, 29.2%), 5/17 (29.4%) of 6B, 16/33 
(48.5%) of 19F, 10/13 (76.9%) of 14, and 717 (100%) of 19A were associated with a 
measurable increase in homologous serum anti-capsular IgG titre (Figure 23). 
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Figure 23. Fold-changes in serum anti-capsular IgG concentrations in response to 
pneumococcal acquisition, by serotype 
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In the acquisitions where an increase in homologous anti-capsular IgG antibody 
titre was detected, the mean fold-changes were 6.00 (95% CI 3.21 - 11.23) for 68,3.86 
(95% CI 2.17 - 6.88) for 14,3045 (95% CI 2.16 - 5.51) for 19F, 4.08 (95% CI 1040-
11.85) for 19A, 4.83 (95% CI 3.11 .-7.52) for 23F (P = .7). Combining data for all five 
serotypes in a linear regression model with robust standard errors to account for multiple 
acquisitions per infant, older age at acquisition was associated significantly with an 
increase in homologous anti-capsular IgG antibody titre (p = 0.05; 95% CI 0.03 - 0.07; P < 
.001) controlling for serotype reacquisitions within an individual (Figure 24). Considering 
serotypes individually, this association remained significant for 68, 19F and 23F (P == .03, 
.02, and < .001, respectively) (Figure 24). Due to the small sample size, the effect of 
reacquisition of a serotype on magnitude of anti-capsular IgG response could only be 
assessed for 19F (22 primary acquisitions and 15 reacquisitions). Although the mean fold-
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change was greater for reacquisitions than primary acquisitions (2.07 vs. 0.97; P =.1), this 
effect was not significant when controlling for age in the linear regression model (Figure 
25). 
Figure 24. Fold-changes in serum anti-capsular IgG concentrations in response to 
pneumococcal acquisition, by age and serotype 
(J) 
0) 
c 
rn 
.c () 
I 
"0 
.E 
(9 
0) 
E 
::J 
'-Q) 
C/) 
100.0 
10.0 
1.0 
0.1 
o 6 12 18 
Carriage acquisition age (visit month) 
o 68 0 14 0 19F 0 19A 0 23F 
24 
136 
Figure 25. Fold-changes in serum anti-capsular JgG concentration in response to 
nasopharyngeal acquisitions of 19F 
Primary acquisitions (i.e. an infant's first acquisition of 19F) are shown as hollow circles 
and reacquisitions of 19F, following at least two consecutive months without documented 
carriage, are shown as filled circles. 
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Antibody response over alternative time spans of one, two, or three months were 
assessed as part of this analysis: there were no significant differences in IgO fold-changes 
within each serotype when these were compared. However, correlation coefficients for 
fold-change versus acquisition age were superior using the four month interval (data not 
shown). 
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5.1.6. Discussion 
The study objective was to examine the serum anti-capsular JgG responses to 
nasopharyngeal acquisition of common pneumococcal serotypes in a population of 
children aged less than two years, in whom pneumococci were carried frequently. Intensive 
sampling and the use of the latest generation of anti-capsular polysaccharide JgG detection 
ELISA permitted refinement of previous fmdings regarding the immunogenicity of 
nasopharyngeal pneumococcal colonisation in this age group (188, 190,301). 
Although serum concentrations of anti-capsular antibodies were generally low, 
detectable increases in serotype-specific antibody concentration were documented in 
almost half (45/94; 47.8%) of the acquisitions studied. Variations were seen in the 
response to individual serotypes: all19A acquisitions, but only 30% of6B or 23F 
acquisitions, resulted in an increased homologous anti-capsular JgG concentration. There 
was variation in the magnitude of response between serotypes (in the second year of life 
the rank order was 14 > 19A > 19F > 23F > 6B), although this did not reach statistical 
significance. These results are in broad agreement with the reported responses to 
pneumococcal conjugate vaccine in infancy, where serotype 14 is highly immunogenic and 
23F is consistently poorly immunogenic (182, 302-307). In the UK PCV13 study, GMCs 
to 19A were higher than all other serotypes following three doses of vaccine, although this 
serotype was ranked seventh in the US study (302, 304). This suggests that there is an 
intrinsic difference in the immunogenicity between the serotypes which is likely based on 
chemical structure. 
As expected, there was a positive association between antibody response and age at 
pneumococcal acquisition, reflecting the maturation of the infant immune response. Infants 
colonised by serotype 14 had a significantly greater increase in specific anti-capsular IgG 
between six and 24 months of age than non-colonised infants, and a similar trend was 
observed for other serotypes studied. The number of infants studied is likely to have 
limited the power to detect small differences between colonised and non-colonised 
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individuals for the less immunogenic capsular types. It was possible to examine the anti-
capsular IgG responses to both primary nasopharyngeal acquisitions and reacquisitions of 
serotype 19F. Increasing age, rather than previous exposure, defined the magnitude of 
response for this serotype. Although, the numbers were small, there was no evidence of 
immune hyporesponsiveness as a result of previous exposure to 19F when reacquisition of 
this serotype occurred. Given the variation in immunogenicity between capsules, this 
finding may not be generalisable to all serotypes and is in contrast to the finding that 
nasopharyngeal colonisation impacts on the magnitude of subsequent serotype specific 
vaccine responses (308, 309). 
The study results agree in part with findings from previous infant cohort studies. 
Gray and co-workers observed no differences between serum anti-capsular IgG 
concentrations, for serotypes 3, 6, 14, and 23, in carriers versus non-carriers at 12 and 24 
months of age. They did, however, observe serum anti-capsular IgG responses to 
colonisation and infection, particularly when these occurrences represented re-exposure to 
a given serotype, although it is important to note that the methodology used to detennine 
antibody concentrations in these studies has been superseded by more accurate assays 
(188,301). In the Finnish birth cohort study, infants with previous exposure to serotype 
llA or 14 pneumococci had a significantly higher homologous anti-capsular GMC at 24 
months of age compared with non-exposed infants (190). A correlation between expOSure 
and homologous anti-capsular IgG concentration at 24 months of age was not observed for 
the other serotypes studied (6B, 19F, and 23F). Infants were found to have anti-capsular 
antibody responses to non-carried pneumococcal serotypes, a finding possibly related to 
the ELISA methodology, in particular the absence of 22F pre-adsorption of the sera prior 
to analysis. 
At 24 months, a proportion of infants had serum anti-capsular IgG concentrations 
above the putative threshold for protection against invasive disease (0.35 J.1g/mL) and this 
ranged from only 5.6% of infants for 23F to 85.7% of infants for 19A. Serotype 14 was the 
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only serotype in which a significantly greater proportion of colonised infants had 
protective anti-capsular IgG concentrations compared to non-colonised infants at 24 
months of age. Notwithstanding the limitations around the derivation of the correlate of 
protection quoted here, these data support the hypothesis that, although anti-capsular 
antibodies are an important defence against invasive pneumococcal infection, other 
immune mechanisms, perhaps mucosal antibody produced by mucosal B cells or T cells, 
are also critical for the observed decline in incidence for invasive disease caused by all 
common serotypes after the first year of life (310). There was no evidence to suggest that 
maternally derived anti-capsular antibodies reduced the risk, or delayed the timing, of 
acquisition of any of the serotypes studied. Previous work has suggested that a serum anti-
capsular IgG concentration of at least 5 Jlg/mL might be required to protect against 
colonisation in adults, a level higher than the GMCs at one month of age for all serotypes 
studied in the current cohort (184). However, few of the infants studied acquired any of the 
target serotypes before six months of age, limiting the possibility of detection of an effect 
of maternal antibodies on nasopharyngeal acquisition. 
Within individuals, significant correlation was found for fold-changes of serum 
anti-19F and 19A IgG, and also for anti-6B and anti-19F/A IgG concentrations, between 
six and 24 months of age. The correlation between anti-6B and anti-19F was not 
unexpected, given that these serotypes were carried at high frequency in the study infants 
with 19 (52.8%) infants being colonised by either 6B or 19F and nine (25%) infants being 
colonised by both serotypes. With the exception of 19A, 6 - 24 month specific anti-
capsular IgG fold-changes were minimal in non-colonised individuals implying that little 
cross-reactive antibody was produced. Serotype 19A was carried relatively infrequently 
(seven (19.4%) infants) but I?A specific IgG was detected in most infants, most probably 
as a result of antibodies induced by 19F colonisation cross-reacting with 19A as seen after 
vaccination with PCV7 (311). 
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A limitation of the study was that determination of serum IgG levels alone does not 
provide a complete picture of the humoral immune response to pneumococcal colonisation. 
Measurement of mucosal IgA antibody concentration as well as determination of antibody 
function, including assessments of avidity and opsonophagocytic activity (OPA), would 
have been desirable (312, 313). However, to date, correlates of protection against invasive 
disease and colonisation have only been established for serum IgG concentrations (184, 
293). 
In conclusion, this study has demonstrated that nasopharyngeal acquisition of 
pneumococci frequently results in a measurable serum IgG response in infants from six 
months of age. By 24 months of age almost 90% of infants had anti-capsular IgG 
concentrations above the putative protective level for certain serotypes. However, anti-
capsular responses varied considerably by serotype although generally increased in 
magnitude with age. Further work on the immunological mechanisms underlying the 
protection from nasopharyngeal acquisition is required. 
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5.2. Serum antibody responses to a large panel of pneumococcal surface protein 
antigens in the first two years of life 
5.2.1. Summary 
Background 
Next generation vaccines against S. pneumoniae are likely to include pneumococcal 
surface or virulence protein antigens, since these could potentially protect against all 
pneumococcal serotypes. Assessment of antibody responses to nasopharyngeal 
colonisation in early childhood may aid vaccine antigen selection. 
Methods 
Nasopharyngeal swabs and serum specimens were collected from birth until 24 months of 
age in 234 mother-infant pairs. Swabs were cultured to detect pneumococcal colonisation. 
Serum IgG titres to 27 pneumococcal protein antigens were measured in 2,264 sera. 
Results 
Antibodies to all protein antigens were detectable in every maternal serum specimen. 
Transplacental antibody transfer was efficient with mean cord:mother titre ratios between 
0.77 - 1.08. Titres to four proteins (LytB, PcpA, PhtD, and PhtE) were significantly higher 
in mothers colonised by pneumococci at delivery. Maternally-derived antibodies to PiuA 
and SprO096 were associated with delayed pneul!l0coccal acquisition in infants in 
univariate Cox proportional hazards models; however this effect was lost in a multivariate 
model including environmental and household factors. In infants, antibodies to several 
proteins (LytC, PhtD, PhtE, PspA, and SP2027) had weak positive correlations with total 
duration of pneumococcal colonisation or number of new acquisitions. No evidence of 
serum IgG-mediated protection from nasopharyngeal colonisation was detected. 
Conclusions 
Nasopharyngeal colonisation in young children resulted in demonstrable serum IgG 
responses to pneumococcal surface and virulence proteins. However, antibodies to these 
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proteins did not protect against colonisation in an environment where there was frequent 
exposure to pneumococci. 
5.2.2. Introduction 
Currently available pneumococcal conjugate vaccines have been shown to 
significantly reduce the incidence of invasive disease, pneumonia, and otitis media caused 
by most of the serotypes covered included in the vaccine, as well as reduce all-cause 
mortality (3-6, 314). The relative increase in incidence of invasive disease by serotypes not 
included in the vaccines reflects changes in nasopharyngeal pneumococcal colonisation 
following vaccine introduction, since it has been demonstrated that PCVs reduce 
colonisation by vaccine serotypes and that non-vaccine serotypes might then appear in the 
nasopharynx (67,68). The next generation of pneumococcal vaccines would ideally protect 
against all serotypes by targeting conserved cell surface or virulence proteins. Vaccines 
containing pneumococcal proteins have been demonstrated to provide protection against 
invasive pneumococcal disease in mouse models. Proteins that have been evaluated as 
vaccine antigens include the pneumococcal pilus (PI-I, comprising three subunits RrgA, 
RrgB, and RrgC), pneumococcal surface adhesin A (PsaA), pneumococcal surface protein 
A (PspA), pneumococcal surface protein C / choline binding protein A (PspC/CbpA) 
pneumolysin (Ply), histidine triad proteins (PhtA-E), neuraminidase (NanA), iron 
transport proteins (PiuA, PiaA) and also novel proteins, such as a protein required for cell 
wall separation of group B streptococcus (PcsB) and serine/threonine protein kinase 
(8tkP), discovered by ANTIGENome scanning (194, 195). 
Nasopharyngeal colonisation has been demonstrated to result in demonstrable 
serotype-specific antibody responses in adults (184), although antibody responses to the 
polysaccharide capsule in young children are more modest (84, 190). Colonisation by a 
vaccine serotype at the time of PCV immunisation has been shown to result in reduced 
vaccine-induced serum anti-capsular IgG concentrations to the homologous serotype (308). 
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As part of the pneumococcal protein vaccine development process, assessments of the 
relationship between nasopharyngeal colonisation and antigen-specific immune responses 
in young children are critical and may predict whether carriage-mediated vaccine 
hyporesponsiveness might be an issue. Previous studies have shown that antibodies to 
several pneumococcal protein vaccine candidates are measurable in adult human sera and 
that pneumococcal contact in early childhood, either colonisation or otitis media, generally 
results in serum IgG antibody responses, although these are variable by protein and 
population (71, Ill, 198-201, 203-211, 315-317). A study of experimentally induced 
pneumococcal colonisation in adults demonstrated significant serum IgG responses to both 
CbpA and PspA (213) while antibodies to the N-terminal ofPspA were shown in the same 
experimental set up to protect against colonisation (212). To date however, most studies 
have been cross-sectional, have described responses to a small number of protein antigens, 
or included limited sampling points, particularly in the second year oflife where 
pneumococcal colonisation remains common and the infant immune system continues to 
mature. 
5.2.3. Aims and objectives 
The aim of this study was to examine the temporal relationships between 
pneumococcal nasopharyngeal colonisation and development of serum IgG to 
pneumococcal surface and virulence proteins over the first two years of life in a population 
where there is early and sustained pneumococcal carriage in infancy. The effect of 
transplacentally transferred IgG antibodies to these proteins on the timing of first 
pneumococcal colonisation in infants was also explored. 
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5.2.4. Methods 
5.2.4.1. Study site and population 
Specimens collected from mothers and infants from the "immunology" follow-up 
group of the Maela cohort were selected for the current study. At delivery, a 
nasopharyngeal swab (NPS) and serum specimen was collected from the mother and a 
serum specimen obtained from the umbilical cord. After delivery, NPS were taken from 
both mother and infant at monthly intervals, from I - 24 months of age. At these visits, a 
serum sample was also collected from the infants. No further serum specimens were 
obtained from the mother (section 2.2.3). 
5.2.4.2. Detection of pneumococcal nasopharyngeal colonisation 
Nasopharyngeal swabs were collected and processed according the standard WHO 
protocol, as described in sections 2.2.4.1 and 2.2.5.1 (70,291). All pneumococcal isolates 
were serotyped by latex agglutination with Quellung confirmation of equivocal results 
(273). 
5.2.4.3. Antigens and serologic methods 
Antibodies were measured using a direct binding electrochemiluminescence-based 
multiplex assay adapted for the simultaneous quantitation of JgG to 27 selected 
pneumococcal antigens (Table 30). These proteins were generously donated by 
GlaxoSmithKline (GSK), Intercell AG, Novartis, PATH, Sanofi Pasteur, and Prof Susan 
Hollingshead (University of Alabama). 
The assay was based on that described for pneumococcal polysaccharide antigens 
utilising MesoScale Discovery (MSD) technology which employs disposable multispot 
microtitre plates (multi array plates; MSD, Gaithersburg, MD) that include integrated 
screen-printed carbon ink electrodes on the bottom of the wells (318). Antigens were 
bound directly to the carbon surface and JgG from serum was detected using a 
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chemiluminescent antibody. The pneumococcal reference serum 007 was used as a 
standard on each plate and assigned a value of 1000 arbitrary units for each antigen (319). 
Antibody levels in unknown sera were expressed as a titre with reference to the amount in 
007. 
Table 30. Protein antigens assessed 
Name Int.1O Protein details Donor 
CbpA PPOI Choline binding protein A, without choline binding domain (CbpA) aSK 
LytB PPII Endo-beta-N-acetylglucosaminidasc (LytB) Sanofi Pasteur 
LytC PP02 Lysozyme (LytC c-ter) aSK 
NanA PP33 Neuraminidase (NanA) UAB 
PcpA PPI3 Choline binding protein (Pcp A) Sanofi Pasteur 
PcsB-l PP06 Secreted 45 kDa protein (pcsB, SP2216-1) Intercell 
PcsB-l PP32 Secreted 45 kDa protein (pcsB, Spr2021) Novartis 
PhtD-l PP03 Pneumococcal histidine triad 0 (PhtD) GSK 
PhtD-l PPI4 Pneumococcal histidine triad protein (PhtD) Sanofi Pasteur 
PhtE PPIO Truncated histidine triad protein (PhtE-T1) Sanofi Pasteur 
PlaA PP09 Part of iron uptake ABC transporter (PiaA) PATH 
PluA PPOS Part of iron uptake ABC transporter (PiuA) PATH 
Ply-l PPI2 Pneumolysin (Wt-Ply) Sanofi Pasteur 
Ply-l PPI7 Pneumolysin (Ply) VAB 
PsaA PP04 Pneumococcal surface adhesin A (psaA, SP 1650) Intercell 
PspA-Faml PPI6 Pneumococcal surface protein A, family I (PspA) UAB 
PspA-Faml PPI5 Pneumococcal surface protein A, family 2 (pspA) UAB 
RrgA-T4 PP22 RrgA pilus subunit, adhesin (RrgA, TIGR4) Novartis 
RrgB-T4 PPI8 RrgB pilus subunit, backbone (RrgB, TIGR4) Novartis 
Rrg8-68 PPI9 RrgB pilus subunit, backbone (RrgB, serotype 6B) Novartis 
RrgB-13F PP20 RrgB pilus subunit, backbone (RrgB, serotype 23F) Novartis 
StkP PPOS Serine threonine kinase protein (StkP, SPI732-3) Intercell 
Str" PP29 Beta-N-acetylhexosaminidase, (StrH, SprOOS7) Novartis 
SP0609 PP31 Amino acid ABC transporter, amino acid-binding protein Intercell 
SP2027 PP07 Conserved hypothetical protein (Sprlt SP2027) Intercell 
SP2194 PP30 A TP-dependent Clp protease, ATP-binding subunit Intercell 
SprOO96 PP24 LysM domain-containing protein Novartis 
5.2.4.4. Serum specimen selection 
Specimens were selected to obtain good coverage at each sampling point during the 
first year of life and to include the time-points from the second year of life with the largest 
number of specimens. The following specimens were included: 
• All mother delivery and cord specimens; 
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• All specimens from infants with a complete first year set of semm samples. In 
infants with a complete first year serum set, sera collected at the 18 and 24 month 
visits were also included; 
• Specimens from the 6, 12, 18, and 24 month visits in the remaining infants, where 
all of these samples were collected; 
• All six infant sera collected from the only infant to reach 24m without becoming 
colonised by S. pneumoniae. 
5.2.4.5. Statistical analysis 
Antibody titres were normalised by log-transformation prior to analyses. Student's 
t-test was used to compare antibody titres and S. pneumoniae colonisation status in mothers 
at delivery. The impact of cord blood antibody titres on the timing of first pneumococcal 
acquisition in infants was analysed by survival analysis. To analyse infant antibody 
kinetics, geometric mean titres and their 95% confidence intervals were calculated for each 
specimen time point, stratifying by infant colonisation status. An infant was included in the 
"colonised" group at every time point following the first isolation of S. pneumoniae from a 
NPS specimen. To summarise kinetics, GMT ratios were calculated by dividing the 6, 12, 
or 24 month GMT by the cord blood GMT. To explore the relationship between 
colonisation in infancy and serum IgG responses, Pearson correlation coefficients were 
determined for antibody titre fold-changes between 6 or 12 months and 24 months and 
pneumococcal colonisation duration (the number of swabs in which S. pneumoniae was 
isolated) or acquisitions (the first appearance, or re-appearance following ~2 consecutive 
negative NPS specimens, of a pneumococcal serotype in the nasopharynx) in the first two 
years of life. Correlation coefficients were also determined for twelve month antibody 
titres and the number of acquisitions in the second year of life, in order to assess whether 
higher antibody titres at twelve months protected against colonisation in the second year of 
life. 
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5.2.5. Results 
2,264 serum specimens from 230 mothers and 222 infants were included in the 
analyses. This selection comprised 230 mother delivery, 184 cord, and 1,850 infant serum 
specimens (Table 31). 
Table 31. Serum specimens analysed 
Study group Time point Number of sera 
(Infant age (m)) 
Mother Delivery 230 
Cord Delivery 184 
Infant 1 134 
2 134 
3 134 
4 133 
5 133 
6 150 
7 133 
8 132 
9 134 
10 132 
11 134 
12 149 
18 99 
24 119 
Total 2,264 
5.2.5.1. Maternal antibody titres and transplacental transfer 
Two hundred and twenty nine mothers had paired serum and NPS specimens 
collected within seven days of birth: 20.1% (46/229) were colonised by S. pneumoniae. 
Every mother had measurable serum IgG antibodies to all proteins studied. Geometric 
mean antibody titres to four proteins were significantly higher in women who were 
colonised by S. pneumoniae at the time of delivery: LytB (1093.5 VS. 747.9, P = .0002); 
PcpA (1264.4 VS. 981.3, P = .04); PhtD, both PhtD-l (830.3 vs. 613.7, P = .02) and PhtD-2 
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(758.1 vs. 576.4, P = .02); and PhtE (789.0 vs. 571.3, P = .02). There was a trend in the 
same direction for antibodies to Ply-l (712.7 vs. 566.5, P = .07) and PsaA (1674.7 vs. 
1216.9, P= .05). 
There were 183 mother-cord blood specimen pairs. Transplacental antibody 
transfer was efficient: the mean ratio of cord to mother serum antibody titres was between 
0.77 and 1.08 for all proteins. 
5.2.5.2. Cord tit res and time to first pneumococcal acquisition 
There were 184 cord blood specimens analysed and the effect of cord serum 
antibody titres on the timing of first pneumococcal acquisition could be examined in 179 
infants, since five infants were lost to follow-up after collection of the cord blood 
specimen. In these infants, the median time at first pneumococcal acquisition was 46 days 
(IQR 16 - 77) and all but one infant had been colonised by the 11 month visit. 
In univariate Cox proportional hazards models, higher serum IgO antibody titres to 
two proteins, PiuA and Spr0096, were significantly associated with delayed pneumococcal 
acquisition (PiuA: HR 0.68,95% CI 0.46 - 0.98), P = .04; Spr0096: HR 0.73,95% CI 0.57 
- 0.95, P = .02). There were similar trends (HR <1 but P = .05 - .1) for PcsB (both PcsB-l 
& -2) and SP2027. There was no evidence of higher cord blood antibody titres being 
significantly associated with earlier pneumococcal acquisition for any of the proteins (i.e. 
HR>I). 
In a multivariate Cox model, which included environmental factors potentially 
associated with earlier infant pneumococcal acquisition, cord blood antibody titres to PiuA 
(HR 0.70,95% CI 0.45 - 1.08, P = .1) or Spr0096 (HR 0.82,95% CI 0.62 - 1.09, P = .2) 
were no longer significantly associated with timing of pneumococcal acquisition but 
maternal smoking (HR 1.49,95% CI 1.01 - 2.21, P = .046) was significantly associated 
with earlier acquisition age with similar trends for maternal pneumococcal colonisation 
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(HR 1.49, 95% CI 1.00 - 2.25, P = .05) and young children in the household (HR 1.39, 
95% CI 0.99 - 1.96, P = .06). 
5.2.5.3. Antibody kinetics in infants 
In the 222 infants studied, 40.3% were colonised by pneumococci at the one month 
visit and between 66.4% and 88.0% were colonised at each subsequent time point. 
Geometric mean serum IgG antibody titres to all proteins fell rapidly after birth to a nadir 
at a median of 4 months (lQR 3 - 5; range: 2 - 8) (Figure 26). Subsequently, GMTs 
increased and this was largely in response to pneumococcal exposure, although kinetics 
varied considerably by protein (Figure 27). The ratio of GMT at birth (cord blood) to 
twelve months of age ranged from 0.03 to 1.08. The twelve-month GMT for four proteins 
had reached cord blood levels (ratio ~1.0): PsaA, SP0609, SP2027, and SP2194. Serum 
IgG GMT ratios for the cord and 24 month specimens were between 0.10 and 2.00. The 
GMT ratio was >1.0 for seven proteins (LytC, NanA, PcsB (PcsB-l & -2), SP0609, 
SP2027, SP2194, and Spr0096) and <0.5 for another seven (CbpA, PhtE, Ply-2, PspA 
(PspA-Faml & -Fam2), RrgA-T4, RrgB-23F, and StkP) (Figure 28). Evidence of increases 
in specific IgG in the absence of detectable colonisation was seen for certain proteins, most 
clearly pneumolysin (Ply-l & -2) (Figure 27). 
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Figure 26. Geometric mean serum IgG antibody titres to pneumococcal proteins by 
age, with 95% confidence intervals 
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Figure 27. Geometric mean serum IgG antibody titres to pneumococcal proteins, by 
age and pneumococcal colonisation status 
Solid lines represent infants who had become colonised by S. pneumoniae and dashed lines represent infants 
who remained uncolonised. Age "0" indicates cord blood specimens. 
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Figure 28. Mean fold-changes in serum IgG antibody titres in the first two years of 
life 
Titres at 6, 12, and 24 months compared to cord blood titres. 
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In the 99 infants who had complete sets of 24 monthly NPS, pneumococcal 
colonisation was identified in a median of 19 swabs per infant (IQR 16 - 21 , range 6 - 24). 
These infants had a median of eight serotype acquisitions (IQR 7 - 10, range 2 - 15) in the 
first two years of life. To assess whether the length of time an infant carried a 
pneumococcus was associated with changes in specific IgG titre serum anti-protein IgG 
fold-changes from 6 - 24 months of age (i.e. following the loss of maternally-derived 
antibody) were compared with the number of months in which pneumococci were 
identified in the nasopharynx over the first two years of life. Duration of colonisation Was 
not associated with an increased IgG but for anti-PiaA and PiuA IgG, titres were 
negatively correlated (Table 32). As an alternative measure of pneumococcal exposure, the 
total number of pneumococcal serotype acquisitions was compared with antibody 
responses and a small positive correlation was found for PspA-Fam2 specific IgG. 
Restricting both analyses to colonisation in the second year of life, i.e. when the immune 
system is more mature, antibody titres to four proteins (Lyte, PhtD-l, PhtE, and SP2027) 
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were weakly positively correlated with the number of months in which pneumococci were 
identified in the nasopharynx and titres to PhtD (both PhtD-l and -2) were positively 
correlated with number of new pneumococcal acquisitions over this time (Table 32). 
To determine whether serum IgG anti-protein antibodies were protective against 
colonisation, twelve month antibody titres were compared with the number of new 
pneumococcal acquisitions occurring in the second year of life but no protection was 
demonstrated. In contrast, IgG titres specific for three proteins were weakly correlated with 
an increased risk of carriage; Ply (Ply-2; r = 0.21,95% CI 0.02 - 0.40), PspA-Faml (r = 
0.29,95% CI 0.10 - 0.47), and StkP (r = 0.20, 95% CI 0.03 - 0.41). 
Table 32. Associations between serum JgG antibody titre and pneumococcal 
acquisitions or colonisation duration in infants 
For clarity, only statistically significant results (P < .05) are showri. 
Protein 
LytC 
PhtD-l 
PhtD-2 
PhtE 
PlaA 
PluA 
PspA-Fam2 
SP2027 
Colonisation duration 
6-24m IgG titre fold-
change and 
colonisation 0-24m" 
-0.27 (-0.41 - -0.02) 
-0.40 (-0.56 - -0.21) 
Acquisitions 
12-24m IgG titre fold- 6-24m IgG titre fold 
change and colonisation change and acquisitions 
lJ-24m" 0-24m" 
0.22 (0.01 - 0.40) 
0.23 (0.03 - 0.42) 
0.21 (0.01 - 0.40) 
0.22 (0.02 - 0.41) 
0.25 (0.04 - 0.43) 
12-24m IgG titre fold 
change and acquisitions 
lJ-24m" 
0.22 (0.02 - 0.41) 
0.21 (0.0 I - 0.40) 
• Pearson correlation coefficients (with 95% confidence intervals) for fold change in serum IgG antibody titre 
between either 6 or 12 months and 24 months versus number of months colonised by, or new acquisitions of, 
S. pneumoniae in either the first two years of life or just the second year 
5.2.6. Discussion 
This study has docum~nted the development of serum IgG to a large panel of 
pneumococcal surface and virulence proteins, and the effect of transplacental transfer of 
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these antibodies, in a population of SE Asian infants where pneumococcal colonisation 
occurs early in life and is sustained until at least 24 months of age. 
Serum IgG antibodies to all proteins were detected in mothers sampled at delivery. 
Antibody titres to LytB, PcpA, PhtD, and PhtE were significantly higher in mothers who 
were concurrently colonised by pneumococci at the time of delivery, indicating that these 
\0 
proteins are immunogenic in adults. However, they did not appear to protect their infants 
from early colonisation. While higher cord blood IgG titres to PiuA and SprO096 were 
associated with a delay in infant pneumococcal colonisation in univariate analyses, the 
association was lost in a multivariate Cox model where only environmental factors 
remained a significant influence on the timing of initial infant colonisation. Previous 
studies in young infants from the Philippines and Papua New Guinea concluded that 
maternally derived anti-pneumolysin antibodies were associated with delayed infant 
colonisation (71, 111). The Papua New Guinean study also found that higher maternal anti-
PspA family 1 antibodies were associated with earlier colonisation. Reproducing the 
logistic regression analysis described in the Philippine study did demonstrate a trend 
towards delayed colonisation with higher anti-Ply titres in the Maela cohort (data not 
shown), but the Cox regression model remained a more appropriate analysis for this 
dataset. Differences in environmental factors (and the fact that these were included in the 
Cox model in the current study), nasopharyngeal sampling frequency, or assay 
methodology may account for the differences between the Maela results and those from the 
Philippines. 
Infants began developing antibodies to selected proteins from two months of age, 
and this was largely in response to nasopharyngeal colonisation. Certain proteins were 
clearly more immunogenic than others in young infants. For example, antibodies to PsaA 
rose rapidly from two months and the GMT at 12 months was greater than the cord blood 
GMT. This protein has previously been shown to be highly immunogenic in studies from 
Kenya and the Philippines (111, 211). Responses to other proteins were more modest 
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under one year of age, but infants had considerable antibody responses in the second year 
oflife (e.g. PhtD and PhtE). A small number of proteins, notably CbpA, StkP, and PspA 
were poorly immunogenic throughout the study period. Although antibodies to 
pneumococcal pilus proteins are highly protective against invasive disease, antibody 
responses to pilus proteins RrgA, RrgB, and RrgC were relatively modest following 
colonisation, and this likely reflects the non-conserved nature of the pilus-encoding genes 
amongst pneumococci (224). Indeed, the PI-l prevalence was only 35.2% in pneumococci 
carried by the Maela cohort (section 6.1). 
The relationship between serum IgG titres at 12 months and the risk of carriage 
during the second year of life was assessed and there was no protective effect found for 
antibodies to any of the proteins, in terms of a reduction in the number of new 
pneumococcal acquisitions. Indeed, for Ply (Ply-2), PspA-Faml and StkP, the opposite 
was true: higher IgG titres at 12 months were associated with a greater number of 
nasopharyngeal acquisitions in the second year of life. This might indicate relatively 
greater pneumococcal exposure, as a result of household or community contact, in these 
infants which would explain higher antibody titres at 12 months of age. This -conclusion 
fits with the observation that, for several proteins, fold-changes in antibody titres between 
six or 12 and 24 months were positively correlated with either the number of new 
pneumococcal acquisitions or the total number of months an infant was colonised. An 
alternative explanation for the positive correlation between 12 month IgG titres and 
pneumococcal acquisitions in the second year of life is that these antibodies, or mucosal 
IgAl antibodies to the same protein(s), facilitate pneumococcal colonisation, perhaps by 
enhancing attachment to the nasopharyngeal mucosa as has been demonstrated previously 
for anti-capsular JgA 1 antibodies (320). The absence of a protective effect of antibody on 
colonisation may reflect the likely high level of exposure to pneumococci in the 
community in this population but has also been documented for children in Finland and the 
Netherlands and in adults in the UK (184, 200, 203, 206). These finding were in also 
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agreement with results of a mouse colonisation model which concluded that serum 
antibodies to PsaA, PspA, or PpmA (putative proteinase maturation protein A) were not 
responsible for protection against nasopharyngeal colonisation (321). However, there is 
evidence that this may not be the case for all human age groups: colonised children aged 2 
- 12 years in the UK had lower CbpA and Ply antibody titres than non-colonised children, 
indicating possible protective effects (208). Also, PspA has previously been shown to 
protect against experimental colonisation of healthy North American adults (212). Of 
course, these results do not necessarily predict the protective quality of the immune 
response elicited by active immunisation against any of the antigens, although the negative 
correlation between antibody responses to PiaA and PiuA and number of swabs positive 
for pneumococcus in the first two years oflife suggests that tolerance and 
hyporesponsiveness may occur if these proteins were used as components of a 
pneumococcal vaccine. 
The early acquisition and persistence of pneumococcal colonisation in the 
nasopharynx of the study infants were both the most important positive and negative 
aspects of this study. After three months of age more than two-thirds of infants were 
colonised at each monthly time point, pennitting detennination of the kinetics of serum 
IgG development to pneumococcal proteins in a population almost continually exposed to 
S. pneumoniae. In tenns of pneumo~occal colonisation, this population is similar to many 
developing world settings where effective pneumococcal vaccines with broad coverage 
(i.e. not restricted to 7 - 13 serotypes) will have the most benefit. The large panel of 
protein antigens studied and inclusion of serum samples from the second year of life, along 
with associated colonisation data, builds on the findings of the work from Papua New 
Guinea and the Philippines, the two cohorts most similar to the Maela cohort in terms of 
pneumococcal exposure (71, 111, 210). However, this high level of colonisation, coupled 
with the monthly swabbing interval, limited the ability to detect small differences in the 
timing of first pneumococcal acquisition in relation to cord blood antibody titres. In Papua 
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New Guinea weekly swabs were taken from infants during the first month of life, resulting 
in a higher resolution than achieved in the Maela study (71). Detection of correlation 
between antibody titres and colonisation duration or pneumococcal acquisitions were also 
not completely ideal in the current study, since the monthly swabbing interval and the 
imperfect sensitivity of the culture technique may have resulted in missed pneumococcal 
carriage episodes. 
In conclusion, this study demonstrates clearly that there is considerable variation in 
the immunogenicity of pneumococcal surface and virulence proteins in infancy. However, 
nasopharyngeal colonisation by S. pneumoniae in the first two years of life results in 
demonstrable serum IgG responses to these proteins but these antibodies do not provide 
protection against subsequent colonisation in an environment where there is frequent 
exposure to pneumococci. 
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6 Potential modifiers of pneumococcal colonisation: the pneumococcal 
pilus 
6.1. Assessment of Streptococcus pneumon;ae PI-l prevalence in carried and 
transmitted isolates from mother-infant pairs on the Thailand-Burma border 
6.1.1. Summary 
Background 
Streptococcus pneumoniae PI-! encoded pilus enhances in vitro adhesion to the respiratory 
epithelium and may contribute to pneumococcal nasopharyngeal colonisation and 
transmission. The pilus subunits are regarded as potential protein vaccine candidates. The 
aim of this study was to determine PI-l prevalence in carried pneumococcal isolates and 
explore its relationship to transmissibility or carriage duration. 
Methods 
Eight hundred and ninety six pneumococcal carriage isolates collected from mother-infant 
pairs during the Maela cohort study were selected for analysis. These isolates were chosen 
according to specific carriage and transmission definitions and PI-l peR and genotyping 
by Multi Locus Sequence Typing was done on all. 
Results 
Overa1135.2% of the isolates were PI-! positive, but PI-l presence was restricted to 10 of 
the 34 serotypes studied and most frequently associated with serotypes 19F and 23F. 
47.5% of transmitted and 43.3% of non-transmitted pneumococci were PI-l positive (OR 
1.2; 95% CI: 0.8 -1.7; P = .4). The duration of first ever infant pneumococcal carriage was 
significantly longer with PI-l positive organisms, but this difference was not significant at 
the individual serotype level. 
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Conclusions 
PI-l is commonly found in pneumococcal carriage isolates but does not appear to be 
associated with pneumococcal transmissibility or carriage duration. 
6.1.2. Introduction 
The pneumococcal pilus-I is encoded by the pilus islet-I (PI-I; rlrA islet) and is 
composed of three subunits, RrgA, RrgB, and RrgC (219-221). The RrgA subunit of the 
surface exposed pilus-I filamentous structure has been shown to enhance pneumococcal 
adherence to respiratory epithelial cells in vitro (218, 219). The impact of this finding has 
not been assessed in human carriage studies to date. 
Immunisation with pilus antigens is protective against lethal intraperitoneal 
challenge in a mouse model and therefore pilus subunits are regarded as potential 
candidates for inclusion in a protein-based pneumococcal vaccine (222). However, PI-l 
presence is not universal: studies of predominantly invasive pneumococci have found that 
PI-I is present in isolates from a limited number ofserotypes, particularly those included 
in the 7-valent conjugate vaccine, and that its presence correlates with MLST genotype (8, 
197,223-226). Interestingly, recent data from Massachusetts suggests that pilus presence is 
advantageous to pneumococci as evidenced by its increasing prevalence in non-vaccine 
serotypes following PCY introduction (322). 
6.1.3. Aims and objectives 
The aims of the current study were to: i) detennine PI-I prevalence in 
pneumococcal carriage isolates from infants and their mothers; ii) detennine which PI-l 
positive clones were associated with carriage in the study region; iii) explore the possible 
functions of the pilus in vivo, ,and in particular evaluate whether PI -I presence had an 
effect on pneumococcal transmission or carriage duration. 
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6.1.4. Methods 
6.1.4.1. Pneumococcal isolates 
Pneumococcal isolates cultured from NPS specimens collected from the 
"immunology" follow-up group (section 2.2.2) of the pneumonia cohort were included in 
this study. Mother and infant pneumococcal carriage patterns for the first twelve months of 
follow-up were reviewed and isolates chosen for further analysis using the definitions 
described below. 
6.1.4.2. Definition of transmission and carriage 
Transmission of a pneumococcus was defined as the presence of an identical 
pneumococcal serotype and MLST genotype in both mother and infant at the same visit 
("concordant transmission") or when isolated from the mother and the infant during a 
"transmissibility episode" but not at the same visit ("discordant transmission"). A non-
transmitted pneumococcus was a carried serotype that never appeared in the other member 
of the mother-infant pair during the "transmissibility episode" as defined below (Figure 
29). "Transmissibility episodes" were identified by carriage within a mother-infant pair 
where there was the same pneumococcal serotype cultured from ~2 NPS (from mother 
and/or infant), separated by ~2 NPS negative for that serotype. For serotypes 1 and 5, 
known to be carried for very short durations, a single positive NPS could define non-
transmission. 
For the determination of carriage duration in infants, a pneumococcal acquisitioll 
was defmed as midpoint between the last negative swab and the first positive swab for a 
given serotype. Termination of the carriage episode was similarly defined as the midpoint 
between the first of two consecutive negative swabs and the last positive swab for the 
serotype. 
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Figure 29. Pneumococcal serotype transmission examples 
(A) Non-transmission ofserotypes 19F and NT; 
(B) Concordant transmission of serotype 6B; 
(C) Discordant transmission of serotype 23F. Horizontal arrows represent an infant's first 
year oflife, with the numbers indicating age in months. Pneumococcal serotypes shown 
above these arrows represent carried isolates from the infant and those below the arrows 
are from the mother. Shading highlights the criteria used to select isolates for PI-I PCR 
andMLST. 
(A) Non-transmission 
Infant 
Mother 
(B) Concordant transmission 
Infant 
Mother 
(e) Discordant transmission 
6.1.4.3. PI-l detection 
PI-I presence was determined as previously described (224). Briefly, PCRs were 
performed directly from bacteria using the primers listed in Table 33. Primers were 
designed on conserved regions on the boundaries of PI-I (459for, 470rev) and within PI-I 
(PO I rev, Pllfor, POSfor, POSrev). 
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Table 33. PI-l peR primer sets 
Forward Sequence (5'-+3') Reverse Sequence (5'-+3') 
primer primer 
459 for AACTGAATTGACACAACGTGTCTT 470 rev GCCACACAAGATGTTGATGCTTTT 
459 for AACTGAATTGACACAACGTGTCTT POI rev AGCGACAAGCCACTGTATCATATT 
P08 for TGAGATTTTCTCGTTTCTCTTAGC P08 rev AATAGACGATGGGTATTGATCATGT 
Pll for GCCATTTGGATCAGCTAAAAGTT 470 rev GCCACACAAGATGTTGATGCTTTT 
6.1.4.4. Multi Locus Sequence Typing 
MLST was performed as previously described (30). Briefly, PCR amplifications 
were performed directly from the bacteria using the standard primer pairs. Sequences were 
obtained on both strands using an ABI 3730xl DNA Analyser (Life Technologies 
Corporation, USA). Sequence type was determined using the MLST website 
(http://spneumoniae.mlst.net). eBURST (http://spneumoniae.mlst.netleburstl) was run with 
default settings on the entire MLST database and each ST assigned to a clonal complex 
(CC) (31). CCs were named in accordance with the ST number of the founder predicted by 
eBURST. 
All MLST work and eBURST analysis was performed by Dr Michele Barocchi, Dr 
Monica Moschioni, and Ms Sara Melchiorre at the Novartis Vaccines and Diagnostics 
laboratories, Siena, Italy. 
6.1.4.5. Data analysis 
Chi-squared test, Fisher's exact test, and odds ratios were used to compare 
proportions. Carriage duration was estimated by survival analysis methods, using the log-
rank test to compare groups (73). 
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6.1.5. Results 
6.1.5.1. Pneumococcal isolates and PI-l prevalence 
In the ftrst twelve months of follow-up, 4,921 surveillance NPS were collected 
from the 234 mother-infant pairs (84.7% of expected). 2,497 pneumococci were cultured 
and 896 (35.9%) of these isolates were included in the current work. All pneumococcal 
isolates meeting the criteria described below were included, resulting in thirty-four 
serotypes being represented in the strain selection. These serotypes accounted for 90.1 % 
(2,25112,497) of isolates cultured from swabs collected in the first year of follow-up. 
The PI-l status was successfully determined for 887/896 (98.9%) isolates: 35.2% 
(312/887) were positive. PI-l positive isolates were restricted to 10 serotypes: 4, 6A, 6B, 
9V, 14, 19F, 19A, 23F, 33C, and NT (Figure 30). 
Figure 30. PI-l presence by serotype in carried pneumococci 
887 pneumococci, representing all commonly carried serotypes. 
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6.1.5.2. PI-l and transmission 
To analyse whether PI-I presence had an effect on pneumococcal transmission 
within the mother-infant pairs, a panel of strains was selected and analysed by both PI-l 
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PCR and MLST (to define genotype). The serotypes selected for study were those 
contained in, or related to, current conjugate vaccines (PCV13 + 6C) as well as non-
typeable pneumococci which were overrepresented in the study population (the commonest 
pneumococcal "type" identified from mother swabs and the third commonest in infants). In 
the first year of follow-up, these serotypes accounted for 69.6% and 59.8% of 
pneumococci carried by infants and mothers, respectively. In the case of a potentially 
transmitted pneumococcal serotype, i.e. isolates carried by both mother and infant at the 
same visit, or at sequential visits, single isolates from both mother and infant were selected 
for study. For non-transmitted pneumococci, i.e. pneumococci carried by only the mother 
or infant, a single isolate was studied. Additionally, every isolate from carriage episodes of 
all serotypes in eight mother-infant pairs was analysed to determine the c10nality of 
pneumococcal carriage. 
Of the 489 isolates selected for the primary analysis, PI-l PCR was uninterpretable 
in six, resulting in 483 analysable pneumococcal isolates. Ovenill, 219/483 (45.3%) of 
these isolates were PI-l positive. PI-l was found in non-typeable pneumococci and in 6/14 
serotypes studied, all of which, apart from one 19A isolate, were PCV7 serotypes (Table 
34). 
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Table 34. Pneumococcal serotype distribution, pilus presence, and isolate 
transmission category in mother-infant pairs 
Serotype Total, Transmitted·, PI-I present, 
N N (% within serotype) N (% within serotype) 
1 12 4 (33.3) 0 
3 11 4 (36.4) 0 
4 4 2 (50.0) 0 
5 10 2 (20.0) 0 
6A 16 6 (37.5) 0 
6B 54 27 (50.0) 29 (53.7) 
6C 15 4 (26.7) 0 
7F 5 2 (40.0) 0 
9V 8 4 (50.0) 5 (62.5) 
14 46 28 (60.9) 15 (32.6) 
t8C 7 4 (57.1) 0 
t9F 89 50 (56.2) 81 (91.0) 
19A 14 4 (28.6) 1 (7.1) 
23F 82 38 (46.3) 63 (76.8) 
NT 110 57 (51.8) 25 (22.7) 
Total 483 236 (48.9) 219 (45.3) 
a Concordant and discordant transmission combined 
PI-l was found most frequently in 19F (91 %) and 23F (77%) although these 
serotypes, according to the MLST and eBURST analyses, were dominated by a single 
clonal complex each (CC271 - 19F; CC802 - 23F). Overall, PI-l positive pneumococci 
were members of a restricted group of clonal complexes (Figure 31). 
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Figure 31. PI-l presence by clonal complex 
483 carried pneumococci (PCV 13 serotypes plus 6C and NT). 
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By serotyping a representative isolate alone, 253/483 (52.4%) pneumococci would 
have been classified as transmitted (153 concordant; 100 discordant) and 230/483 (47.6%) 
as non-transmitted. Combining MLST and serotype, nine concordant and eight discordant 
"transmitted" isolates (17/483; 3.5%) were reclassified as non-transmitted, resu lting in a 
final total of 236/483 (48.9%) transmitted and 247/483 (5 1. 1%) non-transmitted 
pneumococci. PI-l presence was not correlated with transmission: 47.5% ( 112/236) of 
transmitted and 43.3% (I 07/247) of non-transmitted pneumococci were PI- I positive, with 
an odds ratio of 1.2 (95% CI 0.8 - 1.7, P = .4), and no significant differences at the 
individual serotype level. 
An additional 91 pneumococcal isolates, from seven mother-infant pairs and one 
mother-twin infant unit, were analysed to confirm that sequential isolates of the same 
serotype within an individual, and isolates of the same serotype within a mother-infant 
pair, were indeed identical. In all mother-infant pairs each serotype carried was represented 
by a single ST per carriage/transmission episode with three exceptions (Table 35). 
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Table 35. Detailed study of pneumococcal carriage in the first year of life in eight mother-infant pairs 
N 
Pneumococcal serotypes and their MLST genotype (in parentheses) are given for each nasopharyngeal sampling point. t--..... 
Pair Category Infant age (m) 
. 
1 2 3 4 5 6 7 8 9 10 11 12 
Pair] Infant 19A (230) 19A (230) 14 (63) 14 (63) 14 (63) NT (4133) 6C(4420) 6C (4420) 6C (4420) 6C (4420) NT (4133) 
Mother 35F (441S) 14 (63) 7F (3545) 7F (3545) 
Pair 2 Infant NT (4136) NT (4136) NT (4136) NT (4136) NT (4136) NT (4136) NT (4136) NT (4136) 
Mother NT (4136) 7F (3545) 7F (3545) NT (4136) 7F (3545) 7F (3545) 7F (3545) 1F (3545) NT (4136) NT (4136) NT (4136) NT (4136) 
Pair 3 Infant 14 (63) 14 (63) 14 (63) NT (4451) 14 (63) 14 (63) 19F (SI) 22A(910) 19F (S1) 22A(910) 
Mother 32A(5092) 32A(5092) 32A(5092) NT (5121) 14 (63) NT (4451) 14 (4451) NT (4451) 32A(5092) NT (4451) 19F (SI) 
Pair 4 Infant 19F (4414) 19F (4414) 19F (4414) 19F (4414) 19F (4414) 19F (4414) 23F (S02) 19F (4414) 19F (4414) 23F (S02) 
Mother 37 (447) 37 (447) 37 (447) 37 (447) 37 (447) 37 (447) 19F (4414) 
PairS Infant 1 NT (44S) 33C (5096) 33C(5096) 17F (509S) 21 (5103) 21 (5103) 19F (5106) 19F (5106) 19F (4414) 19F (4414) 6A(4936) 19F (4414) NT (44S) 
(twins) Infant 2 I1F (509S) 21 (5103) 21 (5103) 17F (509S) 21 (5103) 21 (5103) 21 (5103) 19F (4414) 6A(4936) 6A (4936) 
Mother NT (44S) 1 (217) NT (44S) 
Pair 6 Infant NT (4133) NT (4133) 19B (5095) 1 (217) NT (4133) 9V(280) 9V(2S0) 19F (4414) 19F(4414) 19F (4414) 19F (4414) 
Mother 19B (5095) 19B (5095) NT (4133) 9V (5123) 9V(2S0) 
Pair 7 Infant 45 (5097) 45 (5097) 23F (S02) 23F (S02) 23F (S02) 6B (315) 23F (802) 23F(S02) 23F (S02) 
Mother 23F (802) 23F (S02) 23F (S02) 6B (315) 23F (802) 
Pair 8 Infant 23F (4413) 23F (4413) 23F (4413) 23F (4413) 23F (4413) 23F (4413) 
Mother 23F (4413) 23F (4413) 
6.1.5.3. PI-l and first pneumococcal carriage episode duration in infants 
To analyse the correlation between PI-I presence and the duration of infant 
carriage, the PI-I status was determined for 316 isolates from fIrst carriage episodes of all 
common serotypes (defIned as serotypes with at least ten carriage episodes). These 
episodes included first episodes of carriage of each serotype, not only an infant's first ever 
pneumococcal carriage episode. PI-l status for the entire carriage episode was inferred 
from the PI-l PCR result of a single isolate. 
Given the well described association of shorter carriage in individuals with prior 
pneumococcal exposure, analysis was subsequently focussed on only first ever episodes of 
carriage (i.e. one per infant) (73). From the 316 carriage episodes selected, 216 analysable 
first ever carriage episodes were identified: PI-l PCR data were available for at least one 
isolate in 180 of these (90 PCV13 serotypes, 58 non-vaccine serotypes, and 32 non-
typeable pneumococci). Median and mean durations ofthese fI~st pneumococcal carriage 
episodes were 63 days (95% CI 61 - 91) and 105 days (95% CI 91 - 119) respectively, but 
varied considerably by serotype as previously described (Table 36). 
Table 36. First pneumococcal carriage episode duration for the six commonest 
serotypes 
Serotype Number of episodes Carriage duration (days), 
median (95% CI) 
68 13 121(90-153) 
14 8 62 (30 -151) 
19F 21 213 (63 - 243) 
23F 21 184 (62 - 277) 
35F 9 121 (30 - 180) 
NT 33 31 (31- 61) 
Comparing the 180 carriage episodes where PI-l PCR results were available, PI-l 
positive carriage episodes (511180; 28.3%) were significantly longer than those associated 
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with a PI-l negative organism (median 152 days (95% CI 93 - 213) vs. 61 days (95% CI 
57 - 90); P < .0001) (Figure 32). However, the analysis of carriage duration was 
confounded by serotype. Serotypes 19F and 23F had the longest duration of carriage and 
were both predominantly PI-l positive. To analyse the relative contribution of serotype and 
PI-l to carriage duration a Cox regression model was fitted: stratifying carriage by 
serotype, PI-l presence was not associated with a significant change in carriage duration 
(HR 0.7 (95% CI 0.4 - 1.2; P = .2)). 
Figure 32. Impact of pilus on first pneumococcal carriage episode duration in infants 
Stratified by vaccine or non-vaccine serotype and PI-l presence. All NVT isolates were PI-
1 negative. 
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6.1.6. Discussion 
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This study is the largest investigation of the prevalence and possible function of the 
PI-l encoded pilus in carriage isolates of S. pneumoniae reported in the literature to date. 
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As serotypes are commonly used as the basis for defining transmission, it was of interest to 
determine in the frequency with which a molecular analysis may confound the analysis of 
transmission. By genotyping, discrepancies were discovered in only 3.5% of transmission 
events classified by serotype. The study also demonstrated that pneumococci of the same 
serotype are predominantly clonal within a discrete carriage episode. It can therefore be 
concluded that serotype can be used to define transmission events and carriage episodes 
with relatively high confidence, but the inclusion of genotyping is vital to ensure complete 
accuracy. 
Because of the selection criteria for isolates included in the study, the overall pilus 
prevalence for the population cannot be described. However, in the 887 carriage isolates 
analysed the pilus prevalence was 35.2%. Of the 34 serotypes analysed, PI-lwas only 
present in non-typeable isolates and nine other serotypes: 65% ofPCV7 isolates were PI-l 
positive compared with 9% of non-vaccine serotypes. Interestingly, Basset et al., 
; 
examining nasopharyngeal and invasive pneumococcal isolates from the American Indian 
collection, also found that PCV7 strains were significantly more likely to be PI-l positive 
than non-vaccine serotypes, but the overall proportion of PI-I positive isolates was slightly 
lower (223). They, along with other authors, demonstrated that PI-l positive strains were 
contained within a small number of clonal complexes (224-226). Indeed, in the current 
study it was demonstrated that PI-I, positive isolates were clustered predominantly within 
four dominant clonal complexes (CC 15, CC271, CC3l5, and CC802). The strong 
association between serotype/clonal complex and pilus presence, along with strain 
selection criteria, and the different regional distribution of the clones may explain the 
variability in PI-l prevalence between different studies. 
A pilus-attributable effect on pneumococcal transmissibility could not be 
demonstrated. However, there are limitations to the study which may be important 
confounders for this analysis. The carriage study was carried out in a densely populated 
refugee camp where 15% of the population are <5 years old and there is likely to be 
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frequent transmission of nasopharyngeal organisms both within families and between 
members of the community. Despite using a combination of serotype and sequence type to 
increase the accuracy of the transmissibility categories, the possibility that "non-
transmitted" strains were effectively transmitted between mother or infant and others but 
were not detected cannot be excluded. Several studies have documented the clustering of 
pneumococcal serotypes and genotypes within families, which highlights the difficulty of 
assigning a defmitive "non-transmitted" label to isolates collected from an incomplete 
household group (170, 176). However, the study focused on mother-infant transmission 
since it was felt that the absence of a strain in one member of this pair would be the best 
marker for relative non-transmissibility in the early months oflife. In addition, both 
concordant and discordant time-point pneumococcal serotype/ST identifications in the 
mother-infant pair were included as "transmitted", as long as they occurred no more than 
two months apart. However, the study sampling frequency may have been too low to 
demonstrate transmission of serotypes carried for very short durations. Also, in the 
presence of multiple serotype carriage, a common occurrence in infancy and one that is 
underestimated by standard culture protocols (section 4), a particular serotype may become 
undetectable for a period of time before re-emerging as the dominant serotype which may 
result in incorrect categorisation regarding transmissibility. 
Although in the crude analysis PI-l presence was associated with longer first 
pneumococcal carriage episode in infants, no significant association between carriage 
duration and PI-l could be found at the individual serotype level. This is likely to be the 
result of the low numbers of carriage episodes of individual serotypes (resulting in wide 
confidence intervals around the carriage duration estimates) and the restricted number of 
clones within each serotype. !he number of carriage episodes analysed could have been 
increased by looking at all carriage episodes of each serotype rather than restricting to each 
infants first ever carriage episodes, but this would have introduced other confounding 
factors, such as the impact of previous carriage and immune factors in subsequent carriage 
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episode duration. Therefore, it is possible that, as a result the study sample size, a small 
effect of pilus on either transmission or carriage duration may have been missed. 
In conclusion, SE Asian pneumococcal carriage isolates had similar pilus 
prevalence to previously described strain collections, which is helpful in the on-going 
assessment of likely global coverage of a pilus subunit-containing vaccine. Despite its 
known role in pneumococcal attachment, an unequivocal impact of PI-I presence on 
transmissibility or carriage duration could not be determined. 
177 
7 Potential modifiers of pneumococcal colonisation: other inhabitants of 
the nasopharynx 
7.1. The relationships between non-pneumococcal bacterial colonisation, viral 
infection and pneumococcal nasopharyngeal colonisation 
7.1.1. Summary 
Background 
Interactions between the various colonisers of the nasopharyngeal space are complex and 
incompletely understood. The aim of this study was determine the impact of co-
colonisation by bacteria and viruses on pneumococcal colonisation in infants and their 
mothers. 
Methods 
Nasopharyngeal swabs collected from infants during the Maela cohort study were cultured 
onto both CNA-blood and chocolate agar plates to detect bacterial colonisers, in particular 
H. injluenzae, M catarrhalis, S. aureus, and S. pneumoniae. The impact of viral infection, 
detected by PCR of nasopharyngeal aspirates during pneumonia episodes, on bacterial 
colonisation was also assessed in these infants. Maternal swabs collected at six-monthly 
intervals were re-cultured to determine interactions between S. pneumoniae and S. aureus. 
Results 
Staphylococcus aureus was acquired at an early age (median 17 days) but only 65.8% were 
colonised during the first 24 months of life. H. injluenzae and M catarrhalis were acquired 
slightly later (median 46 and 61 days, respectively) and colonisation was almost universal. 
In a multivariate model, recent antimicrobial use (OR 0.4, P < .001) and S. aureus 
colonisation (OR 0.3, P < .001) were negatively associated with pneumococcal 
colonisation, whereas H. injluenzae (OR 2.9, P< .001) or M catarrhalis (OR 2.1, P < 
.00 I) colonisation were positively associated. During first pneumonia episodes, detection 
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of respiratory syncytial virus was negatively associated with pneumococcal colonisation 
(OR 0.5, P = .02). Although a trend to a negative association between S. pneumoniae and 
S. aureus colonisation in mothers was found in a crude analysis, this was lost when 
controlling for clustering (OR 0.7, P = .3). 
Conclusions 
Co-colonisation of the nasopharynx by several bacterial pathogens was common, and 
occurred early, in Maela infants. The observed negative association between RSV infection 
and pneumococcal colonisation requires further study. 
7.1.2. Introduction 
Bacterial colonisation of the nasopharynx is a complex dynamic and interactive 
process. Previous studies of children from geographically diverse locations have generally 
documented positive correlations between nasopharyngeal colonisation by S. pneumoniae, 
H. injluenzae, and M catarrhalis (105, 235, 241-243) and a negative correlation between 
S. aureus and S. pneumoniae (48, 233, 234). Viral infection of the respiratory tract 
predisposes to bacterial colonisation by several mechanisms which reduce clearance or 
increase adherence of bacteria to the respiratory epithelium (2S6, 257). Few studies of 
colonisation have specifically focussed on the interactions between both bacteria and 
viruses (241, 245). 
7.1.3. Aims and objectives 
The aim of this study was to explore the relationships between both common 
bacterial and viral colonisers of the nasopharynx. 
7.1.4. Methods 
Three selections were made from specimens collected during the Maela cohort 
study. 
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7.1.4.1. Associations between bacterial nasopharyngeal colonisers in infants 
Nasopharyngeal swab specimens collected from the "immunology" follow-up 
group of the Maela pneumonia cohort were further analysed. 
Ten microlitres of thawed STGG from all 4,191 infant NPS were cultured onto a 
chocolate agar plate (Clinical Diagnostics, Bangkok, Thailand) at the same time as 10 JlL 
STGG was cultured onto CNA-blood agar (bioMerieux, Marcy L'Etoile, France) to detect 
S. pneumoniae colonisation as previously described (section 2.2.5.1.2). After overnight 
incubation at 35-37°C in 5% C02, plates were examined for the presence of target 
organisms (H. injluenzae and M catarrhalis). Colonisation by S. aureus was established 
by examination of the CNA-blood agar plate. Target organisms were confirmed by 
standard microbiological techniques as described in section 2.2.5.1.3. Briefly, H. 
influenzae was confirmed by X+V factor dependent growth. All isolates of H. injluenzae 
were serotyped by slide agglutination using polyclonal and monoClonal antisera (Becton 
Dickinson, Franklin Lakes NJ, USA). M catarrhalis was confirmed by colony 
morphology and trybutyrin production (Rosco Diatabs, Taastrup, Denmark). S. aureus was 
identified by DNase production and the slide coagulase test. 
7.1.4.2. Associations between Staphylococcus aureus and Streptococcus pneumoniae 
colonisation in mothers 
To further explore the potential interactions between S. pneumoniae and S. aureus 
colonisation, nasopharyngeal swabs from mothers who had provided swabs at the delivery, 
6 month, 12 month, 18 month, and 24 month visits were thawed and 10 JlL ofSTGG was 
re-cultured onto CNA-blood agar plates. S. aureus was identified as described previously. 
7.1.4.3. Associations between bacterial nasopharyngeal colonisers and viral infection 
All cohort infants (i.e. "immunology" and "routine" follow-up groups combined) 
had a nasopharyngeal swab and aspirate collected if they were brought to the clinic unwell 
and met the WHO clinical case defmition for pneumonia (section 2.2.3.3). The NPS were 
180 
cultured on CNA-blood agar and chocolate agar plates as previously described (section 
2.2.5.1). For "routine" follow-up infants, whose monthly surveillance NPS were not 
automatically cultured, NPS from the 2 - 3 months preceding the pneumonia episode NPS 
were also cultured. Respiratory viruses were detected in NP A specimens as described in 
section 2.2.5.3. 
7.1.4.4. Data analysis 
Times to acquisition of target pathogens were estimated by survival analysis. For 
longitudinal data, associations between organisms were assessed by generalised estimating 
equations with a logistic link and exchangeable correlation structure to account for 
multiple observations per individual. For the pneumonia episodes, organism associations 
were assessed by multivariate logistic regression. Proportions were compared by chi-
squared test. The organism heat map was generated in StataJIC 12.1 (StataCorp, College 
Station TX, USA) using the "hmap" command. 
7.1.5. Results 
7.1.5.1. Colonisation in infants 
7.1.5.1.1. Acquisition age 
As previously described (section 3.1.5.1), infants acquired pneumococci at an early 
age (median 46 days, IQR 16 -76) and all but one infant followed for more than one year 
carried pneumococci (1801181; 99.5%). H. injluenzae acquisition characteristics were 
similar (median acquisition age 46 days, IQR 16 - 79) and all but one infant carried H. 
injluenzae at least once (180/181; 99.5%). Moraxella catarrhalis was acquired slightly 
later (median 61 days, IQR 44 - 106) but all infants carried the organism at some stage. S. 
aureus was acquired very early (median 17 days (IQR 16 - (0); however only 65.8% 
(119/181) of infants acquired the organism (Figure 33). 
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Figure 33. Time to first acquisition of nasopharyngeal colonisers in immunology 
infants 
(aJ S. pneumoniae, (b) H. injluenzae, (c) M catarrhalis, and (d) S. aureus. 
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7.1.5.1.2. Monthly colonisation point prevalence 
Streptococcus pneumoniae was cultured from 76.3% (3,192/4,182) of infant swabs. 
H. injluenzae was cultured from 64.5% (2,696/4,182), M catarrhalis from 59.4% 
(2,483/4,182), and S. aureus from 6.8% (286/4,182) swabs. Ninety five percent of H 
injluenzae isolates were non-typeable and 68.8% (99/144) of typeable isolates were type b. 
Monthly point prevalence of each organism is summarised in Figure 34. At the three 
month NPS visit, S. pneumoniae, H injluenzae, and M catarrhalis were detected in 
73.2%,67.5%, and 55.0% of swabs respectively. Monthly point prevalences for these 
organisms subsequently remained >50% for the remainder of the follow-up period. The 
opposite trend was observed for S. aureus: 53.0% of infants were colonised at the first 
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month visit and this proportion subsequently declined rapidly, with only 11.0% of three 
month swabs positive for the organism. 
Figure 34. Point prevalence of nasopbaryngeal colonisers in immunology infants 
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7.1.5.1.3. Associations between pneumococcal colonisation, otber nasopharyngeal 
colonisers, and environment 
Detection of pneumococci plus one (30.9%; 1,293/4,182) or two (37.2%; 
1,555/4,182) additional target organisms was common, occurring in 68.1% of all infant 
NPS specimens. All four organisms were detected in 0.9% (38/4,182) swabs. S. 
pneumoniae was the only target organism detected in 9.6% (30613,192) of swabs from 
which pneumococci were cultured. There was no obvious temporal association between the 
number of target organisms detected and infant age (Figure 35). 
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Figure 35. Heat map of nasopharyngeal colonisation by Streptococcus pneumoniae, 
Haemophilus influenzae, Moraxella catarrhalis, and Staphylococcus aureus 
The figure summarises 100 "immunology" follow-up group infants with complete sets of 
24 monthly swabs. The number of species detected (from 0- 4) is indicated by shading 
(light grey - black)). Each infant is represented by an individual row . 
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By univariate analysis, pneumococcal colonisation was positively associated with 
increasing age, female gender, co-habiting with other young children, detection of 
pneumococci in the preceding months swab, and colonisation by either H. injluenzae or M 
catarrhalis. Recent antimicrobial use and colonisation by S. aureus were negatively 
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associated with pneumococcal detection (Table 37). All factors were included in a 
multivariate logistic regression (GEE) model. Age, additional young children in the 
household, H. injluenzae or M catarrhalis colonisation remained positively associated 
with pneumococcal colonisation whereas antimicrobial use and S. aureus colonisation 
were negatively associated (Table 37). 
Table 37. Associations between environmental factors, other nasopharyngeal 
colonisers and pneumococcal colonisation 
Analyses included all 234 "immunology" follow-up group infants. Results are odds ratios 
with 95% CI for detection of S. pneumoniae. 
Factor Univariate model Multivariate model 
OR (95% CI) P OR (95% CI) P 
Age (/month increase) 1.03 (l.02 - 1.04) <.001 0.98 (0.97 - 1.00) .006 
Female gender 1.34 (1.04 - 1.73) .03 1.22 (0.99 - 1.51) .07 
Large household (>5 people) 1.16 (0.89 - 1.51) .3 1.02 (0.82 - 1.27) .8 
Children <5y in house 1.70 (1.31 - 2.21) <.001 1.41 (1.14 - 1.76) .002 
Episode of antibiotics within 30d 0.47 (0.39 - 0.58) <.001 0.42 (0.34 - 0.54) <.001 
S. pneumoniae in preceding swab 3.31 (2.83 - 3.86) <.001 2.75 (2.31 - 3.28) <.001 
Colonisation by: 
H. influenzae 3.30 (2.84 - 3.85) <.001 2.90 (2.46 - 3.43) <.001 
M. catarrhalis 2.41 (2.09 - 2.78) <.001 2.14 (1.81 - 2.52) <.001 
S. aureus 0.18 (0.14 - 0.23) <.001 0.30 (0.23 - 0.41) <.001 
7.1.5.2. Co-colonisation in mothers 
Analysable swab sets (defined here as complete sets of 0 (delivery), 6, 12, 18, and 
24 month NPS specimens) were available for 111 mothers. Pneumococci were detected in 
26.7% (148/555) specimens, and PCV7 serotypes were found in 21 swabs (3.8%). S. 
aureus was detected in 12.6% (70/555) specimens and there was a trend towards a negative 
association with increasing infant age (OR 0.97, 95% CI 0.95 - 1.00, P = .06). In a crude 
analysis, there was a trend towards a negative association between overall pneumococcal 
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colonisation and S. aureus colonisation: pneumococci were detected in 17.1 % (12170) of 
cultures where S. aureus was also detected compared with 28.0% (136/485) of cultures 
where S. aureus was not detected (P = .05) (Figure 36). However, this association was lost 
when controlling for clustering using a GEE (OR 0.72, 95% CI 0.40 - 1.28, P = .3). 
Exclusion of NT pneumococcal colonisation from the analysis did not alter this fmding 
(OR 0.92,95% CI 0.47 - 1.79, P = .8). There was no specific association between 
colonisation by a PCV7 serotype and S. aureus colonisation (OR 0.83, 95% CI 0.20 - 3.48, 
P=.8). 
Figure 36. Point prevalence of Streptococcus pneumoniae and Staphylococcus aureus 
nasopharyngeal colonisation in mothers 
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7.1.5.3. Colonisation during clinically diagnosed pneumonia episodes 
F our hundred and sixty eight first episodes of pneumonia diagnosed by WHO 
clinical criteria were analysed. The median age at diagnosis was 205 days (IQR 118 - 329; 
range 10 -726; Figure 37). Pneumonia was highly seasonal, with peaks occurring in the 
late rainy season (September to November) each year (Figure 38). 
Pneumococci were detected in 73.3% (343/468) of the NPS specimens. At least one 
virus was detected in 66.2% (310/468) of the NP A specimens. RSV was the most 
commonly detected virus (203; 43.4% ofNPA), followed by adenovirus (158; 33.8%), 
hMPV (39; 8.3%), and influenza viruses (30; 6.4%). Multiple virus detection was 
common, occurring in 23.7% (1111468) ofNPAs. Virus detection was also highly seasonal, 
with a large peak of RSV detection coinciding with the peak of pneumonia incidence each 
year (Figure 38). 
In agreement with the previous analyses of longitudinal data, preceding 
pneumococcal colonisation or colonisation by H. injluenzae or M catarrhalis were 
positively association with pneumococcal detection by univariate analysis. S. aureus 
colonisation was negatively associated with pneumococcal detection. By univariate 
analysis, RSV detection was negatively associated with pneumococcal detection and there 
was a trend towards a positive association between influenza virus detection and 
pneumococcal colonisation (Table 38 & Figure 39). In a multivariate logistic regression 
model, controlling for age, gender, season of diagnosis, recent antimicrobial use, and co-
colonisation, RSV detection remained negatively associated with pneumococcal detection 
(OR 0.52, P = .02; Table 38). 
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Figure 37. Histogram of infant age at first pneumonia diagnosis 
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Figure 38. Seasonality of pneumonia diagnosis, pneumococcal colonisation, and virus 
detection 
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Table 38. Factors associated with pneumococcal colonisation detection at time of first 
WHO clinical pneumonia episode in 468 infants 
The results are odd ratios (with 95% CIs) for detection of S. pneumoniae. All factors were 
included in the multivariate model. 
Factor Univariate analysis Multivariate analysis 
OR (950/0 CI) P OR (95% CI) P 
Age (/month increase) 1.09 (1.04 - 1.14) <.001 1.03 (0.98 - 1.08) .2 
Female gender 1.43 (0.95 - 2.16) .09 1.18 (0.74 - 1.90) .5 
Season at diagnosis 
Hot 
-
Wet 0.86 (0.47 - 1.58) .6 1.37 (0.63 - 2.99) .4 
Cool 0.67 (0.35 - 1.29) .6 1.33 ( 0.60 - 2.97) .5 
Recent antibiotics (<30d) 0.55 (0.33 - 0.92) .02 0.82 (0.45 - 1.49) .5 
Pneumococci identified 8.41 (5.07 - 13.95) <.001 7.20 (4.13 - 12.55) <.001 
in preceding swab (<45d) 
Bacterial colonisation 
S. aureus 0.33 (0.15 - 0.73) .006 0.78 (0.30 - 2.02) .6 
H. injluenzae 2.18 (1.43 - 3.32) <.001 2.06 (1.27 - 3.35) .003 
M. catarrh a/is 1.94 (1.27 - 2.94) .002 1.55 (0.84 - 2.55) .09 
Viral infection 
Adenovirus 1.11 (0.72 - 1.73) .6 1.09 (0.66 - 1.81) .7 
Influenza AlB 2.48 (0.85 - 7.26) .1 2.58 (0.77 - 8.61) .1 
hMPV 1.06 (0.50 - 2.25) .9 0.68 (0.28 - 1.64) .4 
RSV 0.59 (0.39 - 0.90) .01 0.52 (0.30 - 0.92) .02 
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Figure 39. Pneumococcal colonisation status at pneumonia diagnosis by RSV and 
influenza virus peR result and age group 
The graph indicates the proportion of infants colonised with pneumococci at diagnosis of 
their fIrst clinical pneumonia episode, stratified by virus detection (from the NPA collected 
at the same time point) and age group. 
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This study demonstrates the high prevalence of nasopharyngeal colonisation by 
multiple potential respiratory pathogens in Maela infants, a population currently naive to 
pneumococcal conjugate and Hib vaccines. Colonisation by S. aureus preceded the other 
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target pathogens but was virtually absent after six months of age. Co-colonisation by s. 
pneumoniae and at least one of the other target organisms occurred frequently and was 
detected in around two-thirds of all infant NPS specimens. Detection of either H. 
injluenzae or M catarrhalis was significantly positively correlated with pneumococcal 
detection in infants. These results agree with previously published studies from similar 
populations, such as Papua New Guinea and rural Australia (48, 89, 105, 241). Using PCR, 
Kwambana and colleagues documented nasopharyngeal acquisition ages of three (H. 
injluenzae), five (s. pneumoniae), and seven weeks (M catarrhalis) in a cohort of 
Gambian infants (235). A negative association between S. aureus and S. pneumoniae 
colonisation was seen in this study and has also been found in other studies (233, 234). 
Several explanations have been put forward for this observation, which is most marked 
between S. aureus and PCV7 serotypes, including hydrogen peroxide-mediated inter-
species competition (236) or an effect of the pneumococcal pilus (238). However, the 
absence of a negative association in HIV -infected infants suggests that an immunological 
mechanism may be the key (239). Anti-pneumococcal antibodies may cross-react with S. 
aureus and result in inhibition of acquisition of this organism (259). A negative association 
between pneumococcal and S. aureus colonisation was found in Maela mothers, although 
this did not achieve statistical significance perhaps reflecting the sample size and the low 
frequency of carriage of PCV7 serotypes. 
Similar bacterial associations were found in the nasopharyngeal swabs collected 
from cohort infants during their first episode of clinically diagnosed pneumonia. As 
expected a positive association was seen between influenza virus infection and 
pneumococcal colonisation, although this failed to reach statistical significance, possibly as 
a result of the small number of proven influenza infections and the high prevalence of 
pneumococcal colonisation. Infection of the upper airways by influenza virus results in an 
increased load, greater adherence, and increase likelihood oftransmissibility of 
pneumococci and this is mediated by a variety of incompletely understood mechanisms 
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(259, 260). RSV also increases pneumococcal adherence to the upper respiratory tract 
epithelium (261, 262). Pneumococcal conjugate vaccine reduced the number of virus-
associated pneumonias in South African children, including a 22% fall in RSV -associated 
pneumonia (255). There is also a temporal association between RSV activity and invasive 
pneumococcal disease incidence (251). It was, therefore, unexpected to fmd a negative 
association between RSV detection and pneumococcal colonisation, especially given the 
high prevalence of pneumococcal colonisation the study infants. A plausible biological 
mechanism to explain this fmding is elusive and further work is required to assess its 
veracity and importance. A significant limitation of the current study was the selection of 
only pneumonia episodes for inclusion of viral testing. It may be that the negative 
association between RSV and pneumococcal colonisation occurred as a result of this 
specimen selection bias. Jacoby and colleagues perfonned a longitudinal carriage study in 
Australian infants (0 - 2 years) which included bacterial and virus detection at each 
sampling point. Positive associations were found between rhinovirus and S. pneumoniae 
and between adenovirus and M catarrhalis. Unfortunately, they could not explore RSV-
pneumococcal interactions due to a very small number of detections of this virus (241). 
However, a recent case control study from Kenya rarely detected RSV in nasopharyngeal 
specimens from healthy children compared with those with pneumonia, suggesting that it 
might be difficult to study potential RSV -pneumococcal associations in vivo using 
nasopharyngeal specimens from healthy children (323). However, further work including 
RSV peR on NPS-STGG specimens collected from Maela cohort infants at their monthly 
healthy follow-up visits would help to clarify the validity of this observation (324). 
Decreasing costs and next-generation technology are resulting in sequenced-based 
analyses of the nasopharyngeal microbiome; indeed all NPS specimens from 20 Maela 
cohort infants are currently undergoing 16S sequencing at The Sanger Institute, UK (Dr 
Stephen Bentley). Studies to date have inevitably revealed far greater complexity to the 
colonising flora than previous culture-based studies, although none so far have had a 
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longitudinal component (245, 246). Interestingly, a Dutch study of 18-month old children 
found no clear association between viral nuclei acid detection and overall composition of 
the microbiome (245). 
In conclusion, microbial interactions in the nasopharynx are complex and remain 
incompletely understood. The widespread introduction of pneumococcal conjugate 
vaccines, known to perturb the nasopharyngeal flora in culture-based studies, makes this an 
important area for on-going research. Improved detection of organisms by molecular 
approaches, coupled with collection of detailed immunologic and environmental data, will 
increase our understanding of the complex interactions between members of the 
nasopharyngeal microbiome. 
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8 Concluding remarks 
The studies described in this thesis have defined the detailed characteristics of 
nasopharyngeal pneumococcal colonisation in mothers and infants living in an isolated SE 
Asian population. 
8.1. Key findings 
1. Pneumococcal colonisation occurred soon after birth and was persistent over the first 
two years of life. Infants were frequently co-colonised by H. injluenzae and M 
catarrhalis. A negative association was seen between colonisation by S. aureus and S. 
pneumoniae. 
2. Risk factors for earlier pneumococcal acquisition in infants were environmental. 
Transplacentally acquired anti-pneumococcal antibodies did not significantly affect 
the timing of initial infant colonisation. 
3. Previous exposure to a pneumococcal serotype did not generally reduce the risk of 
subsequent nasopharyngeal acquisition of the same serotype, although homologous 
serotype reacquisition was delayed and carriage duration shorter for the more 
immunogenic serotypes. 
4. Pneumococcal acquisitions resulted in serotype-specific anti-capsular antibody 
responses which varied by serotype and generally increased with age. Infants 
developed serum IgG antibodies to a variety of pneumococcal proteins in response to 
colonisation. These responses were not strongly correlated with the overall number of 
pneumococcal acquisitions or colonisation duration. Antibody-mediated protection 
from nasopharyngeal colonisation was not observed. 
5. Colonisation by antimicrobial resistant pneumococci was frequent and, in infants, 
associated with cohabitation with additional young children. Antimicrobial resistance 
was commoner in serotypes covered by the currently available conjugate vaccines. 
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6. Mothers acquired pneumococci less frequently, and carried them for shorter durations, 
than their infants. Transmission of pneumococci within the mother-infant pair declined 
with time. 
7. The pneumococcal pilus did not have any demonstrable effect on transmissibility or 
colonisation duration of pneumococci. 
8. WHO methodology significantly underestimates the prevalence of co-colonisation by 
multiple pneumococcal serotypes and latex sweep serotyping is a cost-effective 
improvement, although it is currently less effective at detection of serotypes present at 
low abundance. 
8.2. General discussion 
Whilst much is known about pneumococcal colonisation and subsequent infection, 
many uncertainties remain. Some of those uncertainties are slightly clearer as a result of 
this work. 
Although perhaps not exciting science, the publication of robust serotype data from 
the pneumococci colonising a rural SE Asian population is important. Of course Maela is 
just one small rural community in a large, and heterogeneous, region. However, the region 
has been repeatedly noted to be poorly represented in the global S. pneumoniae dataset, 
despite having a high reported incidence of pneumonia, and no one study population will 
accurately reflect the entire region. Estimates of likely pneumococcal conjugate vaccine 
efficacy for SE Asia have either been inferred from other regions or based on very limited 
actual data. Whilst the gold-standard serotype data for vaccine planning purposes comes 
from examination of invasive disease isolates the characteristics of colonising 
pneumococci can be effectively used to inform vaccine strategy and future pneumococcal 
vaccine studies may use colonisation as the primary end-point of interest. Therefore the 
inclusion of the Maela serotype data in future meta-analyses for vaccine planning purposes 
will be useful. 
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Development and assessment of improved methodologies to increase the 
understanding of how pneumococcal serotypes interact in the nasopharynx is an important 
research area and highly relevant to vaccine development. Whilst the currently available 
PCVs have dramatically reduced the incidence of serious pneumococcal infection cause by 
vaccine serotypes, increases in non-vaccine serotype colonisation and infection have been 
noted. The development of novel pneumococcal protein-based vaccines with broader 
coverage may further reduce the prevalence of non-vaccine type pneumococci. However, 
on-going surveillance of pneumococcal colonisation to predict and subsequently monitor 
the effect of vaccine introduction will require methods that can more accurately capture the 
pneumococcal diversity in the nasopharynx, particularly the carriage of low abundance 
serotypes not covered by vaccine. Work contained in this thesis has demonstrated two 
methods, microarray-based or latex agglutination-based serotyping, that offer significant 
improvements in the detection of multiple serotype colonisation. Use of either of these 
methods in future colonisation studies would greatly enhance understanding of the 
complexity of pneumococcal interactions and how these are perturbed by immunisation. 
Choice of method would depend on the specific research question and study site/laboratory 
capability. The advantage of the latex sweep method is that it can be performed in 
laboratories with limited resources, assuming that appropriate quality control can be 
implemented. 
The modifiers of pneumococcal colonisation remain incompletely understood. The 
studies described in this thesis have confirmed the bacterial associations reported in 
previous studies. Although both anti-capsular protein and anti-protein antibody responses 
to colonisation were examined in the Maela cohort, an unequivocally clearer signal was not 
forthcoming probably as a result of the near constant colonisation in many study 
individuals. Infants were able to respond to a variety of pneumococcal antigens, but an 
impact on serum antibody on colonisation could not be directly demonstrated. However, 
indirect evidence of immune-mediated effects on colonisation was noted. For certain 
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immunogenic serotypes, primary carriage episodes of the serotype were longer than when 
reacquisition of the homologous serotype occurred, suggesting improved immune mediate 
clearance. In Maela, a crowded refugee camp with many features similar to other 
developing world settings, household and environmental factors appeared to be the key 
determinants of pneumococcal colonisation dynamics in infancy. 
8.3. Limitations 
Inevitably, in retrospect, some aspects of the studies could have been improved by 
different study designs. 
A shorter swabbing interval, at least for the first few months of life, may have 
improved the likelihood of detection of an effect of maternally-derived antibodies on 
timing of infant colonisation (71). It may also have resulted in more accurate determination 
of serotype-specific carriage durations, especially for the more rapidly cleared serotypes 
(285). However, estimates of acquisition rates and trends for carriage duration were not 
significantly different between the Maela study and those from studies of similar 
populations in The Gambia and Kenya (73, 74). 
The mother was the only additional household member to be included in the 
pneumococcal colonisation work. This was a pragmatic choice, based on several factors 
including perceived likelihood of detection of transmission events compared with other 
household members. However, it limited the scope for analyses of pneumococcal 
transmission. It would have been preferable to include all household members in the 
carriage study (87). 
The decision to limit viral detection work was a further limitation. Inclusion of viral 
testing of nasopharyngeal specimens from healthy follow-up visits would have allowed a 
more rigorous analysis of viral-bacterial interactions. Also, testing specimens for a broader 
panel of viruses would have improved this work. However, all specimens from the study 
were stored at -80°C and preliminary work has determined that NPS-STGG specimens 
197 
may be an acceptable alternative to NP A-VTM specimens for detection of respiratory 
viruses (324). Therefore, further work on this important area remains possible. 
The immunology work was restricted to the determination of serum IgG responses. 
Inclusion of analyses of mucosal and cellular immune responses would have strengthened 
this work (177, 178). 
Despite the above, almost all of the aims and objectives stated in section 1.12 were 
addressed. The hypothesis that was not amenable to adequate testing was related to the 
relationships between colonisation and pneumococcal disease. As a result of the cohort 
size, there was only a single blood culture proven pneumococcal disease episode amongst 
study participants. Although it was of considerable interest to study relationships between 
pneumococcal colonisation and subsequent pneumonia episodes, the lack of definitively 
proven pneumococcal pneumonia, a factor common to almost all paediatric pneumonia 
studies, resulted in these analyses being beyond the abilities of this candidate. Approaches 
to mathematical modelling of the serotype colonisation data in relation to clinical and 
radiologic pneumonia episodes are under discussion, but ultimately this work may not be 
possible due the study sample size and uncertainty around the aetiologies of the pneumonia 
episodes. Restricting to x-ray confirmed pneumonia episodes would increase specificity for 
inferring pneumococcal infection, but since Hib vaccine was not available to study 
participants a certain degree of aetiological uncertainty would persist and also this 
approach would also erode the sample size. 
8.4. On-going and future research to build on results from the thesis studies 
The detection of multiple pneumococcal serotype colonisation is important, 
especially with the widespread introduction ofPCVs. The latex sweep method is useful 
technique for detection of serotype co-colonisation and is well suited for use in resource-
poor settings. However, further optimisation of the method is required to ensure that 
serotypes present at low relative abundance can be reliably detected. This work is planned. 
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Mathematical modelling of the cohort data is planned, and this will focus on 
detennination of the characteristics and modifiers of pneumococcal transmission of within 
mother-infant pairs (Dr Ben Cooper, MORU). The frequent sampling and detailed meta-
data will enhance these analyses. Future projects at SMRU are planned to study the impact 
of pneumococcal colonisation in pregnancy on infant outcomes, including infant 
colonisation and immune responses. 
Culture-based studies of colonisation underestimate the complexity of the 
nasopharyngeal microbiome (245). Nasopharyngeal swabs from 20 Maela cohort infants 
are undergoing 16S sequencing at The Sanger Institute (Dr Stephen Bentley and Ms 
Zannah Salter). Previous studies have of the nasopharyngeal microbiome have been cross-
sectional: this study will add an important longitudinal component. 
Rapidly falling costs, and the development of next-generation sequencing 
technology such as Illumina HiSeq (Illumina Inc., San Diego CA, USA), has resulted in 
the reality of sequencing the genomes of entire populations of pneumococci. This approach 
has been successfully applied to a globally successful lineage of invasive pneumococci 
(33). More recently, the genomes of over three thousand GPS-mapped pneumococcal 
isolates collected during the Maela cohort study have been sequenced at The Sanger 
Institute (Pneum03K, Dr Stephen Bentley and Ms Claire Chewapreecha). The aim of this 
study is to describe pneumococcal evolution and transmission in Maela at the genome 
level. 
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11 Appendix 1: ARI study case record forms 
11.1. Mother questionnaire Date: 
Study code: ARI -
Acute Respiratory Infection Study 
Initial Questionnaire - Mother 
Has Mother consented to take part in study and has she signed the consent form? 
MLAcode 
Date of Birth (dd/mm/year) or age Ethnic Group 
Address 
Do you currently smoke (circle)? YES/NO 
If yes what and how many do you smoke a day ___________ _ 
Past medical history 
1. Do you suffer from any medical conditions (circle)? YES/NO 
If yes what (circle) Asthma 
TB 
Heart problems 
Facial/ ear malformations (circle)? 
Any other medical problems (circle)? YES/NO 
Det~s _________________ ~ ___ __ 
2. Prescription of any antibiotics in the last 1 month (circle) YES/NO ~ 
Episode 1 2 3 4 5 
What antibiotic? 
Started 
For how long (days)? 
3. Prescription of other medication in past 12 months (circle? YES/NO 
Episode 1 2 3 4 5 
What medication? 
Started 
For how long (days)? 
Past Obstetric History 
4 Li . st preVlOUS pregnancles 
Number Year of Delivery Preterrn Sex of infant Dead/Alive 
YES/NO /Abortion 
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5. Have all previous pregnancies, deliveries and babies been normal (circle)? YES/NO 
If no please provide details: 
History of Pregnancy 
6. Date of last menstrual period or unsure 
7. EDDbyUSS 
_1_1-
_I_l- or not performed 
B. Date USS first performed __ 1 __ 1 __ 
9. Any abnormality found on USS (circle)? YES/NO 
10. Any episodes of malaria during pregnancy (circle)? YES/NO 
Number of episodes __________________ _ 
11. Any other illness during pregnancy (circle)? YES/NO 
12. Any complications during this pregnancy (circle)? YES/NO 
If answered yes to any of the above questions please provide details: 
Family /Household 
Accommodation 
1. Number of rooms 
2. Open fire in hut for cooking (circle)? 
3. What fuel is used on the fire? 
4. Number of people living in the house in the last one month 
5. Any family member's currently unwell (circle)? 
If yes details: 
6. Details of household members: 
YES/NO 
YES/NO 
Name Relationship DOB or age (years) Work Where work? 
to infant dd/mm/year YIN Campi outside/ c!!r. 
Mother 
Father 
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11.2. Newborn examination 
Date: _ ~ __ / __ Newborn Examination 
Observations 
1. What is the colour of the infant? (circle all that apply) 
Pale yanosed Jaundiced Normal 
2. Is there a rash present? YES/NO 
Describe 
3. Are there any birth marks present? YES/NO 
Describe 
4. Describe the anterior fontanelle 
Raised Normal Depressed 
5. Is there any bruising to the head or face? YES/NO 
Describe 
6. Is the baby's face normal? YES/NO 
Describe 
7. Are the palate and mouth normal? YES/NO 
Describe 
8. Are the limbs, fingers and toes normal? YES/NO 
Describe 
Cardiovascular Examination 
9. Heart rate (per minute) ___ If >160 or < 100 call the medic or doctor 
10. Describe the heart sounds 
Normal Murmur, describe 
11. Are the femoral pulses present? 
Respiratory Examination 
YES/NO 
12. Respiratory rate (per minute) ___ 1f>60 call the medic or doctor 
13. Listen to the chest is it clear? YES/NO 
If no describe the noise and location on the diagram 0 SJ 
14. Are any of the following present? (circle all that apply) 
Chest indrawing Nasal flaring Head bobbing None 
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Abdominal Examination 
15. On palpation of the abdomen, is there a mass / liver/ spleen palpable? YES/NO 
If yes please draw on the diagram 
16. Is the genitalia normal (both testes descended in a boy)? YES/NO 
Describe 
17. Does the infant have a normal anus? YES/NO 
Describe 
Neurological examination 
18. Does the infant have normal muscle tone? YES/NO 
If no describe 
19. Is the infant moving all limbs normally? YES/NO 
If no describe 
20. Does the infant have a normal red reflex? YES/NO 
Is this a normal infant? YES/NO 
If NO doctor or medic to record details (AND PHOTOGRAPH): 
Outcome? (please circle) 
Admitted IPD 
Is this infant in a study? 
If yes refer to study protocol 
Observation 24hours 
If no sign the form and add to AN C card 
YES/NO 
Infant next due to be seen _________ _ 
Home 
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11.4. Monthly follow-up (0 - 12 month) 
Study code: ARJ- f----------l Address ________ _ 
ANC code: MLA- L--______ ---' 
DOB (d,,/momh/,<,,), IL-____ ----' EGA: ___ wks + days Where born? 
Date of , 
Delivery 1 2 3 4 5 6 7 8 9 10 11 12 
.~ " 
Weight (kg) 
Height (em) 
HeadCireum (em) 
Ann Circum (em) 
Feeding 
Feeding Code 
Add water in feeding yin 
Diseases 
Anaemia yin 
HCf % 
Malaria vln 
LRTI vln 
URTI vln 
Otitis yin 
TV 
. yin 
n ".,.ntPr" yin 
Slcin disease yin 
Eye disease yin 
Other problems yin 
: taken 
An';\' 
Vitamins 
n""unrrn' 
Others 
Testing 
Nasopharyngeal swab 
.. ,., 
* 
Cord Blood ~ .~ . . . ' . . ., Blood sample 
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11.5. Monthly follow-up (13 - 24 month) 
Study code: ARI- t-----------i Address ____________ _ 
ANC code: MLA- '--_________ ~ 
DOD (day/month/year): EGA: ____ wks + ___ days 
Date of consultation: 
13 14 15 16 17 18 19 20 21 22 23 24 
Anthropometry 
Weight (kg) 
Height (em) 
Head Circum (em) 
Arm Circum (cm) 
Feeding 
Feeding Code 
Add water in feeding yin I I I I 
Diseases 
Anaemia vln 
HCT% 
Malaria v/n 
LRTI vln 
URTI vln 
Otitis yin 
Diarrhoea yin 
_Dysentery y!n 
Skin disease yin 
Rye disease yin 
Other problems yin 
Medicine taken 
Antibiotics 
Vitamins 
Deworms 
Others 
Testing 
Nasopharvngeal swab 
Blood sample I I I 
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11.6. Infant illness 
Date and time: 
Study code: 
Date of Birth (dd/mm/year) 
Sex 
Age at Examination (months) 
Weight (kg) 
Has the child been assessed using the Emergency Protocol? 
Has the child been in contact with dead or dying birds or with a household member 
with a severe respiratory disease? If yes, isolate the child and call the doctor. 
History 
1. Cough YES/NO 
If yes duration ______ ,days 
Any other complaint by Mother 
describe here: 
2. Fever YES/NO 
If yes duration ______ days 
3. Runnynose YES/NO 
If yes duration ______ ,days 
4. Noisy breathing YES/NO 
Describe 
---------------------------
5. Earache YES/NO 
If yes duration days 
6. Sore throat YES/NO 
If yes duration days 
7. Vomiting YES/NO 
If yes duration days 
8. Diarrhoea YES/NO If yes 
Duration days 
Frequency of stools ___________________ -'/ day 
Is there blood in the stool YES/NO 
9. Rash YES/NO 
If yes duration ________ days 
Describe the rash _________________ _ 
10.Any problems with the baby's eyes? YES/NO 
Describe ____________________ _ 
11.When did the baby last pass urine ___________ ,(hours ago) 
12.How is the baby being fed (circle)? 
Breast feeding / Bottle Feeding / Mixed feeding / Other, give details 
13.Does the baby suck well? YES/NO 
247 
14 H th b b k °bO ° as e a )y ta en any antI totIcs or me diO CIne SInce ast seen? YES NO / 
IEpisode 1 2 3 4 S 
What medicine? 
~tarted 
1F0r how long (days)? 
lS.Does the baby have any medical problems such as heart problems, kidney problems or 
neurological problems? YES/NO 
Details 
16.1s the baby allergic to any medicines? 
Details 
17.Are any family members unwell at the current time? 
Details 
Examination 
Observations 
HR RR 
1. Is the infant (circle): 
Temp 02 saturations 
YES/NO 
YES/NO 
Dextrose CRT 
Alert / Sleepy / Irritable / Responding onlY to voice / Responding onlY to pain / Unresponsive 
2. What is the colour of the infant (circle)? 
Pale / Mottled / Cyanosed / Normal/Jaundiced 
3. Are there any lymph nodes palpable? YES/NO 
If yes where? ________________ _ 
4. Is the infant dehydrated? 
If yes (circle) Mild Moderate 
5. Is the infant's cry normal? 
If no describe 
Cardiovascular Examination 
1. Describe the heart sounds 
Normal Murmur, describe 
Respiratory Examination 
1. Any of the following present (circle all that apply)? 
YES/NO 
Severe 
YES/NO 
Grunting Stridor Chest indrawing 
Tracheal tug Nasal.fladng Head bobbing None 
2. Listen to the chest is it clear? YES/NO 
If no, describe the noise and location on the diagram 
Abdominal Examination 
1. On palpation of the abdomen is there a mass / liver/ spleen palpable? YES/NO 
If yes, please draw on the diagram 
2. Are the genitalia normal? YES/NO 
If no details 
Neurological Examination 
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1. Does the infant have normal muscle tone? YES/NO 
Describe if no 
2. Does the infant have normal posture? YES/NO 
Describe if no 
3. Is the infant moving all limbs normally? YES/NO 
Describe if no 
4. Are the infant's pupils equal and reactive? YES/NO 
Describe if no 
5. Describe the anterior fontanelle (circle) 
Raised Normal Depressed 
ENT Examination 
1. Throat Nonnal/ Abnonnal 
If abnormal describe __________________ _ 
2. Mouth Nonnal/ Abnonnal 
If abnormal describe __________________ _ 
3. Ear Nonnal/ Abnonnal if abnonnal which one R/L/Both 
If abnormal describe __________________ _ 
Skin 
1. Any, rash, pustules, cellulitis or skin abnormality? YES/NO 
Describe rash and location __________________ _ 
Eyes 
1. Any abnormality? YES/NO 
Describe if yes 
Outcome Home Home with follow up AdmitIPD 
Diagnosis 
Treatment (include length of treatment) 
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12 Appendix 2: ARI study laboratory standard operating procedures 
12.1. Nasopharyngeal swab culture (SMRU SOP MBL-6-B) 
12.1.1. Introduction 
Nasopharyngeal swabs are obtained to determine the prevalence of carriage of respiratory 
pathogens (predominantly Streptococcus pneumoniae and Haemophilus injluenzae). 
12.1.2. Method 
12.1.2.1. Specimen Collection and Transport 
Nasopharyngeal samples are obtained with a deep nasopharyngeal swab. To obtain the 
specimen the patient's head should be tipped slightly backward and the swab passed 
directly backwards, parallel to the floor of the nasopharynx. The swab should pass without 
resistance until it reaches the posterior pharynx which is approximately one-half to two-
thirds the distance from the nostril to the ear lobe. If resistance is encountered, the swab 
should be removed, and an attempt should be made to pass the swab through the other 
nostril. Once the swab is in place, rotate the swab 180 degrees or leave it in place for 5 s to 
saturate the tip before removing it slowly. The swab should be stored in cool 
box/refrigerator prior to and during transportation back to the laboratory. 
12.1.2.2. Specimen Processing 
Enter specimen details into the laboratory database/logbook. 
Vortex collection vial (containing the swab and STGG medium) for 10-20 seconds. 
Using a sterile I o III loop, inoculate the following plates (in order): 
1. Chocolate agar (+ bacitracin disc); 
2. Columbia CNA agar with 5% sheep blood (BA-CNA). 
Swabs from mothers should be inoculated onto BA-CNA only. 
Incubate the Chocolate and BA-CNA plates overnight at 35-37°C in 3-10% C02. 
Place the original specimen vial (with swab in situ) into the -80°C freezer. 
NOTE: In most instances, swabs will be frozen -80°C at prior to culture. Before 
inoculating plates, ensure that the STGG is fully defrosted and mixed by vortex. 
12.1.2.3. Follow-up 
Read all plates. 
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Record the semi-quantitative growth of all colony types as follows: 
1 + Growth in quadrant 1 but <10 colonies in quadrant 2; 
2+ >10 colonies in quadrant 2 but <10 colonies in quadrant 3; 
3+ >10 colonies in quadrant 3 but <10 colonies in quadrant 4; 
4+ > 1 0 colonies in quadrant 4. 
Follow up and identify all potential pathogens* (as outlined below and in SOP MBL-4a/b-
B): 
• ~-haemolytic streptococci; 
• Haemophilus influenzae; 
• Moraxella catarrhalis; 
• Staphylococcus aureus; 
• Streptococcus pneumoniae. 
Only Streptococcus pneumoniae should be identified and followed-up from mother swabs. 
Record the presence and quantity of all non-pathogenic colonisers (only perform minimal 
identification to confirm identity* - e.g. Gram stain, catalase, haemolysis type, and oxidase 
reactions). 
* Unless growth of a particular organism is heavy with isolated colonies, make a purity 
plate (Y-a or ~ BA or Choc) before attempting identification tests. 
Antimicrobial sensitivity testing is only to be done on isolates of Streptococcus 
pneumoniae. See SOP MBL-I-B. 
Identification methods 
Or2anism 
Staphylococci Catalase 
Coagulase / Staphaurex 
DNase agar 
Streptococci Catalase 
Strep pneumoniae: see below 
a-haem (opt R): no further ID required 
~-haem: group 
". Enterococci: group 
sub onto bile-aesculin agar 
GNR* Record if LFINLF on MacConkey 
Oxidase 
Haemophili Oxidase 
X and V factors (on nutrient agar) 
Test with anti-sera if H. influenzae 
f3-1actamase test if H injluenzae 
Moraxella Oxidase 
Trybutyrin test 
f3-lactamase test 
Other organisms (e.g. yeasts) Only if felt to be clinically significant 
*Ifpure and heavy, conSIder fullldentIficatlon. 
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12.1.2.4. Follow-up of potential Streptococcus pneumoniae 
Pick two morphologically different a-haemolytic colonies 
(optochin sensitive on primary plate) 
Sub each onto 
~BAwith 
optochin disc 
~ ~ 
Sensitive Indeterminate Resistant 
(~14mm) (7-13mm) «7mm) 
Confirm: Perform: Confirm: 
Gram=GPC Gram stain Gram=GPC 
Catalase = negative Catalase Catalase = negative 
Bile solubility 
... ------
--------. 
Gram=GPC Gram=GPC 
Catalase = negative Catalase = negative 
Bile = soluble Bile = insoluble 
I I . 
Streptococcus a-haemolytic 
pneumoniae streptococcus 
All isolates of Streptococcus pneumoniae should be sub-cultured on to a plain blood agar 
(BA) plate and incubated overnight at 35-37°C in 3-10% CO2• 
From this sub-culture: 
1. Perform antimicrobial sensitivity tests (see SOP MBL-I-B). 
2. Serotype the isolate (see SOP MBL-20-B). 
3. Save the organism (harvest growth from the whole plate with a sterile swab) in a 
labelled fresh vial of STGG medium and store in the -80°C freezer. 
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12.2. Pneumococcal serotyping (SMRU SOP MBL-20-B) 
12.2.1. Introduction 
There are over 90 serotypes of Streptococcus pneumoniae. Traditional serotyping of 
pneumococci is based on the capsular reaction (Quellung reaction): the result of an in situ 
immunoprecipitation between the pneumococcal capsular polysaccharide and its 
homologous antibody. A positive reaction is seen by use of a phase contrast microscope 
where the capsule becomes visible and the pneumococci agglutinates. This method is 
technically demanding, time consuming, and expensive. However, it remains the gold 
standard technique. 
Alternative serotyping methods have been developed to overcome the problems of the 
Quellung reaction. An ideal method for large scale carriage studies, such as those in 
progress at SMRU, is one that is technically simple, rapid (to enable high throughput 
testing), and low cost. A latex agglutination method developed by Lafong and Crothers (J. 
Clin. Pathol. 1988;41 ;230-231) and modified by the MRC laboratories in The Gambia 
(Prof Richard Adegbola, personal communication) meets these criteria and is the primary 
method used at SMRU. 
12.2.2. Method 
12.2.2.1. Specimen Processing 
Isolates are either processed in real-time (i.e. directly from the primary culture plate) or 
from sub-cultured frozen isolates (stored in STGG at -80°C). 
12.2.2.2. A. Serotyping using the latex agglutination method 
12.2.2.2.1. Day 1 
Pick a single colony and sub-culture. to a 5% sheep blood agar (BA) plate with an optochin 
disc positioned between the primary pool and 2nd streak. 
Incubate the plate overnight at 35-37°C in 3-10% CO2• 
12.2.2.2.2. Day 2 
Check that the organism is pure and optochin sensitive (zone of2:: l4mm). If mixed growth 
is suspected, re-culture a single colony on to a BA plate (and do not proceed with the 
mixed plate). If the organism is not optochin sensitive (i.e. zone of < 14mm), check a Gram 
stain, catalase reaction, and perfonn a bile solubility test (see Section C). If the organism is 
a GPC, catalase negative, and bile soluble proceed to step 4. If not, the organism is not a 
pneumococcus: re-check the original culture. 
Remove the latex antisera from the reagent fridge and allow to warm up to room 
temperature. Mix thoroughly before use. 
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Using a sterile swab, make a light suspension (0.5 McFarland) of the organism in 2ml 
sterile saline. 
Pipette 10/-11 of each pneumococcal pool latex antiserum (A-I) onto two labelled clean glass 
slides (see figure 1). 
Figure 1 
~IA_o ___ ~ ____ g ____ ~ ____ ~~11 ~ __ O_F ___ O_G ___ ~ ____ ~__ ~ 
Add 10/-11 of the pneumococcal suspension to each drop of latex antiserum. 
Mix and rotate for 2 minutes and observe for agglutination. A positive reaction for the 
particular pool is indicated by agglutination: proceed to step 10. 
If no positive result is seen with the pool latex antisera, proceed to typing using the 
Quellung reaction, starting with Omniserum (see Section B). If a negative reaction is seen 
with Omniserum, check a Gram stain, catalase reaction, and perform a bile solubility test 
(see Section C). 
Following the scheme outlined in Section E, repeat steps 6 - 8 using the appropriate group, 
type and factor specific latex antisera to determine the final serotype. Again, a positive 
reaction is indicated by agglutination. 
Equivocal results must be confirmed by the Quellung reaction (see Section B). 
Record the result on the serotyping results sheet. 
12.2.2.3. B. Serotyping using the Quellung reaction 
Prepare a heavy suspension of the test organism in a few drops of sterile saline. 
Using sterile disposable loops, place I III each of methylene blue (0.3% solution) and the 
cell suspension onto a clean glass slide and mix. There should be a maximum of three 
drops per slide. 
Add 1/-11 of the appropriate antiserum using a disposable loop. Include a negative control 
for each isolate (i.e. no antiserum added). 
Cover with a cover slip and examine under an oil immersion objective lens. A positive 
reaction is seen as a change in the refractive pattern around the edge of the pneumococci. 
This gives the appearance of a thickening or swelling ofthe capsule. Comparison must be 
made with the negative control. 
If there is a positive result with one of the antiserum pools, continue with full typing as 
outlined in Section E. If negative with antiserum pools A-I, try Omniserum. 
Ifnegative with Omniserum (and GPC, catalase negative, bile soluble) then record the 
isolate as non-typeable. 
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12.2.2.4. C. Bile solubility test 
Two sterile polystyrene bijoux bottles are required for bile solubility testing of each 
suspect strain of S. pneumoniae. 
Take a loop of the suspect strain from fresh growth on a blood agar plate and prepare a 
suspension (1-2 McFarland) in 0.5 ml of sterile saline. 
Divide the suspension into two equal amounts (i.e., 0.25 ml per bottle). Add 0.25 ml of 
saline to one tube and 0.25 ml of 10% sodium deoxycholate (10g Sodium deoxycholate in 
100mi sterile distilled water) to the other. 
Shake the tubes gently and incubate them at 35°- 37°C for 30 minutes. 
Examine the tubes for lysis of cells in the tube containing the bile salts. A clearing of the 
tube, or a loss in turbidity, is a positive result. 
12.2.2.5. D. Preparation of latex antisera 
(Following the SOP of the MRC laboratories, Banjul, The Gambia: kindly provided by 
Prof Richard Adegbola) 
12.2.2.5.1. Reagents 
GBS - Glycine buffered saline (PH 8.2) 
Glycine 1.5g 
NaCI 11.7g 
Distilled water 200ml 
Adjust pH to 8.2 with 20%NaOH 
GBSIBSA - Glycine albumin buffered saline 
BSA O.1g 
GBS 100ml 
Latex beads - 0.82~ diameter latex beads from Sigma (LB-8) 
12.2.2.5.2. Preparation Procedure 
Measure l590~1 ofGBS into a labelled sterile bijou bottle. 
Add to ..... l of appropriate pneumococcal antiserum (from SSI). 
Dilute the latex beads 1 in 8 in sterile saline in a universal container. 
Add 1600 ..... 1 of the dilute latex beads to the GBS-antiserum. 
Incubate at 37°C in the waterbath for 2 hours shaking at 15 minutes intervals. 
Add 3200 ..... 1 of GBSIBSA. 
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Incubate overnight at 4°C. 
Test with known bacterial suspension for quality assurance (e.g. ATCC 49619 -19F). 
Store in the reagent fridge. 
Allow to wann up to ambient temperature before use. 
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12.2.2.6. E. Serotyping scheme 
Pool P Q R S T Non-vaccine groups/types 
A 1 18* 4 5 2 
8 19* 6* 3 8 
C 7· 20 24·,31,40 
D 9* 11* 16*,36,37 
E 12* 10* 33* 21,39 
F 17· 22* 27,32*,41* 
G 29,34,35*,42,47* 
H 14 23* 15* 13,28* 
I 25*,38,43,44,45,46,48 
.. 
-IndIcates that there are > I types WlthlD the group 
Type Factor sera 
6b 6c 
6A + -
68 
-
+ 
7b 7c 7e 7f 
7F + - - -
7A + + 
- -
78 
- - + -
7C 
- - - + 
9b 9d ge 92 
9A 
-
+ 
- -
9L + 
- - -
9N + 
- + -
9V 
- + - + 
lOb lOd lOf 
10F + - -
lOA 
-
+ 
-
lOB + + 
-
lOC + 
-
+ 
llb llc llf l1g 
llF + - - + 
llA 
-
+ 
- -
lIB + - +. + 
llC + + + -
lID + + - -
12b 12c 12e 
12F + - -
12A 
-
+ -
12B + + + 
lSb l5c ISe ISh 
l5F + + - -
15A 
-
+ - -
15B + - + + 
lSC 
- -
+ 
-
16b I6c 
l6F + -
l6A 
-
+ 
l7b l7c 
17F + 
-
l7A 
-
+ 
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Type Factor sera 
18c 18d 18e 18f 
18F + 
-
+ + 
18A - + - -
18B - - + -
18C + 
-
+ 
-
19b 19c 19f 7h 
19F + 
- - -
19A 
-
+ 
- -
19B 
- - - + 
19C 
- -
+ + 
22b 22c 
22F + 
-
22A 
-
+ 
23b 23c 23d 
23F + - -
23A 
-
+ 
-
23B 
- -
+ 
24c 24d 24e 
24F - + -
24A + + -
24B 
- -
+ 
25b 2Sc 
25F + 
-
25A 
-
+ 
28b 28c 
28F + 
-
28A 
-
+ 
32a 32b 
32F + 
-
32A + + 
33b 33e 33f 6a 20b 
33F + (+) 
- - -
33A + (+) - - + 
33B 
- -
+ 
- -
33C 
-
+ (+) - -
33D - - + + -
35a 35b 35c 29b 42a 
35F + + - - -
35A + - + - -
35B + 
-
+ + 
-
35C + - + - + 
4la 4tb 
41F + + 
41A + 
-
47a 43b 
47F + -
47A + + 
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12.3. Detection of multiple pneumococcal serotype colonisation by latex agglutination 
(SMRU SOP MBL-24-B) 
12.3.1. Introduction 
There are over 90 serotypes of Streptococcus pneumoniae. 
Multiple serotypes may be carried concurrently in the nasopharynx, but detection of these 
by conventional culture and Quellung serotyping is costly, time-consuming and inefficient. 
A latex agglutination serotyping method has been used to detect multiple pneumococcal 
carriage by the MRC laboratories in The Gambia. This method is described in the current 
SOP (see also SOP MBL-20-B - Pneumococcal serotyping). 
12.3.2. Method 
12.3.2.1. Day 1 
NOTE: In most instances, nasopharyngeal swabs will be frozen at -80°C at prior to 
culture. Before inoculating plates, ensure that the STGG is fully defrosted and mixed by 
vortex. 
Vortex the cryotube (containing the swab and STGG medium) for 10-20 seconds. 
Using a sterile 1 o III loop, inoculate a Columbia CNA agar with 5% sheep blood (BA-
CNA) plate. 
Incubate the plate overnight at 35-37°C in 3-10% CO2• 
Place the original specimen vial (with swab in situ) back into the -80°C freezer. 
12.3.2.2. Day 2 
Check growth on the plate: 
If~1 + growth of a-haemolytic colonies, proceed to step 2. 
If <1 + growth of a-haemolytic colonies, re-subculture 50111 STGG on to a BA-CNA plate. 
Remove the latex antisera from the reagent fridge and allow to warm up to room 
temperature. Mix thoroughly before use. 
Using a sterile swab, make suspend all of the colonies from the plate in 0.5 - 2ml sterile 
saline (to make at least a density of 0.5 McFarland). 
Pipette lOll1 of each pneumococcal pool latex antiserum (A-O onto two labelled clean glass 
slides (see figure I). 
259 
Figure 1 
~I~ ____ ~ ____ ~___ ~ ____ ~~II ~ __ O_F ___ ~ ___ O_H ___ ? __ ~ 
Add 10J..lI of the organism suspension to each drop oflatex antiserum. 
Mix and rotate for 2 minutes and observe for agglutination. A positive reaction for a 
particular pool is indicated by agglutination. 
Following the scheme outlined in SOP MBL-20-B, repeat steps 6 - 8 using the appropriate 
group, type and factor specific latex antisera to determine the final serotype(s). Again, a 
positive reaction is indicated by agglutination. 
Record the results on the serotyping results sheet. 
A NPS may contain> 1 pneumococcal serotype: follow-up all positive reactions 
according to the typing scheme (See SOP MBL-20-B). 
It is possible to determine the presence of non-typeable pneumococci in a culture: a weak 
reaction with Pool B and Group 19 latexes, but no reaction with the Group 19 factor 
latexes, is observed. 
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12.4. Respiratory virus PCR (SMRU SOP MBL-34-P) 
12.4.1. Introduction 
Several important respiratory viruses are sought using real-time RT-PCR (rRT-PCR, 
Taqman): 
• Adenovirus (Adeno) 
• Influenza A (FluA), Swine influenza A [2009 HINl] (SwFluA), influenza B 
(FluB), plus sub-typing assays for influenza A (HI, H3, and SwHl) 
• Human metapneumovirus (hMPV) 
• Respiratory syncytial virus (RSV) 
US-CDC assays are used to detect Adeno, FluA, SwFluA, FluB, and RSV. A previously 
published assay is used for hMPV (Maertzdorf Jet aI., J Clin Mic 2004). Detection of the 
human RNaseP gene is used as an intemaVspecimen control (Emery SL et aI., Emerg Inf 
Dis 2004). Periodically, additional respiratory viruses may be sought (e.g. rhinoviruses and 
parainfluenza 1-4) using commercial PCR kits. 
12.4.2. Important points 
12.4.2.1. Specimens 
A nasopharyngeal aspirate (NPA) is the specimen of choice, although combined nose and 
throat swabs may be used for detection of influenza viruses). CpC protocols state the 
following: 
12.4.2.1.1. Acceptable specimens: 
• Respiratory specimens including: bronchoalveolar lavage, tracheal aspirates, 
sputum, nasopharyngeal or oropharyngeal aspirates or washes, and nasopharyngeal 
or oropharyngeal swabs. 
• Swab specimens should be collected only on swabs with a Dacron tip and an 
aluminium or plastic shaft. Swabs with calcium alginate or cotton tips and wooden 
shafts are unacceptable. 
12.4.2.1.2. Specimen rejection criteria: 
• Specimens not kept at 2-4°C (for up to 4 days) or frozen at -70°C or below. 
• Incomplete specimen labelling/documentation. 
• Insufficient specimen volume. 
12.4.2.2. PCR technique 
Meticulous technique is required for consistent PCR results - refer to the SMRU "Working 
in the PCR laboratory SOP". 
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12.4.2.3. Reagents required 
• Invitrogen SuperScript III Platinum One-Step Quantitative RT -peR Kit. 
• Sterile distilled water (RNase and DNase free). 
• Forward and reverse primers (See SOP MBL-32-P - Microbiology PCR primers 
and probes). 
• Dual-labelled probes (See SOP MBL-32-P - Microbiology PCR primers and 
probes). 
• Positive control virus RNAs (Appendix B). 
• Clinical specimens. 
12.4.2.4. Equipment required 
• Pipettes and sterile barrier pipette tips 
o O.lml or 0.2ml PCR reaction tubes (O.1ml: Corbett, cat. no. 3001-002; 
0.2ml: Axygen) 
• Cold racks for 1.5 microcentrifuge tubes and 0.2ml PCR reaction tubes 
• Sterile 1.5 ml microcentrifuge tubes 
• Powder-free gloves 
• Microcentrifuge 
• Vortex mixer 
• Real-time PCR detection system (Corbett Rotorgene 6000) 
12.4.3. Method 
12.4.3.1. Equipment preparation 
• Work surface, pipettes and centrifuges should be cleaned and decontaminated with 
10% bleach followed by 70% alcohol to minimize risk of contamination: prepare 
fresh bleach solution each day. 
• Ensure cold racks are frozen. 
12.4.3.2. Reagent preparation 
• Remove the clinical specimen extracts from the -BO°C freezer and put in the class II 
cabinet in the DNAIRNA extraction laboratory to defrost. 
The following steps are carried out in cabinet, in the reagent preparation laboratory: 
• Keep all reagents on cold rack during assay set up. 
(a) Primers and probes 
• Thaw frozen aliquots of primer and probes (thawed aliquots of primers and probes 
may be stored in the dark up to 3 months at 2-8°C; label with an expiry date). 
• Vortex all primers and probes. 
• Briefly centrifuge all primers and probes and then place in cold rack. 
(b) Real-time RT-PCR reagents 
• Place Master Mix and enzyme in cold rack. 
• Thaw the 2X Reaction Mix vial. 
• Mix the 2X Reaction Mix by vortexing for 15 sec. 
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• Briefly centrifuge 2x Reaction Mix and enzyme (Taq mix) then place in cold rack. 
12.4.3.3. Setting up the rRT -PCR reaction 
12.4.3.3.1. Controls included in each rRT-PCR run 
• No Template Control (NTC): 
o Validates reagent integrity (negative). 
• Viral Template Control (VTC): 
o Validates reagent integrity (positive). 
• Mock Extraction Control (MOCK): 
o Validates the extraction procedure and reagent integrity (negative). 
12.4.3.3.2. Assay set up 
• The following assays can be combined on the same rRT-PCR run (same reaction 
conditions): 
o RNP + FluA + SwFluA + FluB + FluA typing (HI + H3 + SwHI) 
o Adeno+RSV 
• hMPV is performed on a separate rRT-PCR run (different reaction conditions). 
• Maximum number of specimens on a PCR run: 
o Single virus = 69 (+3 controls); 
o Rapid influenza detection [RNP + FluA + SwFluA + FluB] = 15 (+12 
controls). 
• Reaction assay mixtures are made as a cocktail ("the master mix") and dispensed 
into the reaction tubes (O.lml or 0.2 ml depending on the number of specimens). 
• Extracted nucleic acid, viral template controls, or water is then added to the 
appropriate test reactions and controls. 
In the office area: 
• Calculate the amounts of reagent required (see Appendix A) for the master mix. 
• The electronic master mix worksheet is located on the SMRU server. 
The following steps are carried out in the cabinet, in the reagent preparation laboratory: 
• Label the reactions tubes on the lid according to the scheme from the worksheet 
and place in a cold rack. 
• Make up the master mix: 
o Mix reagents by pipetting up and down. 
• Add 20 JlI of each master mix into each tube. 
• Before moving the plate to the DNNRNA extraction laboratory, set up the NTC 
reactions in the reagent preparation laboratory: 
o Pipette 5 JlI of nuclease free water into the NTC tubes. 
o Cap NTC tubes. 
Now move to the DNA/RNA extraction laboratory: 
• Ensure that the clinical specimen extracts are fully defrosted (stored at -80°C 
following extraction). 
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• Make a 1: 10 dilution of extracted nucleic acid (this step improves performance 
in the RNaseP assay - removes false negatives; unpublished data): add 10 III of 
extract to 90 III nuclease free water. 
• Vortex for a few seconds the tubes containing the clinical specimen extracts. 
• Briefly spin the extracts in the microcentrifuge. 
• Pipette 5 III of the extract into all the tubes labelled for that specimen (e.g., 
specimen "S 1 '\ Adeno + RSV). Cap the tubes immediately after adding the 
extracted RNA. 
• Repeat the above steps for the remaining specimen extracts. 
• Add 5 III of mock extracted sample to the MOCK tubes. Cap the MOCK tubes. 
• Finally, pipette 5 III of positive control into all VIC tubes. Cap the VIC tubes. 
Now move to the peR amplification laboratory: 
• Switch on the Rotorgene 6000 machine and laptop. 
• Load the specimens in the order described in the worksheet (NrC, clinical 
specimens, MOCK, VIC). 
• Select the correct rRI -PCR run file. 
• Start the rRI-PCR run. 
• Copy and paste the run details (assay set up) into the Rotorgene software from 
the worksheet. 
• At the end of the run, analyse the results and print (and save the report). 
• Remove the tubes from the machine without opening and put in a sealed plastic 
bag for disposal (red bag). 
• When all assays are completed for a specimen, enter the data into the 
Microbiology laboratory database. 
12.4.4. Interpretation and limitations (from CDC protocols) 
12.4.4.1. RNP PCR (InternaVspecimen control) 
All clinical samples should be exhibit RNP reaction curves that cross the threshold line at 
or before 35 CT, indicating the presence of the human RNase P gene. 
Failure to detect RNase P in any of the clinical samples may indicate: 
• Improper extraction of nucleic acid from clinical materials resulting in loss of RNA 
or carry-over ofRI-PCR inhibitors from clinical specimens. 
• Absence of sufficient human cells in sample to enable detection. 
• Improper assay set up and execution. 
• Reagent or equipment malfunction. 
Ifa specimen is RNP negative, re-extract and repeat the PCR (on the next run). 
If all of the specimens are RNP negative (including the VIC), suspect PCR failure and 
repeat the assay. 
12.4.4.2. Adeno, Flu A, SwFluA, FluB, hMPV, and RSV rRT-PCR 
A sample is considered positive when a curve crosses the threshold before 40 CT. 
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This is only true if all quality controls worked properly (i.e. the NTC and mock must be 
negative, and the VTC positive [within 2S.D. of the mean using the process control chart]). 
If any MOCK or NTC is positive, or a VTC is negative, then the run is invalid since either 
contamination or reagent failure has occurred. Repeat the PCR with fresh reagents. 
Additionally, samples with virus PCR CT values between 35 and 40 are considered low 
positive: these results must be confirmed by repeating the PCR on the sample in duplicate 
on the next run (do not repeat all PCR, just the one with the low positive result). 
12.4.4.3. Limitations 
The presence of excess DNA/RNA template in the specimen may result in false negative 
results. If a negative result is obtained and high levels of nucleic acid are suspected, the 
extracted sample may be tested at 2 or more dilutions (e.g. 1: 1 0 and 1: 100) to verify the 
result. 
12.4.S. Appendix A: Specific rRT -PCR assay details 
12.4.5.1. Master mixes (25,.11 reaction volume) 
• Label one 1.5 ml microcentrifuge tube for each primer/probe set. 
• Determine the number of reactions (N) to set up per assay. It is necessary to make 
excess reaction cocktail for the MOCK, NTC and VTC reactions and for pipetting 
error: 
o If the number of samples (n) including all controls = 1 to 14, then N = n + 1 
o If the number of samples (n) including all controls> 15, then N = n + 2 
12.4.5.1.1. FluA, SwFluA, FluB, FluA sUh-typing, and RNP (CDC) 
'/. .\ .. <Xi{< •. ...../. ·.i ............ .. ·..i ·<><\<i.·· ..... ,.,,~~.) C. 
Taq Mix N x 0.50 
2X Reaction Mix N x 12.50 
Forward primer Nx 0.50 
Reverse primer N x 0.50 
Probe N x 0.50 
Nuclease-free water N x 5.50 
T.ad¥ ... ···· ...•................ ......................... .'. ' .. L .. ,.,·· ..• Nx:z ..... >~.}.. .< 
12.4.5.1.2. Adeno and RSV (CDC) & hMPV (Maertzdort) 
Forward rimer 
Reverse rimer 
Probe 
N x 12.50 
NxO.25 
N x 0.25 
N x 0.25 
N x 6.25 
Nx2t.OO 
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12.4.5.2. Reaction conditions 
12.4.5.2.1. Flu A, SwFluA, FluB, FluA sub-typing, and RNP (CDC) 
Reverse Transcription 500 e for 30 min 
Taq inhibitor inactivation 95°e for 2 min 
peR amplification (45 cycles) 95°e for 15 sec 
55°e for 30 sec 
12.4.5.2.2. Adeno and RSV (CDC) 
Reverse Transcription 500 e for 30 min 
Taq inhibitor inactivation 95°e for 2 min 
peR amplification (45 cycles) 95°e for 15 sec 
55°e for 1 min 
12.4.5.2.3. hMPV (Maertzdort) 
Reverse Transcription 500 e for 30 min 
Taq inhibitor inactivation 95°e for 5 min 
peR amplification (45 cycles) 95°e for 30 sec 
58°e for 1 min 
12.4.6. Appendix B: Positive controls (VTC) 
Each rRT-PCR run must include a positive control. Either virus controls from CDC or 
plasmid controls (SMRU) are used. 
The CT value of the positive control must be established prior to introduction and should be 
around 30. Positive control material should be aliquoted into single use tubes and stored at 
-80°C prior to use. 
The batch number and preparation date of the positive control is recorded on every rRT-
PCR worksheet. 
After each rRT-PCR run, the CT value of the positive control is entered into the 
Microbiology laboratory database and plotted on the appropriate process control chart. If 
the CT value of the positive control is greater than 2S.D. from the mean value for the 
current batch, then corrective action must be taken: 
• Repeat the rRT-PCR run with freshly made primers/probe. 
• Consider the need for a new batch of positive control. 
• Consider the need for a new Taq kit. 
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12.5. Primer and probe sequences (extracted from SMRU SOP MBL-32-P) 
12.5.1. Introduction 
This SOP describes the sequences, stock and working concentrations and general handling 
of PCR primers and probes for all SMRU microbiology laboratory PCRs. 
12.5.2. Important points 
Never use primers/probes that have expired. 
12.5.2.1. Primer/probe stocks 
• On receipt of a new batch of primers/probe, dilute as directed by the manufacturer 
(usually to a concentration of IOOJlM). 
• Aliquot the stock into single use tubes (each tube containing sufficient volume to 
make a 100JlI aliquot of working concentration primer/probe): 
o Probes must be protected from light: either cover the tube with foil or use a 
brown opaque tube. 
o Label each tube with the details of the primer/probe (name and 
concentration) and the expiry date (always one year after the preparation 
date). 
o Store stock concentration primers and probes in tbe -20°C freezer in the 
reagent preparation room. Do not re-freeze after thawing. Primers and 
probes may be stored this way for a maximum of one year. 
12.5.2.2. Working concentration primers/probes 
• For each PCR, only a single lOOJlI aliquot of working concentration primer/probe 
should be made at one time: 
o Probes must be protected from light: either cover the tube with foil or use a 
brown opaque tube. 
o Label each tube with the details of the primer/probe (name and 
concentration) and the expiry date (always three months after the 
preparation date). 
o Store working concentration primers and probes in the fridge in the reagent 
preparation room. Do not re-freeze after thawing. Primers and probes may 
be stored this way for a maximum of three months. 
• New aliquots of primer/probe should be tested in paral1el with the old batch to 
ensure activity prior to general use. 
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12.5.3. Primer and probe details 
Taqman probes are labelled at the 5' -end with the reporter molecule 6-carboxyfluorescein 
(FAM) and with the quencher, Blackhole Quencher 1 (BHQl) at the 3 ' -end. 
ITaqman probes are labelled at the 5'-end with the reporter molecule 6-carboxyfluorescein 
(FAM) and quenched internally at a modified "T" residue with BHQI, with a modified 3'-
end to prevent probe extension by Taq polymerase. 
*NLN_P working concentration was 50 JlM in the original paper, however at SMRU 10 
JlM was better when using a 100D Proligo probe stock (ordered in late 2010): 50 JlM 
resulted in non-specific fluorescence in all tubes. 
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